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Abstract 
 
Cathelicidins are cationic host defence peptides (CHDP) with essential roles in 
the innate defence system. These peptides have antimicrobial potential and the 
capacity to modulate innate immunity and inflammatory processes. Neutrophils 
(PMN) are the main reservoir of cathelicidins and play key roles in first line 
defence against infection. The appropriate regulation of PMN function, death, and 
clearance is critical to innate immunity, and the efferocytosis of apoptotic PMN, in 
contrast to necrotic cells, is proposed to promote the resolution of inflammation. In 
this thesis I demonstrate that the human cathelicidin LL-37 rapidly induced 
secondary necrosis of apoptotic human PMN and identify the essential C-terminal 
region of LL-37 required for this activity. In addition to the induction of secondary 
necrosis, higher concentrations of LL-37 also promoted PMN granule contents 
release. LL-37-induced secondary necrosis did not affect PMN ingestion by human 
monocyte-derived macrophages and, in contrast to expectation, was not pro-
inflammatory. Interestingly, the anti-inflammatory effects of apoptotic PMN on 
activated macrophages were retained and even potentiated where LL-37-mediated 
secondary necrosis induced anti-inflammatory granule content release. Consistent 
with the results of in vitro studies, in vivo murine sterile peritonitis model revealed 
the same phenomenon: LL-37-induced secondary necrosis diminished 
inflammatory responses with decreased PMN influx. I also present data on LL-37-
mediated modulation of innate immune effector cell cytokines responses to 
inflammatory signals. I propose that during acute inflammation LL-37 can 
modulate innate immune responses through its activity on cytokine production, and 
that LL-37-mediated secondary necrosis of apoptotic PMN has anti-inflammatory 
  ix 
effects, but may also mediate host damage by promoting the release of potentially 




















































1.1. General introduction 
 
All living organisms are exposed constantly to microorganisms that are present 
in the environment and need to cope with invasion of these organisms into the 
body. The host response to infection and injury depends on both innate and 
adaptive immune systems. The adaptive immune system primarily relies on the 
actions of B and T lymphocytes that activate and develop in response to threats. In 
contrast, the innate immune system is a germ-line encoded scheme to recognise 
conserved patterns. The response of innate immunity is immediate and depends on 
the activity of cells located at primary barriers between host tissue and 
environment such as macrophages, neutrophils (PMN), epithelial cells, mast cells, 
and natural killer cells (NK). These cells express a wide variety of pattern 
recognition receptors (PRR), such as toll-like receptors (TLRs) and scavenger 
receptors that recognise structurally conserved molecules derived from 
microorganisms. The detection of microbes results in the release and activation of 
numerous effector molecules and mediators of host defence, including the 
complement cascade, cytokines, chemokines, and cationic host defence peptides 
(CHDP). 
 
Cationic host defence peptides, existing in organisms from plants to insects to 
invertebrates and vertebrates, are involved in many aspects of innate host defences 
3 
associated with inflammation. Not only do they demonstrate direct antimicrobial 
activity against pathogens, but they also have multiple modulatory properties in 
immune responses [1, 2]. These peptides are mainly stored in the granules of innate 
immune effector cells, such as PMN, monocytes, NK cells, and mast cells, or 
expressed and produced de novo by epithelial cells [3, 4]. Although pleiotropic 
functions of CHDP have been studied, the key mechanisms involved in many of 
the immunomodulatory properties have not been completely understood.  
 
Emerging evidence demonstrates the impacts of CHDP on the functions and 
fates of immune effector cells [2, 5], with perhaps the most promising target being 
PMN. PMN are one of the most prominent effector cells of the innate immune 
system [6]. They are armed with a variety of weapons allowing them to combat a 
broad range of microbes, including generation of reactive oxygen species (ROS) 
and discharge of granule contents to kill pathogens [7]. PMN have a short lifespan, 
and undergo spontaneous apoptosis to ensure their histotoxic constituents remain 
packaged inside the intact cell membrane, followed by the clearance by phagocytes. 
Efficient removal of dead PMN is a prerequisite for the resolution of inflammation. 
Proper regulation of PMN recruitment, activation, death, and removal is thus 
critical to maintain homeostasis; dysregulation of these processes has been 
implicated in the pathogenesis of many inflammatory diseases [8]. 
 
Under physiological conditions, apoptotic PMN are phagocytosed by 
macrophages to promote the resolution of inflammatory responses rapidly with 
limited tissue damage [9]. Many receptors, adaptors, and chemotactic molecules 
4 
are reportedly involved in the process of removing apoptotic cells in various tissues 
[10, 11]. Growing evidence indicates that the phagocytic clearance of apoptotic 
cells and bodies is not only important for the disposal of effete cells, but can also 
result in powerful anti-inflammatory and immunosuppressive effects [12, 13]. In 
contrast to apoptosis, recognition of necrotic cells by phagocytes is less understood 
and cell death by necrosis is typically regarded as being associated with 
inflammation [14]. However, an increasing number of recent studies have shown 
that necrotic cells were not necessarily always pro-inflammatory, and that 
apoptotic cell clearance could also have inflammatory consequences [15]. 
Irrespectively, these reports suggest that the modes of cell death can have 
substantial influences on inflammatory responses and are not as simple as what 
was proposed.  
 
At inflamed sites, increased PMN influx to affected areas and release of their 
stored CHDP can help to contain harmful pathogens. Released CHDP also possess 
multiple effects on PMN. For example, the human cathelicidin LL-37 (a well-
characterised CHDP) induce the generation of ROS from human PMN and 
enhances the engulfment of bacteria [16, 17]. LL-37 also modulates the response of 
PMN to LPS [16, 18] and promotes immune responses by attracting PMN and 
other immune effector cells [19]. In addition, CHDP have a complex influence on 
PMN death [20, 21]. However, the mechanisms by which CHDP modulate PMN 
death remain elusive, and whether CHDP modulate inflammatory responses by 
altering innate immune cell death is still unknown. My studies therefore focus on 
the effects of CHDP on human PMN death, trying to characterise the mechanism 
5 
involved. In addition, I address the impacts of CHDP on inflammatory responses, 
by modulating cell death and by altering cytokine responses in response to pro-
inflammatory stimuli in vitro and in vivo.  
 
CHDP have been regarded as potential candidates to develop novel therapeutic 
drugs due to their multiple functions in modulating immune responses.  Studying 
the definitive pathways by which they interact with immune cells provides chances 
to exploit their potential to fight harmful pathogens and avoid side effects of over-
reacted inflammatory responses.  It is hoped that better understanding of the 
mechanisms involved in modulation of PMN death by CHDP, the effects of CHDP 
on phagocyte clearance and the subsequent inflammatory response, and the 
physiological significance of these observations, can provide advanced knowledge 

















Cationic host defence peptides (CHDP) play critical roles in innate immune 
responses. They are found in all classes of life and are evolutionarily conserved. 
These peptides share many key features such as positive charges, ranging in size 
from 12 to 80 amino acid residues, and an amphipathic structure [24]. Initially it 
was believed that their sole role in innate immunity was to kill invading 
microorganisms thus they were described as “antimicrobial peptides”. However, in 
vitro and in vivo evidence now suggests that these peptides play diverse and 
complex roles in the immune system, such as anti-endotoxic capacity, stimulation 
of cell cytokine production, chemotaxis of immune effector cells, alteration of 
transcriptional responses of antigen presenting cells, modulation of dendritic cell 
differentiation and function, triggering of mast cell degranulation, promotion of 
angiogenesis and wound healing, and modulation of cell death [2, 25] via unknown 
or known receptors (Table 1.1) and pathways. 
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Peptide Receptor Function Target cells 
Human alpha 
defensins 
Unknown (chemokine receptor) Chemotaxis 
naïve CD45RA/CD4 T cells, 




immature dendritic cells, 
memory CD45RO/ CD4 T cells [27] 
LL-37 FPRL-1 Chemotaxis human PMN, monocytes, and T cells [19] 
LL-37 two unknown receptors Chemotaxis, degranulation mast cells [28] 
LL-37 P2X7 Promote processing of IL-1beta human monocyte [29] 
LL-37 EGFR Activate MAPK/ERK, release IL-8 epithelial cells [30] 
LL-37 Atypical endocytic processes 
MAPK signalling, chemokine, 
cytokine production 
epithelial cells [31] 
LL-37 CXCR2 Migration, function PMN [32] 
LL-37 EGFR Migration keratinocyte [33] 





human monocytes, PMN, macrophages, 




MAPK signalling, chemokine, 
cytokine production 
Monocytes [36] 





1.2.2. Major families of CHDP 
 
Two major families of host defence peptides in mammals are widely studied. 
The first family, the defensins, containing six highly conserved cysteine residues 
which form three pairs of intramolecular disulfide bonds, are classified into α-, β-, 
and θ-defensins based on alignment of these disulfide bonds (α-defensins are 
linked in a 1-6, 2-4, and 3-5 pattern, whereas the disulfide bonds in β-defensins are 
in a 1-5, 2-4, and 3-6 pattern. θ-defensins are circular without a free N- or C-
terminus) [37]. Alpha-defensins are stored in the primary granules of granulocytes 
[38] and are made in Paneth cells in crypts of small intestine [39, 40] while beta-
defensins are generated by monocytes, macrophages, keratinocytes, or mucosal 
epithelial cells of the respiratory, digestive, urinary, and reproductive systems [41, 
42]. θ-defensins can be isolated from PMN and bone marrow of non-human 
primates [43]. The expression of these peptides is greatly increased following 
injury or infection.  
 
Cathelicidins are another family of cationic host defence peptides and named 
based on the highly conserved N-terminal region known as the cathelin (cathepsin 
L inhibitor) domain. They fold into amphipathic structure, retaining both cationic 
and hydrophobic faces to facilitate the interaction with negatively charged 
membrane [44]. In humans, only one cathelicidin gene (CAMP) has been found to 
date, on chromosome 3p21.3. It encodes an inactive precursor protein with an 
approximate mass of 18 kDa and is thus named hCAP18. hCAP18 is mainly stored 
in PMN specific granules at a concentration as high as 630 µg/109 cells [45, 46] 
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and is mainly processed by a PMN proteinase (protease-3) to release its mature 
form, LL-37 [47].  Other granulocytes (such as macrophages, NK cells and mast 
cells) [48], epithelial cells from a variety of tissues (such as urinary and respiratory 
tracts), and colon enterocytes also release or secrete this peptide during infection, 
injury, or inflammation [49-56]. LL-37 is composed of 37 amino acids rich in 
lysine and arginine which begins with two leucine residues with +6 net charge and 
forms an α-helix structure [44]. In addition to LL-37, the prostate-derived protease 
gastricsin can also process hCAP18, generating the alternative cleavage product 
ALL38 [57]. At the human skin surface, LL-37 is further processed by serine 
proteases or other proteases produced by the skin microflora into different 
derivatives (e.g. RK-31, KS-30 and K20) that have alternate activities [58, 59].  
Thus, although there is only one cathelicidin gene in humans, the peptides 
generated can be varied by post-translational modification. 
 
In addition to PMN granules, human cathelicidin can be found in a number of 
bodily fluids, including gastric juices, saliva, seminal plasma (42-143 µg/ml), 
sweat (5 µg/ml), blood, airway surface liquid, and breast milk [60, 61]. LL-37 
detected in the bronchoalveolar lavage of healthy individuals is at concentrations 
around 2-5 µg/ml, and is increased by 2-3 folds during infections [4]. In addition, 
plasma has been reported to contain hCAP18 bound to lipoproteins at a 
concentration of 1.2 µg/ml [62].  
 
The induction of CHDP often involves signalling mediated by PRR or responses 
to pro-inflammatory cytokines. For example, although keratinocytes express 
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human beta-defensin hBD1 mRNA constitutively, hBD2, hBD3, and hBD4 are 
induced by stimulation with TLR ligands, TNF-α, IL-1β, INF-γ, and 1,25- 
dihydroxyvitamin D3 [63-73]. Cathelicidin expression is moderately inducible 
upon stimulation with pro-inflammatory cytokines such as IL-1α [74] or bacterial 
components [75]. Recently, it was found that active form of vitamin D, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) induced gene expression and protein 
production of cathelicidins in isolated human epithelial cells, keratinocytes, 
macrophages, monocytes, and PMN [53, 72]. A recent study demonstrated that LL-
37, induced by active form of vitamin D, triggered autophagy in affected cells and 
promoted the eradication of intracellular pathogens [76, 77]. 
 
1.2.3. Physiological significance of CHDP 
 
The importance of CHDP to human immunity is indicated by the increased 
susceptibility to infection of individuals with a specific granule deficiency and 
patients with morbus Kostmann [78, 79] (conditions in which PMN deficiency in 
defensins and cathelicidin, respectively, constitute key components of the disease). 
Additionally, smaller amounts of Paneth cell α-defensins are found in patients with 
Crohn’s disease compared with the amount in normal controls [80]. Moreover, in 
the case of chronic cystic fibrosis lung disease or psoriatic skin lesion, LL-37 
expression has been detected at higher concentrations (~15 µg/ml and ~1.5 mg/ml 
respectively) than that observed in unaffected individuals (~5 µg/ml and ~0 µg/ml) 
[3]. Conversely, expression of hBD2 and the cathelicidin LL-37 is diminished 
substantially in atopic dermatitis, a skin condition often accompanied by bacterial, 
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fungal, or viral infection [3]. These clinical findings suggest that CHDP play an 
important role in first-line defence, but uncontrolled upregulation of these peptides 
can result in chronic inflammatory disorders. 
 
1.2.4. Antimicrobial capability of CHDP 
 
In vitro, most CHDP have antimicrobial activity against a range of microbes 
including gram-positive and gram-negative bacteria, protozoa, fungi and some 
viruses [2]. Studies have shown their capacity to directly disrupt the microbial cell 
membrane and thereby result in killing [81, 82]. In general, positively charged 
peptides are attracted by electrostatic forces to the negative phospholipid head 
groups on the membrane surface capsular polysaccharides, including 
lipopolysaccharide (LPS) in Gram-negative bacterial cell wall and teichoic acids 
and lipoteichoic acids (LTA) in Gram-positive bacteria. Then the nonpolar face of 
peptides will allow insertion into the membrane through hydrophobic interactions. 
Once CHDP gain access to the cytoplasmic membrane they interact with the lipid 
bilayer, alter membrane structure and create a physical hole causing cellular 
contents to leak out [81, 82].  
 
However, several mechanisms have been described for microbial resistance to 
CHDP. For example, the expression of LL-37 and hBD1 was reduced or turned off 
by Shigella infection [83]. In addition, microbes such as S. aureus, Bacillus 
anthracis, and Burkholderia cenocepacia produce metalloproteinases which can 
effectively degrade LL-37, contributing to the resistance of these pathogens to LL-
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37 [84-86]. Another effective strategy used by S. aureus is to change the 
composition of its cell membrane. The alterations decrease the susceptibility of 
pathogens to the peptides and contribute to their pathogenicity [87]. Furthermore, 
LPS of P. aeruginosa found in cystic fibrosis airway has altered lipid A structure 
associated with resistance to CHDP [88], suggesting another mechanism 
underlying the sustained infection and inflammation. 
 
   It should be emphasised that most of antimicrobial experiments were conducted 
in conditions with low ionic strength and neutral pH in vitro which may not reflect 
real physiological situations. The antimicrobial activities of many CHDP are 
inhibited by the presence of serum and divalent cations (1-2 mM) [1]. This 
observation casts doubt on the idea that these peptides have a purely antibiotic 
function in vivo [89, 90]. For instance, the concentration of CHDP is normally 
around than 2-5 µg/ml at mucosal sites, whereas the MIC of LL-37 for a range of 
common bacteria is between 15-30 µg/ml under optimal ionic conditions. Although 
it is possible that at certain settings CHDP can reach high levels to exert their 
microbe-killing capability (eg. leukocyte granules, or extracellular traps composed 
of DNA, histone, and CHDP [91, 92], inflamed sites), the additional or alternative 










Because of the differences of plasma membrane contents in prokaryotic and 
eukaryotic cells (cholesterol content and asymmetric distribution of phospholipids 
in the cytoplasmic membrane in eukaryotic cells), it is proposed that CHDP are not 
toxic to host cells. In addition, the cytotoxic effects of peptides to eukaryotic hosts 
in vivo may also be substantially attenuated by serum components by binding to 
the peptides [62, 89, 90]. However, several studies have also reported that these 
peptides at high concentrations also destroy eukaryotic cells in vitro. For example, 
higher concentrations (exceeding 13 µM) of LL-37 is cytotoxic to eukaryotic cells 
such as peripheral blood leukocytes and T cell line [25], which may be associated 
with cationic peptide-induced membrane permeabilisation [93, 94]. In addition, 
two bovine cathelicidins, BMAP-27 and BMAP-28, were found to induce cell 
death in cell lines and fresh haematopoietic tumour cells [94-96], leading to the 
hypothesis that CHDP might also have a role in tumour surveillance [93, 97, 98]. 
 
Tumour cells differ in membrane composition from nontransformed cells and 
such differences can result in higher susceptibility of tumour cells to membrane-
permeabilising peptides [99]. CHDP inhibit cancer progression either by triggering 
necrosis via the cell membrane lytic effect or inducing apoptosis via mitochondrial 
membrane disruption. For example, treatment with or intracellular expression of α-
defensins induces tumour cell apoptosis or necrosis, inhibiting tumour growth [100, 
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101]. A murine model showed that intratumoural expression of these peptides 
decreased neovascularisation and increased dendritic cell recruitment and 
maturation, suggesting a potential in cancer therapy [102]. However, contrast 
findings addressed that ovarian and breast cancers had overexpressed hCAP18/LL-
37, suggesting that the peptide may contribute to tumourigenesis through direct 
stimulation of tumour cells, initiation of angiogenesis, recruitment of immune cells, 
and promotion of cancer metastasis [103, 104]. Taken together, the cytotoxic 
activity of CHDP on eukaryotic cells may depend on their unique structure and 
would be affected by the properties of target cells and the working conditions (eg. 
pH, ions, serum components).  
 
1.2.5.2. Modulation of cell death 
 
CHDP have the capability to modulate inflammatory responses by modifying 
immune cell death. For instance, β-defensins prolong PMN lifespan by 
downregulation of pro-apoptotic proteins, upregulation of anti-apoptotic proteins, 
and inhibition of mitochondrial membrane potential change and caspase-3 activity 
[105]. Murine β-defensin 2 (mDF2β) induced DC maturation, but also promoted 
atypical death of antigen-presenting cells (APC) [106].  
 
In addition to the lytic activity on cells, high concentrations of LL-37 induced 
apoptosis in airway epithelial cells in vivo [107], and LL-37 at physiologically 
relevant concentrations induced apoptosis in infected airway epithelial cells via 
mitochondrial depolarisation and caspase-dependent pathways [20, 107, 108]. 
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Moreover, in carcinoma and Jurkat lymphoma cell line, LL-37 contributed to 
caspase-independent apoptosis [109, 110]. In certain circumstances, the membrane 
perturbation induced by LL-37 could be antagonised by the presence of serum 
components in human serum and is not dependent upon signals via known 
receptors (FPRL-1, EGFR) [107]. 
 
By contrast, LL-37 has also been described as a potent inhibitor of human PMN 
apoptosis [20, 21]. The alternate consequences of LL-37-mediated modulation of 
apoptotic pathways in different human primary cells suggest an 
immunomodulatory role for this peptide in innate host defence.  In addition, LL-37 
protects primary human keratinocytes from apoptosis through up-regulation of 
cyclooxygenase-2 (COX-2) expression, suggesting a role of this peptide in reduced 
keratinocyte apoptosis in psoriasis [111]. Moreover, human cathelicidin is required 
for vitamin D3-induced autophagy in human monocytes and for suppressing 
intracellular Mycobacterium tuberculosis survival [76]. Nevertheless, it remains 
unclear how this peptide interacts with eukaryotic cells and how it affects immune 
consequences by altering cell death. Given that the mode of cell death can direct 
subsequent inflammatory response, peptide-modified cell death might be expected 






1.2.6. Anti-endotoxic and anti-inflammatory 
properties 
 
1.2.6.1. TLR superfamily 
 
TLRs are evolutionarily conserved receptors expressed by various immune cells 
and non-immune cells such as macrophages, DC, PMN, epithelial cells, 
keratinocytes, and fibroblasts [112-115]. TLRs play a vital role in immune system, 
belonging to a major family of pattern-recognition receptors (PRRs) to detect 
signature molecules of pathogens or danger signals from damaged self. TLRs are 
composed of N-terminal extracellular leucine-rich repeats (LRRs) which are 
responsible for recognition of pathogen components or danger molecules, a 
membrane-spanning domain, and a conserved C-terminal cytoplasmic domain 
Toll/IL-1 receptor (TIR) domain, which is required for downstream signalling 
[116-118].  In addition to the physiological surveillance functions, TLRs are 
upregulated in the affected tissue in inflammatory disorders, implying that their 
signalling is involved in the pathogenesis of chronic inflammation [119].  
 
To date, 10 TLR members have been identified in humans and each of them 
recognise distinct molecules [113]. For instance, lipoproteins or lipopeptides, such 
as peptidoglycan (PGN) and lipoteichoic acid (LTA), are recognised by TLR2 in 
complex with TLR1 or TLR6, viral double-stranded RNA is recognised by TLR3, 
lipopolysaccharide (LPS) is recognised by TLR4, flagellin is recognised by TLR5, 
single-stranded RNA is recognised by TLR7 or TLR8, and microbial DNA is 
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recognised by TLR9. TLRs are expressed at different cellular compartments. TLR1, 
TLR2, TLR4, TLR5, and TLR6 are found on the cell surface, while TLR3, TLR7, 
TLR8, and TLR9 are located at cytosolic organelles like endosome and ER [118]. 
TLRs sense ligands and induce conformational dimerisation to initiate downstream 
signalling pathways. The signalling pathways of TLRs can be roughly divided into 
two routes: MyD88-dependent pathway and MyD88-independent pathway (Fig. 




Upon stimulation, all TLRs except TLR3 use MyD88 as the adaptor molecule to 
activate downstream signalling pathway while TLR2 and TLR4 require an 
additional adaptor to bridge MyD88 and TIR, namely TIRAP [122, 123]. MyD88 
immediately recruits IL-1R-associated kinase (IRAK) members and tumor 
necrosis-factor-receptor-associated factor 6 (TRAF6). TRAF6 subsequently 
recruits transforming-growth-factor-β-activated kinase 1 (TAK1) and other 
enzymes (UEV1A, UBC13), resulting in the activation of NF-κB and MAPK 
pathways [116, 118]. The activation of NF-κB induces pro-inflammatory cytokine 
and chemokine production, such as TNF and IL-6. In TLR7, TLR8, and TLR9 
signalling, MyD88 is required for the induction of type I IFNs (INF-α) through 





MyD88-independent pathway (TRIF-dependent pathway) 
 
TLR3 and TLR4 initiate a TRIF-dependent pathway (MyD88-independent 
pathway). TRIF directly engages with TLR3, whereas TRAM bridges the TLR4 
interaction [123]. TRIF-dependent pathway mediates the activation of NF-κB 
(through TRAF6 or RIP1) and IRF3, which induces INF gene transcription and 
INF production (INF-α and INF-β) [124, 125]. INF-β subsequently induces the 
expression of a number of genes, such as immunoresponsive gene 1 (IRG1) and the 
gene encoding CXC-chemokine ligand 10 (CXCL10; the product of which is also 
known as INF-γ-inducible 10 kDa protein, IP-10) [118, 126, 127]. In addition to 
inducing the expression of INF-inducible genes, the MyD88-independent pathway 
leads to the upregulation of costimulatory molecules of APCs through the 
induction of INF-β [128]. Taken together, TLR recognition involves complicated 
molecular interactions and signalling pathways which provide a powerful 
mechanism to respond to a variety of foreign pathogens or endogenous danger 
signals.  
 
1.2.6.2. Anti-inflammatory effect of CHDP on TLR 
signalling 
 
Uncontrolled upregulation of TLR-mediated signalling may lead to excessive or 
persistent inflammation and severe immune pathology to the host, including septic 
shock, autoimmunity, metabolic syndrome, and chronic inflammatory diseases 
[114, 115, 129, 130]. CHDP are known to have selective anti-inflammatory effect 
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on TLR stimulation in different cell types [89, 131-134]. For example, in human 
monocytes, cathelicidin LL-37 neutralises the activation of macrophage by LPS 
and LTA at very low concentrations (≤ 1 µg/ml) in physiological salt conditions 
[89, 90, 131, 135]. The peptide has a selective anti-inflammatory effect on TLR 
stimulation [89, 131], selectively inhibiting pro-inflammatory cytokine release 
whereas retaining the TLR-induced signals for cell recruitment [131]. In human 
monocyte-derived dendritic cells, LL-37 not only suppresses pro-inflammatory 
cytokine responses, but also inhibits the surface expression of co-stimulatory 
molecules and decreases the activation of T cells by TLR ligands [133]. In addition, 
LL-37 attenuates pro-inflammatory responses of non-immune cells such as human 
gingival fibroblasts to TLR2/1, TLR3, and TLR4 ligands [132].  Moreover, the 
murine homologue of LL-37, mCRAMP, is capable to blunt activation of MAPK 
and decrease TNF-α release in murine macrophages in response to the agonists of 
TLR4 (LPS), TLR2 (LTA), and TLR5 (flagellin) [134]. Recent study using LL-37 
fragments and physico-chemical parameters revealed that the capability of 
cathelicidins to modulate TLR responses was dependent on their cationicity and 
hydrophobicity [136]. The mechanisms by which CHDP suppress TLR 
inflammatory responses remain elusive and require further studies. 
 
In contrast to the inhibition of TLR-mediated pro-inflammatory cytokine 
responses, cathelicidins can enhance inflammatory responses accompanied with 
certain TLR stimulation in specific cell types [132]. Cathelicidins can activate 
TLR9 by forming a complex with inert extracellular self-DNA fragments, 
triggering robust IFN responses by pDC in chronic skin inflammation [137]. It is 
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likely that CHDP play a dual role in modulating TLR signalling, either mediating 
anti-inflammatory effects or promoting immune responses, dependent on stimuli 
and different cell types. Better understanding of the underlying mechanisms 
involved in the interaction of TLR signaling pathways and CHDP may offer a 
























Fig. 1.1 TLR signalling in immune cells. TLR1, TLR2, TLR4, TLR5, TLR6 are located on the 
cell surface while TLR3, TLR7, TLR8, and TLR9 are located in intracellular organelles. All TLRs, 
except TLR3 recruit MyD88 to activate downstream signalling pathways. TLR2 and TLR4 require 
an additional adaptor molecule, TIRAP, to link their TIR domain and MyD88. On the other hand, 
TLR3 and TLR4 initiate MyD88-independent pathway through recruiting another adaptor molecule 
TRIF (TLR4 needs TRAM for bridging). In the MyD88-dependent pathway, MyD88 recruits the 
IRAK family and TRAF6. TRAF in turn activates TAK1, which induces the activation of 
downstream MAP kinase and NF-κB, resulting in transcription of inflammatory cytokine genes. In 
the TRIF-dependent pathway, TRIF interacts with RIP1 and TRAF6, leading to the activation of 
NF-κB and MAP kinase. In addition, TRIF also interacts with TRAF3, causing the activation of 
downstream IRF3 and IRF7, subsequently initiating the transcription of type I interferons. (The 




1.2.7. Stimulation of cytokine and adhesion molecule 
expression 
 
CHDP can also stimulate cytokine responses. HNP have been reported to 
stimulate IL-8 production by human bronchial and lung epithelial cells [138, 139] 
and increase TNF-α and IL-1β production by human monocytes [140]. However, 
an in vivo study revealed that α-defensins blocked the release of the pro-
inflammatory cytokine IL-1β from LPS-stimulated monocytes, indicating the 
possible role of the peptides in inflammatory diseases [141]. In addition, hBD-2, -3, 
-4, and cathelicidin LL-37 have been found to individually and synergistically 
increase human keratinocyte gene expression and protein production of IL-6, IL-10, 
IP-10, MCP-1, MIP-3α and RANTES through GPCR, providing a mechanism for 
the pathogenesis of skin diseases such as psoriasis [142].  
 
LL-37 stimulates the expression of a wide variety of genes involved in the innate 
immune response, including those encoding chemokines. For example, LL-37 up-
regulates the expression of MCP-1 in macrophages, and induces the secretion of 
IL-8 from human epithelial cell line, keratinocytes, and PMN [30, 89, 143, 144]. 
LL-37 also induces the release of IL-4, IL-5, and IL-1β from mast cells [145]. A 
study showed that at physiological concentrations (2-5 µg/ml), LL-37 significantly 
increased the production of IL-6 and IL-8 by epithelial cells and keratincytes in 
response to pro-inflammatory stimuli such as IL-1β and TLR agonists, suggesting 
it may play an important role in the initiation and regulation of inflammation in 
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epithelia [146]. In addition, LL-37 up-regulates the chemokine receptors CXCR4, 
CCR2, and IL-8RB in macrophages, indicating the multifunctional role of the 
peptide in immune responses [25]. Furthermore, LL-37 induces processing and 
release of the pro-inflammatory cytokine IL-1β by LPS-primed monocytes via 
P2X7 receptor [29]. Along with its individual cytokine modulating effects, LL-37 
can synergise with other mediators to enhance cytokine production, for example, 
the IL-1β and GM-CSF-induced production of cytokines (IL-6, IL-10) in human 
peripheral blood monocytes (PBMC) [147]. Above observations reveal that CHDP 
have massive impacts on many aspects of host defence system by modulating 
numerous cytokine responses. 
 
1.2.8. Other immunomodulatory functions 
 
1.2.8.1. Chemotactic activity 
 
Human α-defensins (HNP-1 and HNP-2, but not HNP-3) have been shown to 
have chemotactic activity mediating the recruitment of monocytes to inflammed 
sites [148]. In addition, the β-defensins hBD3 and hBD4 have been reported to 
attract monocytes and macrophages [149], and hBD2 is chemotactic for mast cells 
[150]. Interestingly, hBD1 and hBD3 are chemotactic for immature dendritic cells 
and memory T-cells through human CC chemokine receptor 6, whereas human α-
defensins selectively induce the migration of human naïve CD4+CD45+ and 
CD8+cells [26, 27]. In addition to defensins, LL-37 uses FPRL-1 and CXCR2 as 
receptors to chemoattract human peripheral blood PMNs, monocytes, eosinophils, 
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and T cells [19, 32, 151]. LL-37 has been also reported to be chemotactic for 
human mast cells using two different receptors, a high-affinity that is not a GPCR 
and a low-affinity GPCR [28]. These findings indicate that these peptides can 
attract immune cells to affected sites and further promote immune responses or 
inflammatory resolution. 
 
1.2.8.2. Leukocyte granule content release  
 
Another mechanism exploited by CHDP to modulate inflammatory reactions is 
to promote leukocyte granule content release. Studies investigating cellular content 
release revealed that hBD2 and LL-37 stimulate mast cell degranulation by 
mobilising intracellular Ca2+ in a GPCR-dependent manner [152]. In addition, LL-
37 increases the gene expression and extracellular release of human α-defensins 
[17]. These data suggest that CHDP can enhance immune responses by augmenting 
other immune mediator or peptide release. 
 
1.2.8.3. Promotion of wound healing  
 
It has been documented that CHDP are mitogenic for epithelial cells and 
fibroblasts and may play a central role in the wound healing process [153, 154]. 
For example, hBD2 was described as being a potent promoter of human 
endothelial cell migration, proliferation and, in the presence of angiogenic factors, 
tube formation, which accelerated wound closure [87, 155]. Additionally, the 
reduction of the cathelicidin LL-37 in chronic wounds impairs re-epithelialisation, 
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suggesting that this peptide may play a part in wound closure [156]. LL-37 also 
induces keratinocyte migration through transactivation of EGFR [33, 157] and 
induces angiogenesis through FPRL-1 [34]. Furthermore, an observation revealed 
that fibrosis in human dermal keloids was inversely related to the expression of 
cathelicidins, suggesting their antifibrotic activity during the wound repair process 
[158]. CHDP-mediated promotion of wound repair serves as another mechanism 
by which these peptides strengthen host defences against invasions. 
 
1.2.9. Impacts on adaptive immunity 
 
The chemotactic capacities of both defensins and cathelicidins predict that they 
might play a role in recruiting T cells, immature DCs and monocytes to sites of 
infection, thereby facilitating the initiation of adaptive antimicrobial immune 
responses [26, 27]. Studies using a mixture of HNP1-3, when simultaneously 
administered with ovalbumin (OVA) intranasally into C57BL/6 mice, enhanced the 
production of OVA-specific serum IgG antibody and the generation of IFN-γ, IL-5, 
IL-6 and IL-10 by OVA-specific CD4+ T cells [154]. Thus, defensins enhance the 
specific immune response by inducing the production of cytokines, which promote 
the adaptive immune response. Also, LL-37 was demonstrated as a potent modifier 
of DC differentiation, up-regulating endocytic capacity and surface expression of 
costimulatory molecules, enhancing secretion of Th-1 inducing cytokines, and 
promoting Th1 responses in vitro [159].  Taken together, CHDP are able to bridge 
innate and adaptive immunity to amplify immune responses. 
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1.2.10. In vivo protection against infection 
 
Evidence supports that hypothesis that CHDP play critical roles in immune 
defence against a broad variety of pathogens in physiological conditions, probably 
dependent on their multiple immunomodulatory functions. This proposal has been 
supported by an innate defence-regulator peptide, IDR-1 a synthetic peptide 
derived from LL-37. Although devoid of direct antimicrobial activity, IDR-1 is 
protective in mouse models of infection with Gram-positive and Gram-negative 
pathogens, including methicillin-resistant Staphylococcus aureus, vancomycin-
resistant Enterococcus, and Salmonella enterica serovar Typhimurium [160]. 
  
In addition, mouse models deficient in cathelin-related antimicrobial peptide 
(mCRAMP), the murine homologue of LL-37, have demonstrated increased 
susceptibility to infection in the skin, urinary tract, gut, and lung [161-164]. 
Transgenic mouse studies have provided more evidence for the physiological 
function of CHDP in antimicrobial host defence. One study showed that matrix 
metalloproteinase-7 [(MMP-7) (an enzyme required for conversion of inactive pro-
α-defensins to active cryptdin peptides)] –null (Mm7-/-) mice had decreased 
clearance of noninvasive E.coli in the small bowel. These mice had higher 
susceptibility to oral challenge with S. typhimurium, indicating the importance of 
defensin expression in intestinal immunity to enteric pathogens [165]. In addition, 
targeted deletion of the mouse β-defensin-1 gene resulted in mice deficient in the 
clearance of Haemophilus influenzae from the lung [166].  
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On the other hand, mice expressing a human α-defensin gene (DEFA5) had 
different enteric microbiota composition and fewer IL-17-producing lamina propria 
T cells [167].  Studies demonstrated that HD-5 transgenic mice, which expressed 
human HD-5 small intestinal Paneth cells, were markedly resistant to oral 
challenge with virulent Salmonella typhimurium [168]. Moreover, overexpression 
of LL-37 in the mouse airway by adenovirus-mediated gene transfer resulted in the 
increased ability to reduce bacterial load from Pseudomonas aeruginosa challenge 
and improved survival after administration of lethal doses of LPS [169]. These in 




It is therefore clear that CHDP are crucial components of the body’s defence 
against infections and are able to modify the immune responses. Understanding the 
mechanisms by which CHDP act, has the potential to inform the development of 














Polymorphonuclear leukocytes (PMN), also called granulocytes, are the most 
abundant white blood cells in humans and an essential component of the innate 
immune system. There are three types of granulocytes: neutrophil, eosinophil, and 
basophil, distinguished by their granules when stained.  
 
The bone marrow of a healthy adult produces up to 1011 PMN a day [170]. PMN 
are terminally differentiated cells. They originate from a precursor pool of stem 
cells and develop in bone marrow. PMN differentiation has classically been 
divided into six stages (myeloblast, promyelocyte, myelocyte, metamyelocyte, 
band, and mature PMN) on the basis of cell size, nuclear morphology, and granule 
contents [171]. After release from bone marrow, PMN enter the circulation where 
they represent more than 50% of circulating leukocytes. 
 
1.3.2. PMN functions 
 
PMN are the first line defence cells against bacteria and fungi infections. They 
ingest microbes by a process known as phagocytosis, and destroy ingested 
microorganisms by the combination of production of reactive oxygen species (ROS) 
and disgorgement of granule contents (degranulation) [172-174]. ROS are derived 
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from superoxide which is produced by a multisubunit enzyme complex called 
nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) at the 
phagosomal membrane. NADPH oxidase catalyses the production of superoxide 
(O2
-), which dismutates rapidly to H2O2. Both O2
- and H2O2 are effectively 
antimicrobial. In addition, granule components such as myeloperoxidase (MPO) 
catalyse a reaction with H2O2 and chloride to form hypochlorous acid (HOCl) and 
singlet oxygen. NADPH oxidase and the MPO-halide system serve as redundant 
mechanisms to kill ingested microbes. This explains why MPO deficiency in 
humans does not necessarily correlate with morbidity from infection [172, 175]. In 
the phagosome, microorganisms are exposed to high concentrations of ROS and 
antimicrobial peptides, both of which are responsible for microbial killing. In 
addition, a novel form of PMN killing technique has been described, named 
neutrophil extracellular traps (NETs). Stimulated PMN release granule proteins 
and chromatin that together form extracellular fibres to bind microorganisms. 
These NETs degrade virulence factors and kill pathogens. NETs appear to be a 
form of innate response that binds microorganisms, prevents them from spreading, 
and ensures a high concentration of antimicrobial peptides at the structure to kill 
microbes [92].  
 
In addition to the direct antimicrobial activity, PMN also orchestrate the 
functions of other immune effector cells, integrating the innate and adaptive limbs 
of the immune response [176-179]. For example, PMN have the ability to produce 
numerous cytokines and chemokines following phagocytosis such as TNF-α, IL-
1β, IL-8, and macrophage inflammatory protein-1α (MIP-1α) [180]. These 
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cytokines contribute to the inflammatory response and the attraction of other 
immune effector cells [181, 182]. PMN can also release granule proteins, 
enhancing the activation of macrophages, promotion of bacterial phagocytosis 
[183], and attraction of monocytes, dendritic cells, and lymphocytes [28, 179, 184]. 
Moreover, PMN also generate CXCL10/ IP-10, which acts as an important 
chemoattractant for activate NK and T-helper type 1 cells [185]. Furthermore, by 
releasing their granule contents, PMN are capable of mobilising and activating 
dendritic cells, thus augmenting adaptive immune responses [179]. Taken together, 
PMN are multifunctional immune cells, destroying microorganisms by 
phagocytosis, superoxide production, degranulation, and being able to orchestrate 
inflammatory and immune processes. 
 
1.3.3. PMN granules 
 
Morphologically, PMN are characterised by a lobulated chromatin-dense 
nucleus and their granules. The different types of granules—primary or azurophil 
granules, secondary or specific granules, gelatinase or tertiary granules and 
secretory vesicles—are not merely containers of proteolytic and bactericidal 
substances, they also serve as reservoirs of membrane receptors [186] (Table 1.2). 
According to the targeting-by-timing hypothesis, PMN granules are formed 
sequentially during myelopoiesis. Primary granules are produced at the stage of the 
early promyelocyte, secondary granules are created in myelocytes, and gelatinase 
granules are formed at the metamyelocyte and band cell stages. Secretory vesicles 
are formed by endocytosis at late stages.  
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1.3.3.1. Primary granules 
 
Primary granules (azurophil granules), which are also described as peroxidase-
positive granules, can be further divided into two major subsets dependent on the 
appearance of defensins: early-appearing defensin-poor azurophil granules and 
late-appearing defensin-rich azurophil granules [186, 187]. A number of proteins 
has been identified in azurophil granules described as follows.  
 
Myeloperoxidase   
 
MPO is a microbicidal hemoprotein, released into the phagosome or to the 
extracellular space upon PMN activation. MPO reacts with H2O2, formed by 
NADPH oxidase, to induce formation of toxic oxidants and radicals which can 
attack the surface membranes of microorganisms [173]. 
 
Alpha-defensins   
 
PMN contain four closely-related -defensins (HNP1-4), which are small 
cationic peptides with antimicrobial and immunomodulatory properties (details are 
found in Chapter 1.2 CHDP). 
 
Bactericidal /permeability-increasing protein (BPI)   
 
BPI is a highly cationic peptide binding to negatively charged LPS in the outer 
membrane of Gram-negative bacteria, promoting the killing of pathogens [188]. 
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Serprocidins (serine proteases with microbicidal activity)   
 
Azurophil granules contain three structurally related serprocidins: proteinase-3, 
cathepsin G, and elastase [189]. Serprocidins are cationic polypeptides with 
proteolytic activity of degrading a variety of extracellular matrix components, such 
as elastin, fibronectin, laminin, collagens, and proteoglycans [189]. They can also 
target and degrade virulence factors and outer membrane components of pathogens, 
contributing to PMN-mediated killing of microbes [190-192]. Serprocidins can 
induce activation of defence cells [193] or process CHDP (eg. proteinase-3 
processes human cathelicidin hCAP-18 to generate active form of peptide, LL-37 
[47]). 
 
1.3.3.2. Specific granules (secondary granules) and 
gelatinase granules (tertiary granules) 
 
In contrast to primary granules, specific and gelatinase granules are peroxidase-
negative. These granules possess three metalloproteases, namely collagenase 
(MMP-8), gelatinase (MMP-9), and leukolycin (MMP-25). MMPs are capable of 
degrading major structural components of the extracellular matrix and are 
important in degrading vascular basement membranes and interstitial structures 
during PMN extravasation and migration [187, 193]. In addition to 
metalloproteases, specific granules contain other proteins distinct from that of 






Lactoferrin is glycoprotein with a broad spectrum of antimicrobial activity based 
on its iron-binding property which impairs bacterial growth by sequestration of 
iron [194]. In addition to its well-established anti-microbial properties, lactoferrin 
can mediate immunomodulatory functions through its direct activity on innate 
immune cells and molecules [195]. 
 
hCAP-18/ LL-37  
 
hCAP18 is mainly stored in PMN specific granules and is mainly processed by a 
PMN proteinase (protease-3) to release its mature form, LL-37 [47]. Like α-
defensins, it is a small cationic, antimicrobial peptide with multiple 
immunomodulatory peptides (details are found in Chapter 1.2 CHDP). 
 
Neutrophil gelatinase-associated lipocalin (NGAL)  
  
NGAL exerts its bacteriostatic activity by binding bacterial catecholate-type 
ferric siderophores and sequestrating ferric-siderophore complexes [196].   
 
Lysozyme   
 
Lysozyme is a cationic antimicrobial peptide present in all granule subsets, with 
peak concentrations in specific granules [197]. Lysozyme is able to cleave 
peptidoglycan polymers of bacterial cell walls and bind LPS to exert its 
bactericidal activity [198, 199]. 
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1.3.3.3. Secretory vesicles 
 
Secretory vesicles appear in segmented PMN. The membranes of secretory 
vesicles are rich in the β2-integrin (CD11b/CD18), receptors for formylated 
bacterial peptides, the LPS/ lipoteichoic acid receptor CD14, and FcγIII receptor 
CD16, all of which are incorporated in the plasma membrane after degranulation 
[174]. Upon stimulation with inflammatory mediators, secretory vesicles mobilise 
and enrich the PMN surface with β2-integrin CD11b/CD18, enhancing the 
























































Degranulation is defined by the translocation of granules to the phagosomal or 
plasma membrane, where granules dock and fuse with the membrane to release 
their contents. Degranulation occurs when receptors (GPCR, such as the formyl 
peptide receptors FPR, FPRL1 [201], chemokine receptors CXCR1, CXCR2 [202], 
and complement receptor C5a receptor [203]) are stimulated with wide variety of 
stimulants such as formyl-methionyl-leucyl-phenylalanine (fMLF) [7], C5a [204], 
platelet-activating factor (PAF) [205], TNF [206], LPS [207], and proteins derived 
from pathogens [208]. The excessive PMN granule content release would cause 
many inflammatory disorders, such as acute lung injury, severe asthma, 
rheumatoid arthritis, and septic shock [204]. Therefore, degranulation process of 
PMN should be tightly regulated to avoid uncontrolled release of tissue-destructive 
constituents.  
 
It is postulated that degranulation involves four distinct steps: granule 
recruitment, granule docking, granule priming, and granule fusion to target 
membrane [209]. The translocation and exocytosis of granule contents of PMN 
require increases of intracellular Ca2+ and the reorganisation of the actin 
cytoskeleton [204]. Using Ca2+ ionophores such as A23187 or ionomycin induces a 
hierarchy of granule secretion [210]. The order of release in responses to elevating 
concentrations of Ca2+ is secretory vesicles > tertiary granules (gelatinase granules) 
> secondary granules > primary granules, which also reflects their responses in 
physiological conditions [211]. Upon initiation of inflammation, PMN interact 
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with the endothelium which results in discharge of secretory vesicles. While PMN 
pass through the endothelium and basement membrane, high concentration of 
gelatinase, a collagenolytic protein, is being released. Once PMN reach the 
extravascular tissue, primary and secondary granules undergo exocytosis, acting as 
defences against insults [186]. 
 




PMN are inherently short-living cells with a half life of 6-10 hours in the 
circulation before undergoing spontaneous apoptosis. Constitutive death of PMN is 
a critical process for modulating PMN number and function and plays an essential 
role in PMN homeostasis. The removal of apoptotic PMN by macrophages is a 
mechanism to clear effete PMN and to facilitate the resolution of inflammation [9].  
 
Apoptotic PMN display morphological characteristics such as cell shrinkage, 
condensation of chromatin, and loss of the multilobed shape of their nucleus. They 
are nonfunctional, with impaired chemotaxis, respiratory burst, and degranulation 
[212]. Molecular alterations on their cell surface have also been reported [213, 
214]. For example, a marked downregulation of FCγRIII (CD16) [213], leukosialin 
(CD43), and L-selectin (CD62L) [215] have been found in PMN undergoing 
apoptosis. The apoptotic pathway in PMN is executed by caspases and involving 




Caspases are cysteine proteinases that initiate or execute cellular programs. The 
caspase family is composed of two major subfamilies that are related to either 
inflammation (e.g. caspase-1, 4, 5, 13) or apoptosis (e.g. caspase 2, 3, 6, 7, 8, 9, 10). 
Caspases are expressed as proenzymes (zymogens) that contain three domains: an 
N-terminal prodomain, the p20, and a small C-terminal domain p10 subunit. PMN 
have been reported to express a variety of caspases, including caspase-1, -3, -4, -8, 
and -9 and their activation during PMN death is well documented [216-218]. 
 
Two main pathways lead to the activation of caspase cascades. The first of these 
depends on the participation of mitochondria (receptor-independent; intrinsic 
pathway) and the second involves the interaction of a death receptor with its 
ligands (extrinsic pathway). The intrinsic apoptosis pathway is characterised by the 
loss of mitochondrial transmembrane potential and the release of pro-apoptotic 
factors such as cytochrome c, apoptosis-inducing factor (AIF), and endonuclease G 
(EndoG) into the cytosol or nuclei. Binding of cytochrome c and dATP causes the 
adaptor molecule Apaf-1 to form a large multimeric complex called the 
apoptosome. Apaf-1 in the apoptosome recruits procaspase-9 which in turn is 
processed by autocatalysis to activate the downstream execution phase of apoptosis 
[219].  
 
Although PMN contain a paucity of mitochondria and low levels of cytochrome 
c, they possess a lower threshold requirement for cytochrome c to activate caspases 
and their low content of cytochrome c is compensated by the elevated expression 
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of Apaf-1 [220]. In addition to cytochrome c, the loss of mitochondrial membrane 
potential results in the release of AIF and Endo G. Both AIF and EndoG can 
translocate into nuclei and cause nucleosomal DNA fragmentation, one of the 
hallmarks of apoptosis, leading to cell death independent of caspases [221-223].  
 
Different from the intrinsic pathway, the extrinsic apoptosis pathway is initiated 
by the activation of “death receptors” of the tumour necrosis factor receptor (TNFR) 
family instead of involving mitochondria factors. Members of this family are 
characterised by two to five copies of cysteine-rich extracellular repeats. Death 
receptors also have an intracellular amino acid stretch within the carboxy terminus 
of the receptor called the “death domain” (DD). Ligation of death receptors causes 
the rapid formation of a death-inducing signalling complex through the receptors 
DD, which is responsible for coupling the death receptor either to the activation of 
the NF-κB signalling pathway or to a cascade of caspases, resulting in apoptotic 
cell death [224]. 
 
In activating the caspase cascade, DD recruits procaspase-8. Via aggregation of 
two or more procaspase-8 molecules, procaspase-8 becomes activated and then 
goes on to trigger the apoptotic cascade [225-227]. Recent studies also revealed 
that caspase-8 could be activated by cathepsin D, which was released from 
azurophilic granules in a ROS-dependent manner, suggesting another mechanism 
of induction of PMN death mediated by granule content [228]. In addition, 
evidence indicated that inflammatory caspase members such as caspase-1 may also 
have the capacity to mediate PMN apoptosis. PMN from caspase-1-deficient mice 
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had delayed constitutive apoptosis, and LPS could not inhibit apoptosis in these 
cells, implying a combination caspases functions related to inflammation and 
apoptosis [229]. Little is known to date about the role of inhibitor of apoptosis 
proteins (IAPs), which inhibit activated caspases, in PMN apoptosis. Studies 
demonstrated that G-CSF can up-regulate cIAP2 (cellular IAP2) to promote PMN 
survival [230]. Overexpression of XIAP protects cell survival [231] while this 
factor is negatively regulated by a pro-apoptotic factor, Smac/DIABLO, which is 




PMN also express a number of proteins from the Bcl-2 family. Bcl-2 members 
possess at least one of four conserved motifs known as Bcl-2 homology domains 
(BH1-BH4) and can be subdivided into three categories according to their function 
and structure. The first class is anti-apoptotic members, such as Bcl-2, Bcl-XL, Bcl-
w, Mcl-1, and A1, which exert anti-cell death activity and most contain all four BH 
domains. The second class is pro-apoptotic members, such as Bax, Bak, Bok, 
which share sequence homology in BH1, BH2, and BH3, but not in BH4. The third 
class is “BH3-only” pro-apoptotic members, which include Bid, Bad, Bim, Bik, 
and possess only the central short BH3 domain. Subcellular localisation studies 
have shown that Bcl-2 and Bcl-XL reside on the mitochondrial outer membrane, 
while the pro-apoptotic family members may be either cytosolic or present on the 
mitochondrial membrane. During apoptosis, the pro-apoptotic Bcl-2 family 
members are activated and undergo a conformational change to form channels or to 
induce the rupture of outer mitochondrial membrane. The translocation of pro-
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apoptotic Bcl-2 family members to mitochondria facilitates cytochrome c release 
and leads to downstream caspase activation. In contrast, the anti-apoptotic proteins 
Bcl-2 and Bcl-XL prevent cytochrome c release from mitochondria and thereby 
preserve cell survival [233, 234].  
 
It is now agreed that human PMN do not express the anti-apoptotic protein Bcl-2 
but do express Mcl-1 and A1. Mcl-1 was initially isolated from a human 
myeloblastic leukemia cell line and it is increasingly recognised as a key regulator 
of immune cell proliferation and longevity. While PMN are undergoing apoptosis, 
Mcl-1 levels decline rapidly, suggesting that PMN survival is regulated by Mcl-1 
expression [235]. A1 is another protein important for PMN survival and is 
upregulated by G-CSF or LPS, mediators known to promote PMN survival [236]. 
PMN also express the pro-apoptotic proteins Bax, Bid, Bak, and Bad, which have a 
relatively longer half life than anti-apoptotic proteins and hence their constitutive 
expression explains why bloodstream PMN have such a short survival time [235]. 
Bax, which inserts to mitochondrial membrane and causes cytochrome c release, 
has been demonstrated as an important molecule in regulation of constitutive PMN 
apoptosis [237]. In addition, deletion of the BH3-only protein Bim results in PMN 
accumulation at inflammatory sites and delayed apoptosis [238]. Moreover, one of 
the BH3-only proteins, Bid, is cleaved by caspase-8 and translocates to the 
mitochondria, where it triggers cytochrome c release, demonstrating a crosstalk 






A role of calpain, a non-caspase cystein protease, in the regulation of PMN 
apoptosis has also been suggested. PMN apoptosis is blocked by inhibitors of 
calpains [240] and accelerated by reducing the levels of endogenous calpain 
inhibitor, calpastatin [241]. In support of that PMN from patients with cystic 
fibrosis that exhibited delayed apoptosis have increased calpastatin and decreased 
calpain protein levels compared with PMN from control individuals. Inhibiting 
calpain prevents the mitochondrial release of cytochrome c and blocks caspase-3 
processing and activation, leading to prolonged PMN lifespan [242]. These 
findings indicate another mechanism involving calpastatin-calpain system in the 















Fig. 1.2 Molecules involved in PMN apoptosis. Two main pathways are involved in PMN 
apoptosis: intrinsic pathway (main molecules involved are presented as blue color) and extrinsic 
pathway (red color).  Stress stimuli or pro-apoptotic Bcl-2 members Bax and Bak cause the release 
of cytochrome c from mitochondria. Cytochrome c accompanies with Apaf-1, dATP, and recruited 
pro-caspase-9 (C9) to form apoptosome, which can catalyse and activate downstream executioner 
caspase-3 (ProC3), leading to apoptosis. The effects of pro-apoptotic Bcl-2 members can be 
antagonised by the increased level of anti-apoptotic Bcl-2 proteins, such as Mcl-1 and A1. Extrinsic 
pathway, on the other hand, is mediated by the interaction of death receptors and their ligands. Pro-
caspase-8 (proC8) is recruited by death domain and autocatalysed, followed by activating caspase-3. 
In addition, Bid, a pro-apoptotic Bcl-2 member, is cleaved by caspase-8, and triggers cytochrome c 
release, representing a crosstalk between these two pathways (green color). Other mechanisms may 
also involve in PMN apoptosis, such as cathepsin D and calpain induce apoptosis by activating 
caspase-8 and inducing cytochrome c release, respectively. AIF and EndoG are released with 
cytochrome c from mithochondria to nuclei, inducing PMN death in caspase-independent manner. 
By contrast, IAP and calpastatin inhibit PMN apoptosis by inhibiting caspases and calpain, and the 




























Molecules altering PMN apoptosis 
 
PMN death is altered in the presence of stimuli such as pro-inflammatory 
cytokines, pathogen components, phagocytosis [243, 244], and other blood cells 
[245, 246], either accelerate or suppress PMN apoptosis [247]. Inflammatory 
cytokines such as IL-1β, INF-γ, G-CSF, GM-CSF, and TLR agonists have been 
demonstrated to prolong PMN survival [248-252]. The reported effects of IL-6 and 
TNF-α on PMN apoptosis are variable [253-255]. While prolonged incubation 
(>12 h) of human PMN with TNF-α can cause a decrease of apoptosis, TNF-α can 
also induce apoptosis in a sub-population of cells at earlier times of incubation (< 8 
h). TNF-α may activate a death pathway such as the mitogen-activated protein 
kinases (MAPK) pathway or caspase-8 pathway in susceptible cells, but stimulate 
an anti-apoptotic pathway mediated by NF-κB in surviving cells [180, 253, 256]. 
In addition to cytokines, hypoxic conditions at inflammatory sites delay apoptosis 
in human PMN [257, 258]. Ligation of PMN adhesion receptors can also extend 
PMN lifespan [259, 260]. Moreover, some antioxidants such as catalase delay 
apoptosis when PMN are incubated under normoxic conditions [258, 261]. 
Furthermore, dexamethasone, despite being a potent anti-inflammatory agent, has 
the paradoxical effect of inhibiting PMN apoptosis [262, 263]. Suppression of 
PMN apoptosis has been implicated in the enhancement of inflammatory responses 
and pathogen clearance. 
 
PMN apoptosis can also be actively promoted. PMN are susceptible to Fas-
induced apoptosis and an interaction between Fas and Fas ligand (FasL) was 
originally suggested as a mechanism to explain constitutive PMN apoptosis [264]. 
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However, although PMN express both Fas receptor and Fas ligand, PMN from Fas 
receptor or Fas ligand deficient mice showed normal apoptotic rate as control mice, 
arguing against the Fas/FasL system as the mechanism underlying spontaneous 
apoptosis induction in PMN [265]. In addition, PMN apoptosis is accelerated 
following bacterial ingestion as part of effective immunity, but is also accelerated 
by bacterial exotoxins as a mechanism of immune evasion. Pyocyanin, a toxic 
metabolite generated by Pseudomonas aeruginosa, has been shown to dramatically 
increase PMN apoptosis both in vitro and in vivo [266, 267].  
  
Chemicals such as cycloheximide and actinomycin D (inhibitors of translation 
and transcription, respectively) accelerate PMN apoptosis in vitro. An elegant 
study also showed that cyclin-dependent kinase (CDK) inhibitors, which were used 
as an anti-tumour drug, induced caspase-dependent PMN apoptosis in vitro by 
reducing anti-apoptotic protein Mcl-1. In vivo, CDK inhibitors also enhanced the 
resolution of established inflammation by promoting apoptosis of inflammatory 
cells, demonstrating a therapeutic potential of CDK inhibitors for inflammatory 




Necrosis is a form of cell death characterised by cell swelling and lysis. External 
factors such as infection, toxins, or trauma induces necrosis and results in the 
release of intracellular contents. As PMN are very rich in peptides, proteases, and 
oxidants, it is expected that the leakage of their highly cytotoxic contents would 
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potentiate inflammation and cause tissue injury [269]. Indeed, excessive releases of 
proteases such as elastase, a variety of inflammatory cytokines, and reactive 
oxygen species are observed in chronic inflammatory lung disorders where 
accumulated PMN lose their plasma membrane integrity [270-276]. It is also 
suggested that there is a deficiency in the capacity to engulf apoptotic PMN in 
chronic lung inflammatory diseases such as COPD and cystic fibrosis, resulting in 
pathogenic PMN apoptotic secondary necrosis [277]. Secondary necrosis of PMN, 
like primarily necrotic PMN, is believed to be pro-inflammatory by discharging 
their histotoxic mediators to the surroundings, causing tissue injury. It is also 
implicated in lung infections by Gram-negative bacteria which induce PMN death 
and impair the uptake of scavenger phagocytes [267, 278], leading to detrimental 
inflammatory conditions. In addition to inflammation, secondarily necrotic PMN 
have been found in autoimmune disorders where cell clearance is impaired and 
cells release their autoantigens and cytotoxic molecules [279-282]. These findings 
support the concept that prompt removal of dead PMN is critical to promote the 
resolution of inflammation whereas dysregulation of the process can result in 




Human PMN can undergo autophagy-like cell death following Sialic acid 
binding immunoglobulin-like lectin-9 (Siglec-9) ligation and concurrent 
stimulation with certain PMN survival cytokines [283]. However, a widely used 
inhibitor of autophagic cell death, 3-MA, failed to delay PMN spontaneous death, 
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suggesting that autophagy may not be a predominant mechanism for PMN 




A novel form of PMN death named NETosis has been described. This death 
process involves extrusions of plasma membrane and nuclear material composed of 
granule components and histone in an NADPH oxidase dependent manner [92]. 
Distinct from other modes of death, NET-induced death shows neither classical 
apoptotic morphology, nor necrotic features [285]. It is a form of active cell death 
occurring in activated PMN and allows them to bind and kill microbes effectively, 




PMN are a key component of immunity and play a major role in inflammatory 
events. Appropriate control of granulocyte function, death, and removal is critical 
to maintain tissue homeostasis. Therefore, it is necessary to gain a better 










Cells can die in a genetically controlled process (programmed cell death) or in 
response to noxious external stimuli, including heat shock, infection, oxidative 
stress, toxic challenge, or radiation, resulting in accidental cell death. Programmed 
cell death (PCD) is a well-orchestrated mechanism to eliminate damaged, used-up, 
or misplaced cells during development, homeostasis, and immune regulation of 
multicellular organisms [286, 287]. Dysregulation of cell death is associated with 
numerous pathologies, such as degeneration, autoimmunity, immune deficiency, 
and cancers. Distinct cell death pathways results in different morphological and 
physiological outcomes. Three major types of cell death, namely apoptosis, 




The term “apoptosis” was first coined by Currie and colleagues in 1972 to 
describe a type of programmed cell death that the authors repeatedly observed in 
various tissues and cell types. ‘Apoptosis’ in Greek is used to describe the ‘falling 
off’ of leaves from a tree and is to indicate the dying cells releasing contacts with 
neighboring cells and being detached from the surrounding tissue [288]. The 
authors defined apoptotic cells as sharing many morphological features including 
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cell shrinkage, chromatin condensation, and internucleosomal cleavage of genomic 
DNA [225]. The plasma membrane also underwent blebbing and divided cells into 
small apoptotic bodies which contained condensed organelles. Importantly, 
throughout the apoptotic process the plasma membrane on the dying cells remained 
intact without release of intracellular contents to surroundings, suggesting that 
apoptosis was a well-organised process of cell demise. 
 
1.4.2.1. Mechanism of apoptosis  
 
Caspase-dependent cell death 
 
The knowledge of the regulation of apoptosis is mainly based on studies of 
programmed cell death in C. elegans [289]. In this nematode, cell death protease 
(CED-3) is associated with regulated cell demise. Homologous proteins have been 
found in organisms throughout the animal kingdom, and these proteins are related 
to cell death with an apoptotic morphology [290]. To date, 13 caspases have been 
identified in mice and humans, belonging to the apoptotic and the inflammatory 
subfamilies. Apoptotic caspases can be further subdivided into initiator and 
executioner caspases. The subset of caspases that cleave selected substrates to 
produce the changes associated with apoptosis are known as executioner caspases, 
which in mammals are caspase-3, -6, and -7. In most instances, these executioner 
caspases are activated by the activated initiator caspases, such as caspase-8, 
caspase-10, caspase-2, and caspase-9 [291]. Caspase activation involves finely-
controlled cascades and directs regulated cell death. 
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All caspases are expressed as inactive proenzymes consisting of an N-terminal 
prodomain, followed by a large subunit (p20) and a small C-terminal subunit (p10). 
The long prodomain of the initiator caspases contains death domain (DD), 
including protein-protein interaction motifs belonging to death effector domains 
(DEDs) and caspase activation and recruitment domains (CARDs). Initiator 
caspases are recruited to platform molecules via these protein-protein interaction 
domains and are activated by oligomerisation and proximity-induced 
autoproteolysis. Executioner caspases, as mentioned above, are activated by 
proteolytic cleavage of upstream caspases [292, 293].  
 
Two major caspase-dependent signalling pathways are known in mammals: 
extrinsic pathway and intrinsic pathway. In the extrinsic apoptotic pathway, 
extracellular ligands such as TNF-α, FasL or TRAIL bind to the extracellular 
domains of TNF-receptor superfamily and trigger the receptor multimerisation and 
a conformational change on the cytoplasmic face of the receptors [294]. 
Recruitment of the adaptor FADD ensues, followed by recruitment and activation 
of caspase-8 [224]. Active caspase-8 then cleaves and activates the downstream 
executioner caspases-3, which is pivotal for the execution of apoptotic cell death.  
 
Intrinsic pathway, by contrast, is not activated through a transmembrane 
signalling receptor, but through the release of mitochondrial factors. Bcl-2 family 
proteins, which control mitochondrial integrity [295, 296], consists of both pro- 
and anti-apoptotic members that elicit opposing effects on mitochondria. Pro-
apoptotic members can induce mitochondrial outer membrane permeability 
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(MOMP) resulting in the release of pro-apoptotic factors. In contrast, anti-
apoptotic members such as Bcl-2 preserve mitochondrial integrity, blocking the 
discharge of intermembrane pro-apoptotic proteins [297]. During cell stress, pro-
apoptotic proteins are activated and do antagonise the anti-apoptotic Bcl-2 family 
members. Pro-apoptotic proteins oligomerise and form a channel on mitochondria 
membrane through which cytochrome c is released into cytosol. After that, 
cytochrome c associated with Apaf-1, and dATP, form a platform which is called 
apoptosome, to recruit and activate procaspase-9. Like caspase-8, activated 
caspase-9 subsequently cleaves and activates the downstream executioner caspase-
3. 
 
Both extrinsic and intrinsic pathways converge on activating downstream 
executioner caspases, which then cleave structure components, such as nuclear 
lamins and cytoskeletal proteins, and inhibitor of DFF (DNA fragmentation 
factor)/CAD (caspase-activated DNAse) [298-300], contributing to the classical 
morphology of apoptosis (cell shrinkage, chromatin condensation, and DNA 
fragmentation).  
 
There are other pathways mediate the activation of caspases, namely the 
endoplasmic reticulum (ER)-mediated pathway and the granzyme B-mediated 
pathway.  Stress induces the translocation of caspase-7 from the cytosol to ER 
surface, which then activates procaspase-12 on the cytoplasmic side of the ER by 
cleaving its prodomain [301]. The activated caspase-12 subsequently activates 
procaspase-9, and the activation further activates caspse-3, -6, and -7. Since 
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mitochondrion is not involved in this pathway, there is no cytochrome c release 
from mitochondria [291]. Moreover, granzyme B, which is a serine protease that is 
present in cytotoxic granules of CTLs and NK cells, along with other pro-apoptotic 
mediators, can induce the activation of caspase-3 [302, 303]. Granzyme B also 
cleaves Bid, which translocates to mitochondria and recruits Bax, inducing 
apoptosis in a caspase-independent manner [304].  These examples demonstrate 
that apoptosis is not only mediated by either simple extrinsic or intrinsic pathway, 
but that numerous molecules and pathways may be involved in this programmed 
cell death modality. 
 
Unsurprisingly, the expression, processing, activation, and inactivation of 
caspases are precisely controlled in normal cells. The most well-known regulators 
of caspases are inhibitor of apoptosis proteins (IAPs) [305]. IAPs are a family of 
cellular proteins, which are characterised by N-terminal baculovirus IAP repeat 
(BIR) domains and a conservative C-terminal RING domain. The BIR domain can 
bind to caspases and inhibit the activity of caspases. Although IAPs do not directly 
bind and block caspase-8, they inhibit its substrate procaspase-3, arresting the 
cascade of extrinsic apoptotic pathway. In intrinsic pathway, IAPs (mainly XIAP, 
c-IAP1, and c-IAP2) directly bind to the principal caspase, procaspase-9, 
preventing the apoptosis induced by cytochrome c release [306, 307]. Like 
caspases, the activity of IAPs is also regulated by other proteins. Smac/Diablo and 
Omi/ HtrA2, which are simultaneously released from the mitochondria with 
cytochrome c, antagonise the action of inhibitor of apoptotic proteins (IAPs), 
relieving IAPs’ inhibitory interactions with executioner caspases [308-310]. From 
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these reports, it is concluded that caspase cascades are tightly controlled, ensuring 
the proper regulation of cell death. 
 
Caspase-independent cell death 
 
Increasing evidence supports the claim that apoptosis is not exclusively 
controlled by caspase activation. As mentioned above, cytochrome c is not the only 
protein that is released from mitochondria following MOMP, and that other 
proteins originating from mitochondria may mediate cell death via different 
mechanisms. For instance, apoptosis-inducing factor (AIF) and endonuclease G 
(EndoG) are other proteins shown to be released from mitochondria during 
apoptosis. These proteins translocate to nuclei and mediate caspase-independent 
nuclear features of apoptosis such as chromatin condensation and large-scale (~50 
kb) DNA degradation [222, 311, 312]. However, in-depth studies suggest that AIF-
associated cell death appears to require specific upstream components and 
pathways. One important player is poly (ADP-ribose) polymerase 1 (PARP-1), a 
nuclear enzyme involved in DNA repair [313]. In response to excessive DNA 
damage, PARP-1-dependent death program is activated to induce the translocation 
of AIF from mitochondria to the nucleus, nuclear condensation, and 
phosphatidylserine exposure. The collapse of the mitochondrial membrane and 
translocation of AIF can not be blocked by broad-spectrum caspase inhibitors, 
suggesting this pathway is caspase-independent [314].  
 
In addition, endogenous proteases such as caplains and cathepsins can induce 
cell apoptosis. A moderate increase in cytosolic calcium is sufficient for calpain 
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activation, which cleaves the anti-apoptotic Bcl-XL and Bax (the truncated form of 
which is a more potent inducer of apoptosis than the full-length form [315]), 
promoting cell apoptosis. Moreover, these proteases cleave mitochondrial Na+/Ca2+ 
exchanger, inducing Ca2+ overload in the mitochondria and leading to sustained 
ROS production by these organelles [316], resulting in cell death. Besides calpains, 
cathepsins which are released from lysosomes to cytosol, can target mitochondria 
and Bcl-2 family members Bid, Bax, and Bak, inducing cell apoptosis [317]. 
Studies also show that endogenous calpain and cathepsins can promote AIF release, 
leading to caspase-independent cell apoptosis [318, 319]. These data indicate that 
other proteases and molecules rather than caspases can initiate the cell death 
programme. 
 
1.4.2.2. Biological significance of apoptosis 
 
Apoptotic cell death has an important role in organ and tissue remodeling during 
development. In adult organisms, apoptosis is also crucial in maintaining 
homeostasis. Several studies indicate that the role of clearance of apoptosing cells 
is not only to eliminate cell corpses, but also to degrade these cells into harmless 
and reusable molecules [320]. Apoptotic cells can be engulfed very early which 
may explain why under normal physiological conditions cells with typical 
apoptotic morphology are rarely seen in tissues [321, 322]. Dysregulation of 
apoptosis can result in the development of various pathologies, such as cancer, 
autoimmune diseases, or sepsis. Importantly, since apoptotic cells remain their 
plasma membrane integrity before being recognised and ingested by phagocytes, it 
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is generally believed that apoptotic cell death is immunologically silent and does 




In contrast to apoptosis, necrosis was considered as a disorderly mode of cell 
death. Necrotic cells take up water and swell, instead of condensing and shrinking 
as apoptotic cells do. This swelling causes the plasma membrane to burst and 
release the cytoplasmic contents to the surroundings. Although it was proposed that 
apoptosis and necrosis were two different modes of cell death involving distinct 
dying mechanisms, increasing evidence now suggests that these two dying types 
represent only the extreme ends of a continuum of cell death with shared events. 
The extent of oxidative stress, the concentration of cellular ATP content, the level 
of Bcl-2, and the mechanisms underlying the opening of mitochondria pores can 
determine the switch of these two types of cell death [323-325].  
 
Secondary necrosis, also called late apoptosis, is the disintegration of the cells 
that have undergone apoptosis, supporting the hypothesis that apoptosis and 
necrosis are part of continuum, rather than fundamentally different types of cell 
death. Secondary necrosis is presented as a mixture of genetically controlled 
apoptotic processes and a necrotic outcome with rupture of the cytoplasmic 
membrane and autolytic cell integration into cell debris [321]. Two assays which 
detect cytoplasmic permeability, namely propidium iodide (PI) and intracellular 
enzyme lactate dehydrogenase (LDH) are frequently used to evaluate necrosis, but 
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cannot distinguish between primary necrosis and secondary necrosis. In fact, 
secondary necrosis has a unique morphology characterised by the co-existence of 
apoptotic features (like nuclear fragmentation and chromatin condensation) and 
necrotic alterations (like cytoplasmic membrane permeabilisation). These cells 
may exhibit specific molecular features (eg. caspase activation, mitochondrial 
protein releases) as they have gone through the apoptotic pre-necrotic phase.  
 
1.4.3.1. Molecular mechanisms of necrosis 
 
The mechanisms involved in necrotic cell death were less understood than those 
in apoptotic cell death. Accidental necrosis results from physicochemical damage 
without involvement of underlying signalling events leading to plasma membrane 
rupture. However, over the past decade it has become evident that under certain 
circumstances, necrosis is the result of strictly regulated dying process [326]. 
Signalling pathways involved in apoptosis such as death receptor activation, the 
caspase cascade, the activation of proteases, and the mitochondrial pathway also 
participate in programmed necrosis [327-329]. 
 
It was observed that some cells stimulated with death ligands along with the 
inhibitors of apoptotic caspase cascade did not survive but died by necrosis [326, 
330, 331], suggesting the dynamic switch between necrosis and apoptosis. Studies 
in RIP1-/- Jurkat cells demonstrated that propagation of necrosis induced by 
triggering of death receptors (eg. Fas, TNF-R, and TRAIL-R) depended on the 
presence of modulator RIP1 (receptor interacting protein 1), a serine/threonine 
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kinase [332]. The term necroptosis was introduced to designate programmed 
necrosis induced by triggering of death receptors under conditions when apoptotic 
cell death execution is prevented (eg. by caspase inhibitors) [332, 333]. Although it 
occurs under regulated conditions, necroptotic cell death is characterised by the 
same morphological features as unregulated necrotic death [333].  
 
In addition to RIP1, recent studies identified RIP3 as a crucial upstream 
activating kinase that regulates RIP1-dependent necroptosis [334-336]. TNF 
treatment or triggering pathogen recognition receptors (PRRs) induce the 
formation of a RIP1-RIP3 pro-necrotic complex and subsequently induce cell 
necrosis by increasing ROS production [336, 337]. Under normal physiological 
conditions, the ligation of cells with TNF receptor stimulates either cell survival 
via NF-κB activation or apoptosis mediated through a cascade of caspase 
activation [327, 338]. However, when caspase activation is blocked, cells are 
redirected to programmed necrosis, apparently acting as a kind of back-up cell 
death pathway [286, 327, 337].  
 
Mitochondrial pathways are also involved in programmed necrosis. The BH3-
only protein Bcl-2 modifying factor (Bmf) binds to Bcl-2 and Bcl-XL, leading to 
mitochondrial outer membrane permeabilisation (MOMP) and apoptosis. Bmf is 
also identified as a core component of programmed necrosis by interfering with 
Bcl-2-mediated blockade of mitochondrial permeability transition (mPT), 
indicating roles of this factor and mitochondria at the crossroad of apoptosis and 
necrosis [328, 339]. Additionally, it has been demonstrated that sequential 
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activation of PARP-1, calpains and Bax following excessive DNA damage is 
required for AIF-induced necrosis [329], further suggesting the importance of 
mitochondria in cell necrosis. 
 
In contrast to the increasing clarification of the mechanisms underlying primary 
necrosis, the factors involved in secondary necrosis are still scarce. It is agreed that 
secondary necrosis is a separate process occurring after completion of apoptosis, 
followed by a transition to a necrotic cell. In the first process, molecular alterations 
induce the classic apoptotic morphology with intact plasma membrane enclosing 
apoptotic cells or apoptotic bodies. The typical apoptotic process is subsequently 
followed by development of necrotic morphology, with the alterations involving 
activation of self-hydrolytic enzymes, swelling of the cells or apoptotic bodies, and 
rupture of the cytoplasmic membrane [277]. Similar to primary necrosis, the 
involvement of ROS production is suggested in the transition to secondary necrosis 
[277]. In addition, calpains and lysosomal enzymes have been found to participate 
in the cytoplasmic membrane damage in secondary necrosis [340-342]; inhibition 
of lysosomal enzymes results in inhibition of secondary necrosis in epithelial cell 
lines [343]. These findings indicate that molecules directly involved in the 







1.4.3.2. Physiological significance of necrosis 
 
It has been proposed that under some conditions necrosis is involved in 
physiologically relevant processes and can substitute for apoptosis to eliminate 
unwanted cells. For example, during the development, removal of interdigital cells 
in the presence of the caspase inhibitor or in Apaf-1-/- mice occurs by a caspase-
independent necrosis-like process [344]. Additionally, necrosis can function as a 
backup mechanism to eliminate damaged cells infected by some viruses and 
intracellular bacteria which suppress caspases or apoptotic signals [334, 337, 345]. 
Induction of necrosis under these conditions will also activate immune responses, 
promoting recovery of hosts. However, inefficient clearance of necrotic cells may 
result in the spread of pathogens. 
 
It is generally believed that necrotic cell death is often associated with 
pathological conditions. In necrosis, the cellular content leakage and cytokine 
secretion into the extracellular environment [15], where they may act a “danger 
signal” and are associated inflammation. Several mediators have been described as 
endogenous danger signals, including defensins, cathelicidins, uric acid, proteases, 
nucleosomes, high-mobility group box (HMGB1) protein, and heat shock proteins 
(HSP) [346-350]. As an example, high mobility group 1 (HMGB1) protein, which 
acts as an architectural chromatin-binding factor, is secreted passively by necrotic 
or damaged cells. Outside the cells, it binds with high affinity to RAGE (the 
receptor for advanced glycation end products) and TLR, mediating inflammatory 
signals [351, 352]. In apoptotic cells, HMGB1 is bound firmly to chromatin 
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because of generalised underacetylation of histone, or is oxidised by activated 
caspases during apoptosis, thus withholds the signal to activate inflammatory and 
immune responses [346, 353, 354]. Recently, Yamasaki et al. demonstrated that a 
nuclear protein (SAP130) is released by late apoptotic or necrotic cells and can be 
recognised by Mincle, a transmembrane C-type lectin receptor (CLR) mainly 
expressed in macrophages. Macrophages are then activated to produce 
inflammatory cytokines and chemokines, confirming that “danger signals” from 
necrotic cell death can promote inflammation [355]. 
 
The biological significance of secondary necrosis is less understood [356] as 
initially it was regarded as an in vitro condition deprived of proper scavenger 
system that does not occur in vivo. However, more evidence suggests that 
secondary necrosis does exist in physiolgical conditions, such as in lactating breast 
[277]. When secondarily necrotic cells are shed into ducts (like breast alveolar 
lumen, guts, and airway lumen), they could be expelled and the release of their 
cellular contents may not be critical [277]. However, when the load of dying cells 
exceeds the local capacity for phagocyte-mediated clearance in solid organs, 
secondary necrosis could be pathological through the uncontrolled release of 
cellular components. The leakage of cell contents may cause tissue injury, and the 
secondarily necrotic cells or their debris may be taken by antigen presenting cells, 
inducing inflammation and autoimmunity. For example, secondary necrosis of 
hepatocytes resulting in severe hepatitis has been described in animal models with 
extensive hepatocyte apoptosis induced by stimuli (eg. death receptor ligands, toxic 
substances) [357-359]. Secondary necrosis is also found in brain subjected to focal 
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ischemia [360], acute myocardia infarction [361], and cystic fibrosis (CF), and 
systemic lupus erythematosus (SLE) [12]. Thus, extensive and persistent secondary 




Pyroptosis is a more recently recognised form of regulated cell death with 
morphological and biochemical properties distinct from necrosis and apoptosis 
[362]. Pyroptosis occurs most frequently in monocytes, macrophages, and dendritic 
cells upon infection with intracellular pathogens (for example, Salmonella, 
Francisella and Legionella) and is likely to form part of the antimicrobial response. 
This death modality is caspase-1-dependent and characterised as cell death with 
plasma membrane rupture, cellular swelling, osmotic lysis, and activation and 
release of IL-1 family cytokine and other cellular contents. Features characteristic 
to apoptotic pathways such as loss of mitochondrial integrity and release of 
cytochrome c do not occur during pyroptosis [363]. Although pyroptosis is 
regarded to be a form of programmed cell death, it is clearly different from the 
immunologically silent cell death represented by apoptosis. Thus, the term 
pyroptosis (from the Greek ‘pyro’, relating to fire or fever, and ‘ptosis’, meaning a 
falling) is used to describe the inherently inflammatory process of this caspase-1-





1.4.4.1. Mechanism of pyroptosis 
 
Pyroptosis retains morphological features from both apoptosis and necrosis. In 
pyroptotic cell death, caspase-1 mediates pore formation on the plasma membrane 
of host cells, resulting in dissipation of the cellular ionic gradient. The drop of 
ionic gradients produces a net increased osmotic pressure, water influx, and cell 
swelling, eventually resulting in osmotic lysis and release of inflammatory 
intracellular contents [365].  Pyroptotic cells also undergo DNA fragmentation and 
nuclear condensation like apoptotic cells but the mechanisms underlying this are 
distinct and still unclear [366]. 
 
Instead of the apoptotic caspases, caspase-1 is the enzyme that mediates this 
process of cell death. Like all caspases, caspase-1 is present in the cytosol as an 
inactive zymogen. After stimulation by microbial and endogenous signals, the 
dormant procaspase-1 zymogen is self-activated by proteolytic cleavage into the 
enzymatically active heterodimer composed of two 10- and 20- kilodalton subunits 
[367]. In analogy to activation of caspase-9 in the apoptosome, caspase-1 is 
activated in a complex called the inflammasome. The inflammasome, a molecular 
platform for recruitment and activation of procaspase-1, is composed of Nod-like 
receptor (NLR) family members and the adaptor ASC [368]. NLRs detect 
conserved microbial structures called ‘pathogen-associated molecular patterns’ 
(PAMP) or danger-associated molecular patterns (DAMP) (i.e. uric acid crystals, 
asbestos, or silica) in host cytosol and drive the formation of inflammasomes [369, 
370]. To date, four inflammasomes have been characterised, namely NLRP1, 
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NLRP3, NLRC4/IPAF and AIM2 inflammasomes according to the NLR involved 
[366, 371]. However, the precise mechanism by which the activation of various 
inflammasomes by diverse stimuli remains elusive. 
 
Active caspase-1, however, does not only contribute to cellular demise, but also 
to the cleavage of pro-inflammatory cytokines into their mature, biologically active 
form. The inflammatory cytokines IL-1β and IL-18 undergo caspase-1-dependent 
activation and secretion during pyroptosis [366]. IL-1β is a pro-inflammatory 
cytokine produced mainly by immune effector cells. It functions in many aspects 
of immune and inflammatory responses by generating fever, activating immune 
cells, and promoting the recruitment of leukocytes to the affected sites. IL-1β is the 
primary cause of inflammation and has been implicated in a variety of 
inflammatory disorders [372-374]. IL-18 induces INF-γ production and is 
important for the activation of T cells, macrophages and other cell types [375, 376]. 
Through these mechanisms, caspase-1-mediated processing of IL-1β and IL-18 is a 
crucial component of the host defence against infections. 
 
Two signals are required for the production and release of IL-1β and IL-18 (Fig. 
1.3). The first signal is pro-inflammatory cytokines such as TNF-α, IL-1, and TLR 
ligands which induce the transcription of IL-1β mRNA in immune effector cells 
[377, 378]. The second signal, such as ATP, triggers the P2X7 receptor, causing 
potassium efflux [379, 380]. The drop of intracellular potassium results in 
assembly of the inflammasome components with inactive procaspase-1. 
Procaspase-1 is then processed into active form, followed by process of the 31-kDa 
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inactive IL-1β precursor form into the bioactive 17-kDa IL-1β. An influx of 
calcium into the cell with an increase in intracellular calcium levels provides a 
mechanism by which mature IL-1β is released from the cell [373]. Other second 
signals can come from the cathelicidin-derived peptide LL-37 [29] or bacterial 
toxin nigericin ionphore [381], leading to pore formation and intracellular 
potassium efflux. This two-step process ensures the well-regulated release of pro-
inflammatory IL-1β and IL-18. 
 
Interestingly, although formation of caspase-1-dependent pores in the plasma 
membrane is correlated with cytokine release [365], cell lysis or cell death is not 
always required for the release of activated IL-1β and IL-18. Pharmacological 
inhibition of cell lysis does not prevent caspase-1-dependent pore formation or 
cytokine secretion [365], suggesting that cytokine secretion and cell death are both 
















Fig. 1.3 Steps in the synthesis and secretion of IL-1β induced by IL-1β (or can be substituted 
by other pro-inflammatory cytokines and TLR ligands). Primary blood monocytes or tissue 
macrophages are activated by pro-inflammatory stimuli (step 1) to increase the transcription (step 2) 
and translation (step 3) of precursor IL-1β. Secondary stimulus such as ATP, nigericin, or bacterial 
toxins then signals through P2X7 receptor (step 4), leading to a rapid efflux of potassium from the 
cell (step 5a). The drop of intracellular levels of potassium (step 5b) triggers the assembly of 
inflammasome (step 6). The assembled components of the inflammasome initiate the processing of 
procaspase-1, resulting in the formation of active caspase-1. Active caspase-1 processes the IL-1β 
precursor (step 7) to generate mature IL-1β, followed by secretion of active mature form of IL-1β to 
extracellular environment (step 8 & 9). The figure is taken from Dinarello CA. Annu. Rev. 






1.4.4.2. Biological significance of pyroptosis 
 
Pyroptosis is part of the host defence system against pathogens and a potent 
inducer of inflammation. Mice deficient in caspase-1 (which lack the capacity of 
pyroptosis and activation of the pro-inflammatory cytokines IL-1β and IL-18) are 
more susceptible to infection than wild type mice and IL-1β and IL-18 double 
knockout mice. These observations suggest that pyroptosis or other caspase-1-
dependent events, instead of cytokines alone, are involved in the control of 
infection. However, inappropriate or overwhelming caspase-1 activation can be 
detrimental and results in pathological inflammatory diseases [366]. 
 
1.4.5. Conclusion  
 
Cells can die by distinct mechanisms with differing impacts on inflammation 
and immune response. Physiological cell death such as apoptosis is thought to be 
anti-inflammatory and intrinsically immune tolerogenic, whereas pathological cell 
death (necrosis or pyroptosis) is inherently immunogenic and elicits inflammatory 
reaction [382]. Apoptotic cells remain intact membrane integrity, preventing 
intracellular content from being discharged, and also possess modified 
immunostimulatory molecules to promote tolerance [383]. However, this concept 
is oversimplified and controversial as cells dying by apoptosis can be highly 
immunogenic [384-386], whereas necrotic cells can be anti-inflammatory in certain 
circumstances [387, 388].  
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Different forms of cell death may occur concomitantly under physiological or 
pathophysiological conditions, and their impacts on inflammation and immune 
responses merit further investigation. It seems that cells are equipped with a range 
of machinery to undergo different forms of cell death, and that different stimuli in 
various environments at varied time points can result in diverse outcomes. Thus, 
the identification of the mechanisms that regulate the different modalities of cell 























Phagocytosis (from Greek, phago- ‘eating’, -cyte ‘vessel’, -osis ‘process’) was 
described in the late 19th century by the Russian biologist Ilya Metchnikoff, who 
observed that amoeboid-like cells in transparent sea star larvae contained ingested 
cells. In lower organisms this process is used to internalise nutrients from their 
surrounding milieu, whereas in multicellular organisms, phagocytosis has adopted 
an important role in host defence and tissue homeostasis [390].  
 
Phagocytosis is defined as a process of uptake of large particles (> 0.5 µm) into 
cells dependent on receptor recognition. The engulfing processes form phagosomes 
and subsequently fuse with lysosomes to become phagolysosomes where the 
ingested material is digested or degraded [391]. Monocytes/ macrophages, 
immature DC, and PMN are very efficient at internalising particles thus have been 
referred to as professional phagocytes. On the other hand, most of cells (except 
lymphocyte and red blood cells) have some phagocytic capacity and are termed as 





1.5.2. Main purposes of phagocytosis 
 
Two main purposes of phagocytosis have been described: “sensing the invaders” 
and “burying the corpses” [390]. Containment of infection can be achieved by 
ingestion and degradation of pathogens. A wide range of receptors act in 
surveillance and recognise the conserved molecular pattern of microorganisms, 
followed by degradation of microbes. The other goal of phagocytosis is to ensure 
the safe disposal of unwanted cells from self, which is a fundamental element to 
regulate normal tissue turnover and homeostasis. [393]. In this chapter, I will focus 
on phagocytosis of dead cells and the ensuing biological responses. 
 
1.5.3. Factors affect the rates of phagocytosis 
  
The capacity and efficiency of phagocytosis can be modulated by the presence 
of cytokines, pathogen metabolites, and pharmacological agents [266, 394-397]. 
Studies reveal that pro-inflammatory mediators such as LPS, HMGB1, and TNF-α 
inhibit apoptotic PMN being taken up [396, 398]. Additionally, bacteria 
metabolites and proteases during infection may also interfere with the efferocytosis 
of dead cells [399, 400]. Glucocorticoid, by contrast, reverses the pro-
inflammatory stimuli-mediated inhibition of phagocytosis and plays an important 
role in therapeutics of inflammatory diseases [394, 396]. These findings suggest 
that several factors present at affected sites can modulate the efficiency of cell 
clearance by phagocytes. 
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1.5.4. Molecules involved in recognition and clearance 
of apoptotic cells 
 
The most favourable fate for dying cells, to avoid inflammation and host damage, 
is removed by phagocytes, avoiding dead cells from releasing cytotoxic substances 
that can damage neighboring cells [15, 390, 401]. This process has been named 
‘efferocytosis’ (from effero-to carry to the grave, to bury in Greek). Clearance of 
apoptotic cells involves an elaborate combination of mechanisms of “tethering” 
and “tickling” [402]. This involves a large variety of eat-me signals which ensure 
the first tethering of the apoptotic cell to the phagocyte, followed by the interaction 
of molecules and receptors on target cells and phagocytes, triggering the process of 
internalisation [401, 402].  
 
1.5.4.1. Come-get-me signal 
 
The first step in the process is recruitment of professional phagocytes to the sites 
of the apoptotic cells. To attract phagocytes, apoptotic cells can secret lipid factors 
such as lysophosphatidylcholine (LPC) in a caspase-3-dependent fashion [403]. A 
recent study revealed that nucleotides released by apoptotic cells can also act as a 
find-me signal to promote recruitment of phagocytes, facilitating dead cell 
clearance [404]. Another interesting report showed that apoptotic cells can also 
release lactoferrin, which inhibits migration of granulocytes but attracts 
mononuclear phagocytes. These data suggest a well-regulated system controlling 
recruitment of phagocytes to remove unwanted dead cells [405, 406]. 
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1.5.4.2. “Eat-me” signal 
 
Once recruited phagocytes arrive in the sites, they have to recognise their targets 
first. Molecules that newly appear on the cell surface and existing molecules 
altered by oxidation and modification during apoptosis serve as “eat me” signals to 
facilitate recognition and ingestion by phagocytes [407-409]. The best 
characterised is the loss of phospholipid asymmetry and the translocation of 
phosphotidylserine (PS) from the inner to the outer leaflet of the plasma membrane, 
which occurs very early during apoptosis [407, 409]. Studies showed that apoptotic 
targets that failed to express PS or that had masked PS were not recognised and 
engulfed by phagocytes [410, 411], suggesting the importance of PS exposure for 
phagocytosis. However, a study showed that PS externalisation on apoptotic cells 
alone is not sufficient to trigger cell clearance. Instead, the presence of oxidised PS 
in conjunction with non-oxidised PS on cell surface is required for removal of 
apoptotic cells [412].  In addition, a study using nematode Caenorhabditis elegans, 
demonstrated that annexin I, which co-localises with PS and is also externalised 
during apoptosis, is required for efficient clearance of apoptotic cells [413]. 
Interestingly, living cells also expose PS, such as activated B cells and T 
lymphocytes although the change of PS distribution serves different functions [414, 
415], suggesting that PS externalisation is not the only factor to serve as 
recognition ligand. Indeed, calreticulin is another general ligand of apoptotic cells, 
binding and activating LDL-receptor-related protein (LRP) on the engulfing cells 
[416]. Since both surface PS and calreticulin can also be found on viable cells, it 
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was proposed that there must also be molecules expressed on living cells which 
protect them from efferocytosis [416-418]. 
 
1.5.4.3. “Don’t eat-me” signal 
 
Living cells protect themselves from engulfment by expressing “don’t eat-me” 
signals. Brown et al. demonstrated that an interaction between CD31 molecules on 
living leukocytes and macrophages mediated the detachment of leukocytes from 
macrophages [419]. During apoptosis, this detachment signal is disabled, therefore 
enabling the phagocytosis of dying cells. Thus, CD31, a member of the 
immunoglobulin superfamily functions as a “don’t eat-me” signal [419].  In 
addition, CD47 on red blood cells serves as a don’t-eat-me signal, acting through 
the SIPRα receptor [416-418]. The knowledge of “don’t eat-me” signal had been 
limited on CD31 and CD47 until recently, a novel “don’t eat-me” signal, 
plasminogen activator inhibitor-1 (PAI-1), was found [420]. PAI-1, an inhibitor of 
fibrinolysis, has been found having elevated levels in inflammatory conditions, in 
which activated PMN accumulate in tissues and contribute to organ dysfunction. 
Study showed that phagocytosis of viable PAI-1 deficient PMN and PMN treated 
with anti-PAI-1 antibodies was enhanced associated with the increased expression 
of calreticulin and LRP [420]. These data suggest that both “eat-me” and “don’t 







Several macrophage receptors have been implicated in efferocytosis, including 
phosphatidylserine (PS) receptor [421], complement receptors [422], scavenger 
receptors [423], the αvβ3/CD36/thrombospondin recognition receptors [424], CD14 
[425], and CD44 [426]. Blocking each of these receptors alone causes partial 
inhibition of apoptotic cell engulfment, suggesting a redundancy in the engulfment 
pathways [427].  
 
Phosphatidylserine receptor (PSR) 
 
As mentioned above, transposition of PS from the inner leaflet of the plasma 
membrane to the outer leaflet is a hallmark of cells undergoing apoptosis. Several 
groups had claimed that PSR was required for clearance of apoptotic cells in vitro 
and in vivo [413, 428, 429]. It was believed that human and mouse macrophages 
express the Psr gene, and mice genetically deficient in this gene had accumulation 
of dead cells in the lung and brain during embryogenesis, suggesting its role in 
dead cell removal [429]. However, later studies challenged this original hypothesis, 
demonstrating the nuclear localisation of Psr protein, rather than a transmembrane 
receptor for apoptotic cell recognition [430]. In addition, a comprehensive 
investigation of apoptotic cell clearance in vivo and in vitro demonstrated that 
engulfment of apoptotic cells was normal in Psr knockout mice, suggesting that 
other receptors of PS may be involved in efferocytosis. 
 
73 
Recently, researchers discovered three novel PSR through which apoptotic cells 
are removed by macrophages. Park et al. showed that stabilin-2, which is a 
scavenger receptor, functioned as a PSR and downregulation of this receptor on 
macrophages resulted in decreases of apoptotic cell removal [431]. In addition, 
BAI1, belonging to G-protein-coupled receptor family, served as an engulfing 
receptor in both the recognition and subsequent internalisation of apoptotic cells 
through binding to PS. Knockout of BAI1 in phagocytes resulted in a decreased 
uptake of apoptotic cells [432]. Moreover, Miyanishi et al. identified Tim4 as a 
PSR, showing that inhibition of Tim4 in vivo leaded to an accumulation of 
apoptotic corpse in the thymus and the development of autoantibodies [433]. These 
reports demonstrate that several receptors are involved in the recognition of PS 
expressed on apoptotic cells. 
 
Other receptors than PSR 
 
In addition to the extensively-studied PS receptors, other receptors also mediate 
the recognition and ingestion of dead cells. For example, complement receptors of 
macrophages (CR3 and CR4) can recognise apoptotic cells through detecting the 
complement proteins (iC3b) which bind to exposed PS [422, 434]. Moreover, 
CD36, a class B scavenger receptor, associated with vitronecin (αvβ3 integrin) and 
bridging molecule thrombospondin, promotes binding and uptake of apoptotic cells 
by macrophages [424, 435, 436]. Macrophages derived from CD36 and αvβ3 
integrin knockout mice show significantly reduced apoptotic cell phagocytosis 
[437]. Scavenger receptors other than CD36 have also been implicated in the 
clearance of dying cells [423]. For instance, class A macrophage scavenger 
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receptor (SR-A) has been shown to play a role in the engulfment of apoptotic 
thymocytes. Blockage of the receptor by antibody or disruption of receptor genes 
reduces the dead cell ingestion [423]. Furthermore, CD14 and CD44 on the surface 
of macrophages play important roles in efferocytosis [425]. CD14 mainly functions 
as a co-receptor for LPS/ LPS-binding protein, and can interact with apoptotic cells 
with a region identical to, or closely associated with, a region known to bind LPS 
[425]. CD44, a receptor with broad ligand specificity, has been proposed to trigger 
the rearrangement of cytoskeletal proteins upon stimulation [438]. Ligation of 
human macrophage surface CD44 by divalent monoclonal antibodies augments the 
capacity of ingesting apoptotic PMN in vitro, suggesting that receptor cross-linking 
is a prerequisite for this process [439]. In vivo study showed that CD44-deficient 
mice had reduced capacity to clear apoptotic PMN, demonstrating a critical role for 
this receptor in clearance of dying cells [440]. In summary, there is a redundancy 
of receptors involved in the engulfment pathways to ensure efficient removal of 
apoptotic cells. 
 
1.5.4.5. Bridging molecules 
 
Most of receptors mentioned above do not directly bind to apoptotic cells, but 
engage dying cells via a broad range of bridging molecules. For example, β2 
glycoprotein [441], milk fat globule protein (MFG-E8) [442], protein S [443], 
growth arrest-specific 6 (Gas6) [444], and thrombospondin [424] facilitate 
interactions between macrophages and exposed PS on apoptotic cells. Bridging 
molecules preferentially interact with the oxidised form of PS and promote the 
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recognition of surface-modified dying cells. Thus, the process of recognition and 
clearance of apoptotic cells involves numerous molecules, dependent on the 
divergent receptors expressed on phagocytes. 
 
1.5.5. Molecules involved in recognition and clearance 
of necrotic cells 
 
 It is still elusive how phagocytes recognise necrotic cells  although it has been 
shown that necrotic cells also externalise PS [445] and can be recognised through a 
PS-dependent mechanism [446, 447]. The studies also reveal that phagocytosing 
necrotic cells is less effective than phagocytosing apoptotic cells [446, 447], 
suggesting that the response to phagocytosis of dead cells is more complex than 
simply a response to externalised PS. In addition, studies have been suggested 
overlap in other receptors involved, with the αvβ3/CD36 system and CD14 
implicated in uptake of primary necrotic lymphocytes by macrophages as well as in 
the clearance of apoptotic cells [388].  However, others have demonstrated that 
recognition of apoptotic and necrotic cells occurs via distinct non-competing 
mechanisms [446, 448]. These observations indicate that the existence of common 
pathways for recognising dead cells, with additional mechanisms specific to 




1.5.6. Macrophages ingest apoptotic PMN 
 
Clearance of dead PMN by phagocytes is a critical process to modulate 
inflammtory responses. Under physiological conditions, the speed of 
phagocytosing demised PMN is very quick to prevent toxic intracellular content 
release. Removal of dying PMN has been studied mainly using human monocyte-
derived macrophages. The recognition of apoptotic PMN by macrophages involves 
a change of membrane polarity and a reduction in the expression of surface 
molecules, such as CD16 and CD32. The reduction of CD16 occurs simultaneously 
with PS externalisation while the decrease of CD32 increases the binding of 
opsonins, both of which enhance phagocytosis [449, 450]. Scavenger receptors, 
lectin-like receptors, and CD44 have also been implicated in ingestion of apoptotic 
PMN, but CD14 has only minor significance [435]. 
  
Contrary to the previously dominant paradigm, the recognition of PS as an ‘eat 
me’ signal may not be critical for the removal of apoptotic PMN by resting 
macrophages. Growing evidence suggests other molecules may be involved in 
signalling the clearance. For example, Barth’s syndrome (BTHS), where nearly 
80% of circulating PMN have externalised PS, does not increase the engulfment by 
macrophages [451]. In addition, pretreatment of apoptotic PMN with bacterial 
proteinase resulted in a significant increase in cell uptake by macrophages without 
any change in PS distribution [400]. However, although data showed that 
unstimulated macrophages phagocytose apoptotic PMN mainly using the 
ανβ3/CD36/TSP mechanism, glucan-stimulated macrophages exploit PSR to 
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recognise apoptotic PMN [435]. Thus, the system used for phagocytosing apoptotic 
PMN, like uptake of other types of dead cells, involves a variety of receptors and 
molecules, providing efficient ways of clearance.   
 
1.5.7. Modes used by macrophages to clear apoptotic 
and necrotic cells 
 
Two modes of phagocytosing dead cells have been observed dependent on 
morphological differences: zipper-like phagocytosis and spacious 
macropinocytosis. Zipper-like interaction is found when targets are surrounded by 
pseudopods from phagocytes and surfaces of targets and phagocyctes are tightly 
apposed with no solute taken up during internalisation [452]. In contrast, 
macropinocytosis is characterised with cell surface ruffling and formation of 
membrane invaginations wherein large amounts of external solute are internalised 
together with targets [453]. 
 
The mechanisms responsible for the clearance of dying cells are still 
controversial. Some studies by microscopy show that apoptotic cells are taken up 
by complete engulfment of membrane-bound apoptotic bodies which form tight 
fitting phagosomes without ingestion of fluorescent fluid phase tracer. In contrast, 
primary and secondary necrotic cells are internalised by formation of spacious 
macropinosomes accompanied by uptake of fluid [446, 454, 455]. However, other 
groups have the opposing findings, demonstrating ingestion of apoptotic cells by 
macropinocytosis rather than zipper-like phagocytosis [456]. Irrespective of these 
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findings, these data suggest that different modes for internalisation of apoptotic and 
necrotic cells do exist and may well exist and may be significant in explaning the 
different biological consequences [15, 446].  
 
1.5.8. Consequences for inflammatory and immune 
responses 
 
Increasing number of studies indicate the importance of the nature of cell death 
and phagocytosis in determining following inflammatory consequences. It has been 
widely accepted that the removal of apoptotic cells by phagocytes is non-phlogistic 
whereas the clearance of necrotic cells promotes inflammation [457].  
 
1.5.8.1. Inflammatory impacts of apoptotic cell 
phagocytosis 
 
Fadok et al. first revealed that phagocytosis of apoptotic PMN was not only a 
non-inflammatory process but also actively inhibited the production of cytokines 
such as IL-1β, IL-8, IL-10, GM-CSF, and TNF-α by activated human monocyte-
derived macrophages in vitro [13]. In contrast, the production of anti-inflammatory 
cytokines like TGF-β1 and prostaglandin E2 was increased, suggesting that the 
interaction with apoptotic cells induced anti-inflammatory or suppressive 
properties in human macrophages [13]. Further studies have supported these 
observations, claiming that efferocytosis of apoptotic cells by phagocytes is anti-
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inflammatory and immunosuppressive [14, 458-460]. Molecules involved in 
orchestrating clearance of apoptosis and promotion of tolerance are widely studied. 
Recently, PPAR-δ, a sensor of fatty acids, was also identified as a critical receptor 
to sense lipid flux of engulfing apoptosis, leading to an inflammation-dampening 
result [461]. 
 
Although efferocytosis of apoptotic cells may be primarily anti-inflammatory, 
different receptors involved in apoptotic cells uptake may alter inflammatory 
outcomes. In contrast to the anti-inflammatory effects of apoptotic PMN uptake 
through VnR/CD36 mechanism, phagocytosis of immunoglobulin G-opsonised 
apoptotic cells, mediated by the FcR, increased pro-inflammatory cytokine 
production [13]. In contrast, complement-dependent apoptotic cell clearance by 
MDM has been shown to be anti-inflammatory by blocking NF-κB activation 
albeit that the anti-inflammatory effects are independent of IL-10 and TGF-β [462]. 
However, other reports suggest that apoptotic cell interaction or contact with the 
phagocyte is sufficient to inhibit pro-inflammatory cytokine production, prior to 
internalisation or phagocytosis [462, 463]. The complexity of molecules and 
mechanisms involved in dead cell phagocytosis may explain these results in 
different experimental systems. 
 
In addition to in vitro studies, an in vivo mouse model has been used to 
demonstrate that administration of apoptotic cells can protect mice against LPS-
induced shock. The study suggested that LPS can quickly bind to apoptotic cells 
and these LPS-coated apoptotic cells can be recognised and cleared by 
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macrophages in a CD14/thrombospondin/vitronectin receptor-dependent manner, 
accompanied with suppression of proinflammatory cytokine production [464]. 
Anti-inflammatory effects of apoptotic cells are therefore not only seen in vitro 
conditions, but also mediate protective function against inflammation in vivo.  
 
However, other studies suggest that apoptosis is not anti-inflammatory nor 
beneficial to the host under certain conditions. For instance, it has been shown that 
Fas/ FasL-mediated lung epithelial apoptosis induced release of pro-inflammatory 
cytokines such as TNF-α, leading to inflammation and progression to fibrosis 
[465]. In addition, another in vivo study demonstrated that transfer of apoptotic 
cells exacerbated CLP-induced sepsis [466]. Furthermore, the 
inflammomodulatory effects of apoptosis can be exploited by intracellular 
pathogens such as Trypansoma cruzi to subvert macrophage response, with the 
induction of anti-inflammatory mediators enhancing the growth and survival of the 
parasites [467].  
 
Taken together, all of these findings indicate a diversity of inflammatory 
consequence of phagocytosing apoptotic cells. This may be attributable to the 
complexity of interplay between phagocytes and target cells, and indicates that the 





1.5.8.2. Inflammatory impacts of necrotic cell 
phagocytosis 
 
When it comes to the inflammatory consequences of removal of necrotic or 
lysed cells, the opinions are controversial. However, the prevailing paradigm has 
been claimed that necrotic cells are pro-inflammatory to phagocytosis. Several 
studies suggest that necrotic cells act as a ‘danger signal’ to initiate inflammatory 
responses and mediate activation and maturation of professional phagocytes, such 
as macrophages and dendritic cells [14, 355, 468-470]. Necrotic cells release their 
intracellular proteases which can cleave phagocytic receptors or molecules, 
hindering the clearance of dying cells and resulting in persistent inflammation [269, 
275, 471, 472]. In addition, necrosis leads to release of histotoxic contents like 
proteases and danger signals, leading to tissue damage and further promoting 
inflammation. However, contrasting findings indicate that not all necrotic cells 
behave in the same way. Under certain conditions, necrosis exerts anti-
inflammatory effects on macrophages [446, 447], which may be dependent on PS 
exposure [473]. However, it is unclear whether such anti-inflammatory signals may 
be overridden by pro-inflammatory factors released during necrosis. Because 
necrosis is such a heterogenous cell death mode, it is perhaps not surprising that 




1.5.8.3. Inflammatory impacts of disposal of secondary 
necrosis 
 
The effect of phagocytosis of late apoptotic cells (apoptotic cells that have lost 
membrane integrity), also referred to as post-apoptotic or secondarily necrotic cells, 
is more uncertain [356]. According to many models, late apoptotic cells should 
behave like necrotic cells, due to the loss of cell membrane integrity and release of 
potentially inflammatory intracellular contents [474, 475]. Delayed or altered 
clearance of apoptotic cells leads to sustained inflammation and a variety of 
autoimmune diseases [279, 280, 476]. Cystic fibrosis (CF) lung, for example, is a 
chronic inflammatory condition characterised by chronic bacterial infection and 
massive PMN accumulation. CF patients have significantly higher levels of 
secondarily necrotic PMN in lung, which may be associated with the persistent 
chronic inflammation and clinical impairment [278, 472]. Furthermore, 
autoantibodies from SLE patients opsonise secondarily necrotic cells, and can 
enhance the secretion of inflammatory cytokines upon phagocytosis [477]. 
However, inconsistent with the idea that secondary necrosis is pro-inflammatory, 
some groups have shown that irrespective of membrane integrity, apoptotic cells 
do not become pro-inflammatory through the induction of secondary necrosis [478, 
479]. Late apoptotic cells have equivalent anti-inflammatory effects [448] and 
delayed clearance alone cannot lead to autoimmunity [479-481]. Thus, the impact 
of secondary necrosis upon inflammation remains unclear. 
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1.5.8.4. Immune responses of disposal of dead cells 
 
Apoptosis was proposed to be immunologically silent, whereas necrosis was 
proposed to stimulate an immune response [288]. The uptake of apoptotic cells by 
DCs fails to stimulate activation and antigen presentation [482, 483], whereas 
exposure to necrotic cells, particularly those derived from tumours and their lysates, 
does [14]. However, this idea has been challenged by various observations 
showing that certain subtypes of apoptosis can be immunogenic. For example, the 
apoptosis of tumor cells induced by certain chemotherapy was shown to prime an 
immune response [384]. In addition, antigens from apoptotic cells have been 
shown to be effectively cross-presented to cytotoxic T cells (CTLs) and prime an 
immune response [385, 386, 484].  Recently study further demonstrated that a C-
type lectin receptor CLEC9A (also known as DNGR-1) on dendritic cells can 
recognise signals exposed on necrotic cells, resulting in immunogenicity [470]. 
Taken together, whether a cell undergoes necrosis or apoptosis does not predict 




The biological significance of phagocytosis of dying cells is not only to remove 
dead cells but also to serve a mechanism to modulate consequent inflammatory 
responses. The mechanisms of phagocytosis of dying cells and consequent 
responses are dependent upon the cell type, the means of induction of cell death, 
the stage of apoptosis or necrosis, the type and state of differentiation of the 
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phagocyte, and the surrounding microenvironment [10]. The complexity of factors 
involved may provide an explanation to the various inflammatory and immune 
outcomes after cell clearance.  
 
However, the inflammatory and immune consequences of phagocyte uptake of 
dead cells appear to be more complex than initially proposed. At inflamed sites, 
mixtures of apoptotic and necrotic cells may be presented to phagocytes in the 
presence of other inflammatory factors. Despite data demonstrating anti-
inflammatory effects of both early and late apoptotic cells are completely dominant 
over the pro-inflammatory effects of the necrosis [448, 462, 479], it is unclear 
whether this applies in all scenarios. More studies are required to investigate the 
inflammatory impacts of dead cells on physiological or pathological circumstances. 
 
1.6. Hypothesis and aims of work 
 
CHDP possess multiple immunomodulatory functions on immune effector cells, 
particularly on the first-line defence cell, PMN. Since PMN death and removal 
play pivotal roles in determining the following inflammatory consequences, I 
hypothesised that LL-37 could modulate cell death in human PMN, in vitro and in 
vivo, to influence inflammatory responses. My studies therefore focus on the 
effects of CHDP on human PMN death, and the impacts of CHDP on inflammatory 
responses, by modulating cell death and by altering cytokine production in 































Arg-Gly-Glu-Ser (RGES), Arg-Gly-Asp-Ser (RGDS), oATP, KN-62, and nigericin 
were bought from Sigma-Aldrich (Poole, UK). WRW4, pertussis toxin Bordetella 
pertussis (PTX), and caspase-1 inhibitor (cell-permeable, YVAD-CHO) were 
purchased from Calbiochem/ Merck Biosciences Ltd. (Nottingham, UK). AZ-167 
was synthesized by Keith Finlayson at Centre for Translational Chemistry and 
Biology, the University of Edinburgh (UK). rhGM-CSF was purchased from 
Research Diagnostics Inc. (Flanders, NJ, USA). R-Roscovitine was supplied by 
A.G. Scientific (San Diego, CA, USA). Ultra-pure Lipopolysaccharide (LPS) from 
the Escherichia coli 0111:B4 strain was purchased from InvivoGen (San Diego, 
CA, USA). Dexamethasone was purchased from Organon Laboratories Ltd. 
(Cambridge, UK). rhCD40L and INF-γ were purchased from PeproTech ED Ltd. 
(London, UK). Human TLR agonist kit was supplied by Autogen Bioclear 
(Nottingham, UK), Brewer thioglycollate medium was supplied from Sigma-
Aldrich (Poole, UK). Rabbit polyclonal antibodies against caspase-1, IL-1β, 
caspase-3, cleaved caspase-3, pan-actin, and horseradish peroxidase (HRP)-
conjugated goat anti-rabbit immunoglobulin G antibodies were purchased from 
Cell Signaling Technology (Beverly, MA). LL-37 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVRPTES) and mCRAMP 
(GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ) were synthesised by N-(9-
fluorenyl) methoxycarbonyl chemistry at the Nucleic Acid/ Protein Service Unit at 
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the University of British Columbia (Canada). Peptides were purified by reverse-
phase HPLC and were at least 98% pure. The concentrations of the peptides in 
solution were determined by amino acid analysis. Scrambled LL-37 
(RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL) was purchased from 
CSS-Albachem Ltd. (Gladsmuir, Scotland, UK), and the panel of 16 overlapping 
22-mer partial peptides (from N-terminal peptide 
LLGDFFRKSKEKIGKEFKRIVQ through to C-terminal peptide 
EFKRIVQRIKDFLRNLVRPTES) was synthesized by Jen W. Drijfhout at Leiden 
University Medical Centre (The Netherlands). Human β-defensin-3 was purchased 
from Scientific Marketing (Kent, UK). HNP1-4 was a kind gift from Ole Sørensen 
(Lund Univeristy). Peptides were dissolved in endotoxin-free water (Sigma-
Aldrich, Poole, UK) and stored at -20°C until further use. All reagents were tested 
using a kinetic-quantitative chromogenic LAL assay (Cambrex, Walkersville, MD, 













2.2.1. Effects of CHDP on PMN death 
 
2.2.1.1. Isolation of human blood PMN 
 
Fresh human venous blood was collected according to Lothian Research Ethics 
Committee approval #08/S1103/38 or #1702/95/4/72 using sodium citrate 
anticoagulant (Phoenix Pharma Ltd., Gloucester, UK). Collected blood was 
centrifuged at 300 xg for 20 min at room temperature, platelet-rich plasma was 
removed and added 220 µl CaCl2 (Sigma-Aldrich)/ 10 ml plasma added to generate 
autologous serum. Cells were then gently suspended in 6% Dextran 500 
(Amersham Pharmacia Biotech, UK) in 0.9% saline (Baxter) and sedimented for 
25 min at room temperature. The leukocyte-rich upper layer was then fractionated 
by using three-step discontinuous, isotonic Percoll gradients [213]. Briefly, 
leukocytes were centrifuged at 350 xg for 6 min, resuspended in 55% isotonic 
Percoll (GE Healthcare, Buckinghamshire, UK), layered on top of 70% and 81% 
isotonic Percoll layers, and centrifuged at 720 xg for 20 min at room temperature. 
PMN were then collected from the interface between 70% and 81% Percoll layers, 
washed in phosphate buffer saline (PBS) without calcium or magnesium (PAA 
Labortories, Somerset, UK) and resuspended in IMDM (PAA Labortories) with 
10% fetal bovine serum (FCS, Biosera, East Sussex, UK). Purity of PMN was 
assessed by morphological criteria using cytocentrifuge preparations and FACS 
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analyse. Antibodies against CD14, CD3, and CD19 (Caltag-Medsystems, Ltd.) 
were used to distinguish PMN from PBMC. Granulocyte purity of >98% was 
yielded by this method, and granulocytes were typically 95-98% neutrophils by 
cytocentrifuge identification. Total cell number was assessed by hemacytometer 
counts and by NucleoCounter YC-100 (Chemometec, Allerød, Denmark) 
automated cell number counting. 
 
Alternatively, another method to isolate blood leukocytes was tried [485]. In this 
method, PMN were purified by Ficoll-Paque (Amersham Pharmacia Biotech, 
Buckinghamshire, UK) gradient centrifugation at 4°C to avoid activation. 
Erythrocytes were lysed hypotonically with distilled water and PMN were washed 
with Krebs-Ringer phosphate buffer (Sigma-Aldrich, Poole, UK) containing 
glucose and Mg2+. Collected PMN were resuspended in IMDM with 10% fetal 
bovine serum. 
 
2.2.1.2. PMN death assessment 
 
Freshly isolated human PMN were incubated at 37°C, 5% CO2, at 5×10
6/ml in 
IMDM with or without 10% (v/v) FCS in flexible, 96-well culture plates in the 
presence of LL-37, GM-CSF, R-Roscovitine, LPS, oxidised ATP, WRW4, PTX, 
AZ-167, mCRAMP, scrambled LL-37, human β-defensin-3, HNP, or partial 
peptides at the stated concentrations or in control media in triplicate over the time 
periods detailed. To induce primary necrosis, freshly isolated cells were heated at 
65°C for 30 min. Cell death was assessed by light microscopic evaluation of 
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apoptotic morphology such as cell shrinkage, chromatin condensation, and 
cytoplasmic vacuole formation. Samples (100 µl) of cells were cytocentrifuged, 
fixed in methanol, stained with Reastain Quick-Diff (Reagena, UK), and examined 
at least 100 cells under microscopy. Cells were also examined by stained with 
FITC-labeled AV (Roche Applied Sciences, West Sussex, UK), diluted 1:2000 in 
HBSS (Sigma-Aldrich, Poole, UK) with 5 mM CaCl2, and 3 µg/ml propidium 
iodide (Invitrogen Ltd., Paisley, UK) for flow cytometric evaluation at 4°C. FACS 
Calibur was used, counting ≥ 10, 000 cells, and the data were analysed using 
FlowJo software (TreeStar Inc., Ashland, OR, USA). Total cell counts were 




Fresh isolated human PMN were incubated with or without 5 µg/ml LL-37 for 
20 hr, as described above. Overnight treated or untreated PMN were sorted by 
FACS into Annexin V- PI-, Annexin V+ PI- (apoptotics), and Annexin V+ PI+ 
(necrotics) populations. Unsorted and sorted cells were collected and centrifuged at 
250 xg for 5 min at room temperature, and resuspended gently in 1 ml 2.5% 
glutaraldehyde (Sigma-Aldrich) in 0.1 M sodium cacodylate buffer, pH 7.3 
(Sigma-Aldrich), for 1 h. Cells were washed in three 10-min changes of 0.1 M 
sodium cacodylate and postfixed in 1% osmium tetroxide in 0.1 M sodium 
cacodylate for 45 min before three 10-min changes of 0.1 M sodium cacodylate. 
Samples were then dehydrated in 50%, 70%, 90%, and 100% normal grade 
acetones before two 10-min changes in analar acetone and embedded in Araldite 
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resin. Toluidine blue-stained sections (1 µm) were previewed before 60 nm 
ultrathin sections were cut from selected areas, stained in uranyl acetate and lead 
citrate, and then viewed in a Philips CM120 transmission electron microscope (FEI 
UK Ltd., Cambridge, UK). Images were taken on a Gatan Orius charged-coupled 
device camera (Gatan UK, Oxon, UK). FACS sorting was conducted with 
assistance from Mrs Fiona Rossi and TEM was performed by Mr Stephen Mitchell. 
 
2.2.1.4. Western immunoblotting 
 
Fresh human PMN were exposed to LL-37 at different concentrations for 20 
hours. Cells were washed with PBS without Ca2+ and Mg2+, and proteins were 
extracted using M-PER Mammalian Protein Extraction Reagent (PIERCE/ Perbio 
Science UK, Cheshire, UK) containing 30 µl/ml HaltTM protease inhibitor cocktail, 
30 µl/ml HaltTM phosphatase inhibitor cocktail, 10 µl/ml EDTA solution (all 
PIERCE/ Perbio Science UK, Cheshire, UK), 30 µM pepstatin (Sigma-Aldrich), 
and 10 µM lactacystin (Calbiochem/ Merck Biosciences Ltd., Nottingham, UK). 
Total protein concentrations were determined using a bicinchoninic acid assay 
(PIERCE/ Perbio Science UK, Cheshire, UK). Equivalent total protein (20-50 µg) 
was resolved in Pierce Precise gels (PIERCE/ Perbio Science UK, Cheshire, UK), 
transferred to Immun-Blot polyvinylidene difluoride membranes (Bio-Rad 
Laboratories, Hercules, CA, USA) which were then blocked for 1 hour with 20 
mM Tris, pH 7.4, 150 mM NaCl, and 0.1% Tween 20 (TBST) containing 5% 
skimmed milk powder (TBST/ milk). Subsequently, the nitrocellulose membranes 
were incubated with anti-human cleaved caspase-3 rabbit polyclonal antibody and 
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reprobed with anti-pan-actin (both Cell signaling Technology, Beverly, MA, USA) 
for protein loading correction via densitometric analysis using ImageJ software 
(National Institutes of Health, Bethesda, MD, USA).  
 
2.2.1.5. Burkitt’s lymphoma death assessment 
 
Mutu I Burkitt lymphoma (BL) line was cultured in RPMI 1640 medium with 
10% FCS. Apoptosis was induced by exposure of cells to ultraviolet B (UVB) 
radiation (100 mJ/cm2). Four hours after irradiation, cells were left untreated or 
exposed to 5 µg/ml LL-37 10 min before being assessed by FACS Calibur using 
Annexin V FITC and PI. 
 
2.2.2. Phagocytic studies 
 
2.2.2.1. Culture human monocyte-derived macrophages 
 
Human peripheral blood mononuclear cells (PBMC) were isolated by isotonic 
Percoll gradient centrifugation as described above and incubated at 4×106/ml in 
pre-warmed IMDM followed by plating cells out at 0.5 ml per well in 48-well 
plates incubating at 37°C, 5% CO2, for 1 hr to allow monocytes to adhere. 
Nonadherent cells were then washed out with pre-warmed IMDM; adherent 




2.2.2.2. Microscopy-based phagocytosis assay 
 
PMN were incubated previously for 20 hr, with or without LL-37 (or scrambled 
LL-37) at the stated concentrations, and the level of apoptosis was assessed as 
described. PMN (2.5×106; ~2.5:1 ration of PMN: MDM) were overlaid onto 
HBSS-washed MDM monolayer for 1 hr at 37°C. MDM were gently washed four 
times with IMDM to remove noningested PMN and fixed with 2.5% 
paraformaldehyde (Sigma-Aldrich) for 10 min. PMN MPO was stained with 0.1 
mg/ml dimethoxybenzidine (Sigma-Aldrich) and 0.03% (v/v) hydrogen peroxide 
(Sigma-Aldrich) before analysis by light microscopy, counting at least 200 MDM 
in five randomly selected fields of view to evaluate the proportion of MDM-
containing peroxidase-positive cells. Only MDM that had engulfed PMN clearly 
were scored as positive.  
 
2.2.2.3. Flow cytometry-based phagocytosis assay 
 
Isolated fresh human PMN were then stained with Cell Tracker Green 
(Molecular Probes, CMFDA retained in cell cytoplasm) at 37°C for 20 minutes. 
Labelled PMN were washed twice with PBS and cultured for 20 hr at 37°C in the 
presence of 10% FCS. Prior to the phagocytotic assay the level of apoptosis were 
assessed by cytospin. 4×106/ml apoptotic PMN in 0.5 ml suspension were then 
overlayed on HBSS (PAA Labortories)-washed macrophage monolayers. After 1 
hr incubation at 37°C, macrophages were detached using trypsin/ EDTA solution 
(Cambrex). Samples were analysed by FACS Calibur. Apoptotic cells and 
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macrophage populations were identified by their distinct laser scatter properties. 
The number of FL-1-positive events in the macrophage gate was divided by the 
total number of macrophages to obtain the proportion of macrophages that have 
internalised apoptotic cells. 
 
2.2.2.4. Cytokine production studies 
 
Isolated human blood PMN were incubated at 5×106/ml in IMDM and 10% FCS 
for 20 hr in the appearance or absence of LL-37, scrambled LL-37, or partial 
peptides p1 (LLGDFFRKSKEKIGKEFKRIVQ), p2 
(KIGKEFKRIVQRIKDFLRNLVP), or p3 (EFKRIVQRIKDFLRNLVPRTES) at 
the concentrations indicated. Samples (1 ml) were collected and each split in two, 
and half of each sample was centrifuged at 230 xg before collection of supernatant 
and resuspension of the cells in 0.5 ml X-vivo 10 media (Lonza Biologics, Slough, 
UK), with or without 10% FCS. Washed MDM, with or without concomitant 
exposure to 10 ng/ml E.coli 0111:B4 LPS or 3 µg/ml rhCD40L/ 5 ng/ml rhIFN-γ, 
were then incubated at 37°C, 5% CO2, for 18 hr with 0.5 ml PMN in fresh X-vivo 
10, PMN in the original IMDM with 10% FCS, IMDM with 10% FCS supernatant 
collected from overnight-incubated PMN, or media alone. MDM alone and PMN 
alone in the presence/ absence of LPS and /or LL-37 were also studied as controls. 
Supernatants were collected, centrifuged at 230 xg for 6 min to remove cells and 
particulate debris, and then stored in aliquots at -70°C. The concentrations of 
TNF-α, IL-6, IL-10, IL-12p70, and IL-1β in the supernatants were measured using 
BD Cytometric Bead Array human inflammation kits with a BD FACSArray (BD 
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Biosciences) or Human TNF-α DuoSet ELISA (R&D Systems, Minneapolis, MN, 
USA), according to the manufacturer’s instructions. 
 
2.2.2.5. MTT cell viability assay 
 
After supernatants were collected for cytokine evaluation, 100 µl X-vivo 10 
media and 40 µl MTT working solution (CellTiter 96® Non-Radioactive Cell 
Proliferation Assay, Promega UK Ltd, Hampshire, UK) were added to the 
macrophages attached on plates. Macrophages were incubated for another 1 hr at 
37°C, 5% CO2 followed by measurement of optical density by microplate reader at 
490 nm. 
 
2.2.2.6. Myeloperoxidase (MPO) release 
 
Isolated PMN were suspended at 5×106/ml in IMDM with 10% FCS and 
incubated with different concentrations of LL-37 or scrambled peptide for 20 or 38 
hr, centrifuged at 230 xg for 6 min, and placed immediately on ice, and the 
supernatants were collected . To detect MPO, 100 µl supernatant samples (used 
neat or diluted in PBS) were incubated in the dark for 20 min at room temperature 
with 100 µl substrate solution (1:1 mixture of H2O2 and tetramethylbenzidine; 
R&D Systems), followed by addition of 50 µl 2N H2SO4 stop solution (R&D 
Systems) and colorimetric analyses at 450 nm using a microplate reader. The 
concentration of MPO in the supernatants was evaluated as a percentage of MPO 
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release after complete lysis of fresh control PMN using 0.1% Triton X-100 
(Sigma-Aldrich). 
 
2.2.2.7. Anti-endotoxic effects of HNP and HBD3 
 
MDM were concomitantly incubated with 10 ng/ml LPS and 5 µg/ml HBD3 or 5 
µg/ml HNP for 18 hr in IMDM in the presence or absence of 10% FCS.  Untreated 
MDM or MDM treated with LPS or peptides alone were also studied as controls. 
Supernatants were collected and centrifuged at 230 xg for 6 min to remove cells 
and particulate debris, and then stored in aliquots at -70°C. The concentrations of 
TNF-α in the supernatants were measured using human TNF-α DuoSet ELISA, 
according to the manufacturer’s instructions. 
 




Six to eight week old female Balb/c mice (Harlan, UK) were used. All 
experiments were covered by a Project Licence granted by the Home Office under 
the Animal (Scientific Procedures) Act 1986. Locally, this licence was approved 
by the University of Edinburgh Ethical Review Committee. 
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2.2.3.2. Preparation of 10% (w/v) thioglycollate 
 
Ten gram thioglycollate powder was dissolved in 100 ml PBS. The greenish or 
brown solution was then autoclaved and left in fridge for at least one week before 
use. 
 
2.2.3.3. Sterile peritonitis 
 
Mice were intraperitoneally injected with 0.5 ml of 10% thioglycollate to induce 
sterile peritonitis or 0.5 ml of PBS as controls. Three hours after injection, mice 
were sacrificed by cervical dislocation and peritoneal lavage was performed. 
Briefly, peritoneal wall was explored and 5 ml cold PBS was injected into 
peritoneum with 19 G needles. Peritoneal fluids were then slowly withdrawn and 
collected in 15 ml tubes on ice. Studies were performed with assistance of Ms 
Annie Mackellar and Mr Spike Clay. 
 
2.2.3.4. Effects of LL-37 on thioglycollate-induced sterile 
peritonitis 
 
To evaluate the effects of LL-37 on inflammation in vivo, sterile peritonitis was 
induce in mice followed by the administration of LL-37 peptide or LL-37-mediated 
secondary necrosis of human PMN. Isolated human blood PMN were incubated at 
5×106/ml in IMDM and 10% FCS for 20 hr in the appearance or absence of 25 
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µg/ml LL-37. Samples were then centrifuged at 230 xg before resuspension of the 
cells at 60 × 106/ml in 100 µl X-vivo 10 media. Mice were injected with 0.5 ml of 
PBS or 0.5 ml of 10% thioglycollate along with 100 µl X-vivo 10 media, 100 µl 
human overnight untreated (apoptotic) PMN, 100 µl LL-37-exposed (secondarily 
necrotic) PMN, or 25 µg/ml LL-37 peptide alone. Three hours after injection, 
peritoneal lavage was performed. Lavage fluids were assayed by Nucleocounter to 
determine cell numbers. To determine the PMN influx, cells were immunolabelled 
with FITC-conjugated anti-mouse Ly6G and assessed by FACS Calibur. The 
concentration of cytokines in lavage fluids were evaluated by BD Cytometric Bead 
Array mouse inflammation kits with a BD FACSArray (BD Biosciences). Studies 
were performed with the assistance of Ms Annie Mackellar and Mr Spike Clay. 
 
2.2.4. Effects of LL-37 on IL-1β release  
 
2.2.4.1. Isolation of CD14 positive monocytes 
 
Freshly isolated PBMC were added with CD14 magnetic microbeads (Miltenyi 
Biotec, Surrey, UK) with the concentrations according to manufacturer instruction 
and placed at 4°C in dark for 20 min. Cells then passed through MACS separator 
in separation LS columns (Miltenyi Biotec, Surrey, UK). CD14-labelled cells 
retaining in columns were isolated and washed with FACS buffer [PBS with 2% 
FCS and 5 mM EDTA (Invitrogen Ltd., Paisley, UK)] the purity reaches 96% by 
FACS check with antibody against CD14.  
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2.2.4.2. IL-1β release studies 
 
Isolated CD14 positive monocytes or human MDM were incubated at 106/ml in 
IMDM and 10% FCS for 3 hr in the appearance or absence of 10 ng/ml LPS. Then 
900 µM oATP, 1 µM KN-62, 0.1 µM AZ-167, or 10 µM caspase-1 inhibitor were 
added before LL-37 (50 µg/ml), ATP (5 mM), or nigericin (0.5 µM) stimuli. 
Monocytes were treated with LPS, LL-37, ATP, or nigericin alone, or left 
untreated as cpntrols. One hr after the second stimulus, supernatants were collected, 
centrifuged at 230 xg for 6 min to remove cells and particulate debris, and then 
stored in aliquots at -70°C. The concentrations of IL-1β, pro-IL-1β, TNF-α, LDH 
in the supernatants were measured using human IL-1β DuoSet ELISA, human Pro-
IL-1 beta/IL-1F2 Quantikine ELISA Kit, TNF-α DuoSet ELISA (R&D Systems, 
Minneapolis, MN, USA) or CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega UK Ltd, Hampshire, UK) according to the manufacturer’s instructions.  
 
2.2.4.3. MTT cell viability assay 
 
After supernatants were removed for cytokine measurement, 100 µl X-vivo 10 
media and 40 µl MTT working solution were added to monocytes in the plates and 
incubated for 1 hr at 37°C, 5% CO2. Optical density was then determined by 
microplate reader at 490 nm. 
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2.2.4.4. Western immunoblotting 
 
Isolated CD14 positive monocytes or human MDM were treated with 10 ng/ml 
LPS for 3 hr and second stimuli for 1 hr or left untreated. Supernatants were 
collected followed by the addition of M-PER Mammalian Protein Extraction 
Reagent to extract cell proteins. Total protein concentrations of supernatants and 
cells were determined using a bicinchoninic acid assay.  Equivalent total protein 
(20-50 µg) was resolved in Invitrogen Bis Tris gels (Invitrogen Ltd, Paisley, UK), 
transferred to iBlot nitrocellulose membranes (Invitrogen Ltd, Paisley, UK) which 
were then blocked for 1 hour with 20 mM Tris, pH 7.4, 150 mM NaCl, and 0.1% 
Tween 20 (TBST) containing 5% skimmed milk powder (TBST/ milk). 
Subsequently, the nitrocellulose membranes were incubated with anti-human IL-1β 
rabbit polyclonal antibody and reprobed with anti-human caspase-1 rabbit 
polyclonal antibody (both Cell signaling Technology, Beverly, MA, USA). 
 
2.2.5. LL-37 effects on TLR-stimulated hMDM 
 
MDM were treated with TLR1/2 (Pam3CSK4), TLR2 (HKLM), TLR3 (poly I:C 
LMW), TLR4 (E. coli K12 LPS), TLR5 (S. typhimurium Flagellin), TLR6/2 
(FSL1), TLR7 (Imiquimod), TLR8 (ssRNA40) or TLR9 (ODN2006) at the 
concentrations suggested by the manufacture in the presence or absence of 5 µg/ml 
LL-37 for 18 hr in IMDM with 10% FCS. Supernatants were collected and 
evaluated centrifuged at 230 xg for 6 min to remove cells and particulate debris, 
and then stored in aliquots at -70°C. The concentrations of TNF-α and IP-10 in the 
101 
supernatants were measured using human TNF-α DuoSet ELISA and human 
CXCL10/ IP-10 DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), 
according to the manufacturer’s instructions.  
 
2.2.6. Statistical Analysis 
 
GraphPad Prism 5 statistical software was used to determine statistical 
significance. One-way ANOVA, two-way ANOVA, and student’s t-tests were 
performed depending on data, and p ≤ 0.05 was considered significant. Values 












































CHDP have been described as potent modulator of cell death pathways in 
different human primary innate-immune effector cells. The modulation of survival 
and death of innate-immune effector cells by CHDP could be critical to enhancing 
the clearance of infection and resolution of inflammation. My studies thus focus on 
the effects of CHDP, in particular human cathelicidin LL-37, on the cell death of 
the key first-line defence cell, PMN. I initiated these studies with the hypothesis 
that LL-37 can modulate the cell death in human PMN, in vitro and in vivo, to 




3.2.1. The Percoll gradient protocol is an efficient 
method to obtain more purified PMN compared to 
Ficoll isolation 
 
To compare two methods of PMN isolation, separation of fresh human 
peripheral blood from the same donor was performed simultaneously using two 
protocols as described in the Materials and Methods. Harvested cells were 
characterised by microscopic identification and FACS analyses of 
immuofluorescently labelled cells to determine cell number, purity, and activation 
status (Table. 3.1). Antibodies against CD66B and CD16b were used to detect 
granulocytes [486, 487], against CD3 to detect T lymphocytes [488], against CD14 
104 
to detect monocytes [489], and against CD19 to identify B lymphocytes [490]. 
Activation status was determined by the fluorescent intensity of CD18, a 
component of the leukocyte adhesion molecules (CD11/CD18), and using the 
expression level of adhesion receptor CD62L (L-selectin), which is shed upon 
PMN activation [491, 492]. PMN isolated using Ficoll-Hipaque based (method 2) 
had a higher contamination rate with other cell types, and the total number of cells 
acquired per ml of blood was less than that prepared using a Percoll-based method 
(method 1). Isolating PMN by Percoll gradient, which was routinely utilised in our 
lab, was therefore considered better practice to obtain purified granulocytes. In 
contrast, method 2 was more technically demanding and resulted in greater PBMC 
contamination. Monocytes and lymphocytes were visualised on cytospin slides and 
using FACS antibody analyses, with increased contamination with CD3 (~9%), 
CD14 (~8%), and CD19 (~8%)-positive cells observed when using Method 2. 
Neither method significantly activated the PMN as assessed by expression of 
CD62L and CD18. PMN obtained by the two methodologies were also later 
examined for their responses to LL-37 (cells were gated in the appropriate region 
excluding lymphocytes and monocytes), and showed broadly similar patterns in 
response to LL-37 (data not shown). Thus, the Percoll gradient protocol was 
chosen to isolate PMN for all future experiments.
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Purity Activation status Protocol Cell number/ 




Method 1 1.5×106±7×105 97.62%±0.28% 94.58%±0.44% 1.23%±1.52% 0.05%±0.07% 1.43%±1.94% 46.64 116.28 
Method 2 8.6×105±8×104 78.05%±2.15% 76.66%±4.61% 8.99%±2.00% 8.11%±0.86% 8.27%±1.22% 41 125.74 
 
Table 3.1 Comparisons of PMN obtained by Method 1 and Method 2. Separation of fresh human peripheral blood from the same donor was performed 
simultaneously using two protocols as described. Harvested cells were counted by haemocytometer and FACS analyses of immuofluorescently labeled cells to 
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3.2.2. Human cathelicidin LL-37 decreases PMN 
apoptosis and increases PMN necrosis after 20 hr 
incubation 
 
Our lab and others [20, 21] have demonstrated that the proportion of apoptotic 
(AV+PI-) PMN after 20 hr incubation in vitro was decreased significantly when 
cells were cultured with LL-37, in a dose-dependent manner. The most prominent 
consequence of this was an increased proportion of necrotic (AV+PI+) PMN. To 
clarify the effect of LL-37 on PMN death, a large donor pool (n = 28) was 
evaluated. Fresh human peripheral blood PMN were isolated and incubated in 
culture over a range of LL-37 concentrations in the presence of 10% FCS. The 
level of apoptosis was assessed by FACS Calibur quantification of FITC-labelled 
annexin V and propidium iodide staining (Fig. 3.1). Confirmation of apoptosis was 
obtained by morphological evaluation of cytospins (Fig. 3.2) and gave comparable 
results. Cell exposed to LL-37 were demonstrated to have lower apoptotic rates at 
20 hr (Fig. 3.3A). The decrease was dose dependent, with significant decreases at 
concentrations of 1 µg/ml or greater (p ≤ 0.05). In parallel to the reduction of PMN 
apoptosis, exposing PMN to LL-37 also produced a significant increase in the 
percentage of cells becoming necrotic, especially at 5 µg/ml, up to 40% (Fig. 3.3B). 
Viable cell numbers, unexpectedly, did not change significantly over a range of 
LL-37 (Fig. 3.3C). This contrasted with previous observations in the laboratory 
[20]. This discrepancy likely relates to artifacts from loss of cells to detection at the 
higher concentrations of LL-37 used in the earlier study, the size of donor pool, 
and the statistical methodology employed (ANOVA vs. t-test). LL-37-induced 
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necrotic PMN were observed to be similar to “late apoptotic” cells observed in 
control samples at 20 hr, with less severe loss of membrane integrity than primary 
necrosis induced by 65°C heat treatment for 30 min (Fig. 3.1D). Transmission 
Electron Microscopy was used to confirm the capacity of LL-37 to promote PMN 
necrosis after 20 hr incubation when compared with control cells (Fig. 3.4). 
Untreated control PMN showed typical apoptotic morphology with condensed 
chromatin and intact cell membrane (Fig. 3.4B), while PMN exposed to LL-37 for 
20 hr revealed broken membrane and leakage of intracellular contents (Fig. 3.4C). 
Taken together, these data suggested that human cathelicidin LL-37 could 
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A) Control t=0 
         
 
B) Control t=20 hr 
         
 
                   C) LL-37 5 µg/ml t=20 hr 
         
 
                     D) Primary necrotic 
         
Figure 3.1 Representative FACS plots.  Fresh PMN (A), 20 hr incubated PMN without or with 
LL-37 exposure (B & C), and heat-treated PMN (D) were analysed by FACS quantification of 
annexin V FITC and propidium iodide staining. Apoptotic (Bottom-right; AV-FITC-positive, PI-
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A) Control t=0 
 
B) Control, t=20 hr            
   
C) LL-37 5 µg/ml, t=20 hr 
   
 
Figure 3.2 Representative cytospin images.  (A) fresh PMN, (B) untreated overnight PMN, and 
(C) PMN exposed to 5 µg/ml LL-37 for 20 hr. Representative live PMN are indicated with black 
arrows; apoptosis is determined by morphological characteristics such as cell shrinkage, 
condensation of chromatin, cytoplasmic vacuole formation, and loss of the multilobed shape of their 
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Figure 3.3 LL-37 decreases PMN apoptosis and increases PMN necrosis after 20 hr 
incubation. PMN were incubated for 20 hr over a range of LL-37 concentrations in the presence of 
10% FBS. Modulation of apoptosis and necrosis were examined by FACS analysis in triplicate. 
FACS analysis was used to determine the percentage of PMN, which were (A) apoptotic, (B) 
necrotic, and (C) viable. Figures indicate mean values + SEM for n = 28 for each condition using 28 
different donors. Significance was assessed by one-way ANOVA with Bonferroni’s multiple 
comparison test to compare controls with samples exposed to LL-37 of different concentrations. **, 
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A. Control, t=0 
 
B. Control, t=20 hr 
 
C. LL-37 5 µg/ml, t=20 hr 
 
  
Figure 3.4 Representative TEM images of (A) fresh PMN, (B) untreated, apoptotic PMN, and (C) 
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3.2.3. Higher concentrations of LL-37 do not 
significantly promote PMN viability 
 
Previous data showed that after 20 hr exposure to higher concentrations of LL-
37, slightly higher proportions of viable PMN were observed. Isolated fresh human 
peripheral blood PMN were incubated in culture with LL-37 up to 25 µg/ml in the 
presence of 10% FCS. The level of apoptosis was assessed by FACS Calibur 
quantification of FITC-labeled annexin V and propidium iodide staining (Fig. 3.5). 
A decrease in apoptosis and increase in necrosis were observed as expected. 
Although a trend towards an increased proportion of viable cells was observed at 
higher LL-37 concentrations, this was not statistically significant. We hypothesised 
that increased necrosis at high concentrations of LL-37 may result in a complete 
loss of intact cells from analysis, thus skewing results. To evaluate this accurately, 
total cell numbers were determined using a NucleoCounter YC-100 (ChemoMetec) 
after 20 hr culture over a range of LL-37 concentrations (≤ 25 µg/ml). LL-37 ≥ 10 
µg/ml (~2 µM) was found to induce a significant and concentration-dependent loss 
in total detectable cell number (p<0.01) (Fig. 3.6), suggesting that the apparent 
increase in viable cells at higher concentrations of LL-37 may be an artifact. In 
contrast, incubation with ≤ 5 µg/ml LL-37 did not result in a significant decrease, 
although a degree of cell loss was observed sometimes. LL-37 was therefore used 
at ≤ 5 µg/ml for further studies examining LL-37-mediated modulation of PMN 
cell death pathways. 
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Figure 3.5 LL-37 at higher concentrations (> 10 µg/ml) does not significantly increase the 
proportion of viable PMN detected. PMN were incubated for 20 hr over a range of LL-37 
concentrations in the presence of 10% FBS. The proportions of apoptosis, necrosis, and viable cells 
were examined by FACS analysis in triplicate. (A-C) FACS analysis was used to determine the 
percentage of PMN, which were (A) apoptotic, (B) necrotic, and (C) viable. Figures indicate mean 
values + SEM for n = 3 for each condition using 3 different donors. Significance was assessed by 
one-way ANOVA with Bonferroni’s multiple comparison test comparing controls with samples 
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Figure 3.6 Higher concentrations of LL-37 cause loss of detectable PMN after 20 hr 
incubation. PMN were incubated for 20 hr over a range of LL-37 concentrations in the presence of 
10% FBS. Total cell numbers were assessed by nucleocounter. Figures indicate mean values + SEM 
for n ≥ 11. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison 
test to compare controls with samples exposed to LL-37 of different concentrations. **, p ≤ 0.01; 
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3.2.4. The proportion of eosinophils in the blood 
preparation does not affect the interpretation of LL-
37 effects on granulocyte death 
 
The method I used to isolate neutrophils has great efficiency to separate PMN 
and PBMC, but cannot deplete eosinophils from the PMN population. Eosinophils 
have longer half life than that of neutrophils. They also have different apoptotic 
pathways from neutrophils [493, 494], and anti-inflammatory agents such as 
glucocorticoids can have opposing effects on the rate of apoptosis in neutrophilic 
and eosinophilic granulocytes [495]. I therefore evaluated whether the proportion 
of eosinophils in blood preparations affected the ability of cathelicidins to 
modulate death of the purified granulocytes. The proportion of eosinophils was 
assessed by cytospins to allocate donors into three groups, namely, eosinophil <5%, 
eosinophil 5-10%, and eosinophil ≥10% (Fig. 3.7). Twenty-eight different donors 
were recruited in this study (11 for eosinophil <5%, 11 for 5%-10%, and 6 for 
eosinophil ≥ 10%). The effect of LL-37 upon cell death was consistent in all 
groups. Statistical analyses revealed that the number of eosinophils in the 
granulocyte preparation did not significantly alter the numbers of apoptotic and 
necrotic cells after LL-37 exposure. Thus, although a variable number of 
eosinophils is present in the blood granulocyte preparations, these do not seem to 
alter the effects of LL-37, and this granulocyte preparation will hereafter be 
referred to as PMN. 
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Figure 3.7 The proportion of eosinophils in the blood preparation does not affect the 
interpretation of the effects of LL-37 on PMN death pathways. Fresh human peripheral blood 
granulocytes were isolated and 200 cells were counted on cytospins to determine the proportion of 
eosinophils. Donors were allocated into three groups, eosinophil < 5%, eosinophil 5% - 10%, and 
eosinophil ≥ 10%. PMNs were incubated in culture over a range of LL-37 concentrations (0 µg/ml, 
0.25 µg/ml, 0.5 µg/ml, 1 µg/ml, and 5 µg/ml) in the presence of 10% FCS for 20 hr. Apoptotic, 
necrotic, and viable percentages were examined by FACS analysis in triplicate. (A-C) FACS 
analysis was used to determine the percentage of PMN, which were (A) apoptotic, (B) necrotic, and 
(C) viable cells. Figures indicate mean values + SEM for n = 11 in eosinophil < 5% group, n= 11 in 
eosinophil 5-10% group, and n = 6 in eosinophil ≥ 10% group using 28 different donors. 
Significance was assessed by two-way ANOVA with Bonferroni’s multiple comparison test to 
compare samples exposed to LL-37 over a range of concentrations and the effects of proportion of 
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3.2.5. Time course studies show that LL-37 is not lytic 
to PMN and does not induce death of PMN at early 
time points 
 
Studies showed that LL-37 is cytotoxic to peripheral blood leukocytes at higher 
concentrations (> 50 µg/ml) [25]. Although the concentrations of LL-37 used in 
my experiments were far lower than that having lytic activity, experiments were 
still conducted to determine any direct cell lysis in this system. Fresh human 
peripheral blood PMN were isolated and incubated in culture over a range of LL-
37 concentrations for 0 hr, 1 hr, 4 hr, 6 hr, 12 hr and 20 hr (Fig. 3.8). The 
proportions of apoptotic, necrotic, and viable cells were assessed by microscopic 
observations and FACS Calibur analyses as previously described. Flow analyses 
and light microscopic observation demonstrated that at early time points, (0 hr, 1 hr, 
4 hr, and 6 hr), no substantial cell death was detected irrespective of LL-37 
concentrations, indicating that LL-37 was not lytic nor inducing primary necrosis 
at these time points and concentrations. Apoptotic and necrotic percentages 
remained steady even after 6 hr at 5 µg/ml. The LL-37-mediated decrease in 
apoptosis and increase in necrosis were observed to occur simultaneously after 12 
hr incubation, by which time a substantial proportion of PMN had undergone 
spontaneous apoptosis. This suggests that prior induction of apoptosis may be 
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Figure 3.8 Time course studies show that LL-37 at physiological concentrations does not have 
cytotoxic properties at early time points. Fresh human peripheral blood PMN were isolated and 
incubated in culture over a range of LL-37 concentrations in the presence of 10% FBS for 0 hr, 1 hr, 
4 hr, 6 hr, 12 hr, and 20 hr. (A-F) FACS analysis was used to determine the percentage of apoptotic, 
necrotic, and viable cells. Figures indicate mean values + SEM for n = 3 for each condition in 
triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison 
test to compare control with samples exposed to LL-37 over a range of concentrations. *, p ≤ 0.05; 
***, p ≤ 0.001. 
 
                                                                                    
119 
                              
3.2.6. Pulse treatments demonstrate that LL-37-
mediated modulation of PMN death occurs rapidly at 
later time points 
 
Time course studies indicated that the death-modulating effects of LL-37 on 
PMN were observed at later time points, once PMN apoptosis had occurred. Thus I 
hypothesised that LL-37 induced secondary necrosis of apoptotic cells. In order to 
evaluate this, untreated PMN cultured overnight (20 hr) were exposed to LL-37 
over a range of concentrations for just 10 min before flow cytometric analyses. The 
LL-37-mediated increase in necrosis, and reduction in apoptosis, were found to be 
even more pronounced in these pulse-treated PMN compared to overnight LL-37-
exposed cells, particularly in terms of necrotic rates (p = 0.02) (Fig. 3.9). In 
contrast, PMN exposed to a range concentrations of LL-37 for 4 hr, then washed 
before a 16 hr incubation period in control media, were not significantly different 
when compared to untreated controls (Fig. 3.10). Thus, it is concluded that LL-37 
induces secondary necrosis at later time points once PMN apoptosis has occurred, 
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Figure 3.9 Pulse treatments reveal that LL-37-modified PMN death pathways occur swiftly at 
late time points. Fresh human peripheral blood PMN were isolated and incubated with LL-37 over 
a range of concentrations (20 hr exposure) or without LL-37 in the presence of 10% FCS for 20 hr. 
The overnight untreated PMN were then given LL-37 10 min before flow cytometry analyses (10 
min pulse). (A-C) FACS analysis was used to determine the percentage of apoptotic, necrotic, and 
viable cells. Figures indicate mean values + SEM for n = 3 for each condition in triplicate. 
Significance was assessed by two-way ANOVA with Bonferroni’s multiple comparison test to 
compare control with samples exposed to LL-37 over a range of concentrations and compare the 












                                                                                    
121 








































































Figure 3.10 Early pulse treatments of LL-37 removed before induction of apoptosis have no 
significant effects on PMN death. Fresh human peripheral blood PMN were isolated and 
incubated with LL-37 over a range of concentrations or without LL-37 in the presence of 10% FCS 
for 4 hr, followed by washing and incubation in control media for 16 hr. (A-C) FACS analysis was 
used to determine the percentage of apoptotic, necrotic, and viable cells. Figures indicate mean 
values + SEM for n = 3 for each condition in triplicate. Significance was assessed by one-way 
ANOVA with Bonferroni’s multiple comparison test to compare control with samples exposed to 
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3.2.7. Critical proteins involved in the caspase cascade 
are unchanged in human PMN after LL-37 exposure, 
suggesting the induction of secondary necrosis, 
rather than decreased apoptosis with consequent 
primary necrosis  
 
Time course and short time pulse studies suggested that LL-37-mediated 
alteration of PMN death occurred at late time points. The increase of necrosis was 
always observed when a proportion of PMN had undergone spontaneous apoptosis. 
This phenomenon was more pronounced at very late stages when more apoptotic 
cells were exposed to fresh LL-37, and exposure to LL-37 after the induction of 
apoptosis was required. To examine whether the decrease of apoptosis resulted 
from the anti-apoptotic activity of LL-37 on PMN as previously described [21], 
Western immunoblotting for critical proteins involved in the induction of apoptosis 
via the caspase cascade was performed. If LL-37 was anti-apoptotic in PMN, there 
would be expected to be fewer cells at 20 hr with cleaved caspase-3; if LL-37 
induces secondary necrosis of apoptotic PMN, caspase-3 at late time should be 
unaffected. Isolated PMN were cultured with LL-37 for 20 hr. Proteins were 
extracted from incubated PMN using M-PER with proteinase inhibitor reagents. 
PMN proteins were subjected to Western immunoblotting to study the expression 
of key proteins involved in apoptotic caspase cascade. Results showed that 20 hr 
LL-37 exposure did not change the level of cleaved caspase-3, an executioner 
caspase which is a major convergence point of intrinsic and extrinsic apoptotic 
pathways (Fig. 3.11). This result further supported the hypothesis that rather than 
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mediating anti-apoptotic effects, LL-37 induced already apoptotic cells to become 
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Figure 3.11 Western immunoblot for cleaved caspase-3. Whole cell lysates from freshly isolated 
human PMN incubated for 20 hr were examined by Western immunoblotting for procaspase-3 
(antibody dilute 1:1000), cleaved caspase-3 (antibody dilute 1:1000), which are the critical proteins 
executing apoptosis, and pan-actin (antibody dilute 1:2000) for protein loading control. A) 
Representative image; B) relative quantity compared to control samples (after correction for protein 
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3.2.8. In serum-free conditions, overnight LL-37-
mediated secondary necrosis of PMN is attenuated, 
but the effects of pulse treatment are enhanced. 
 
Serum proteins have been shown to play a pivotal role in inhibiting microbicidal 
and cytotoxic activities of LL-37 [93], and are required for LL-37-induced 
activation of the MAPKs, ERK1/2, and p38 [143]. To study whether varied serum 
conditions affected the function of LL-37 to modulate PMN death pathways, cells 
were incubated in serum-free medium in the presence or absence of a concentration 
range of LL-37 for 20 hr. Baseline apoptotic and necrotic rates were higher in the 
absence of serum than previously observed in the presence of 10% FCS, 
accompanied by less viable cells. LL-37-mediated induction of secondary necrosis 
was largely attenuated in overnight serum-free conditions (Fig. 3.12). In addition, 
to evaluate whether apoptotic PMN were differentially susceptible to LL-37-
mediated induction of secondary necrosis, cells were cultured for 20 hr in LL-37-
free, serum-free media before being exposed to a pulse of LL-37 for the final 10 
min before analyses. Under these conditions LL-37-mediated secondary necrosis 
with a concomitant decrease in apoptosis, was observed in pulse LL-37-exposed 
PMN in the absence of serum (Fig. 3.12 A & B). These data suggest that LL-37-
induced secondary necrosis is not a serum-dependent phenomenon, but that under 
serum-free conditions LL-37 added at the start of a 20 hr incubation period is not 
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Figure 3.12 In serum-free conditions, overnight LL-37-mediated modulation of PMN death is 
attenuated, but the effects are enhanced following pulse treatment. Fresh human peripheral 
blood PMN were isolated and incubated in the absence of 10% FCS in the absence and presence of 
a range concentration of LL-37 for 20 hr, or cells in LL-37-free conditions overnight were given a 
range concentrations of LL-37 10 min before analyses. (A-C) FACS analysis was performed in 
triplicate to determine the percentage of apoptotic, necrotic, and viable cells. Figures indicate mean 
values + SEM for n = 3 for each condition using three different donors. Significance was assessed 
by two-way ANOVA with Bonferroni’s multiple comparison test to compare samples in 20 hr LL-
37 treatment with those of LL-37 pulse exposure and their responses to a range concentration of 
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3.2.9. Interaction of LL-37 with known modulators of 
PMN apoptosis 
 
To investigate whether LL-37 could interact with other modifiers of PMN 
apoptotic pathways, cells were incubated with LL-37 in the presence or absence of 
GM-CSF (a PMN survival factor [496]) or R-Roscovitine (a cyclin-dependent 
kinase inhibitor and inducer of PMN apoptosis [268]). GM-CSF reduced PMN 
apoptosis significantly at 20 hr, increasing the proportion of live cells without 
affecting necrosis. Concomitant treatment with 5 µg/ml LL-37 had no effect on the 
capacity of GM-CSF to promote cell survival but significantly (p ≤ 0.05) increased 
the proportion of necrotic cells with a reciprocal loss of apoptotic cells when 
compared with GM-CSF alone (Fig. 3.13A). R-Roscovitine induced PMN 
apoptosis significantly at 6 hr with minimal necrosis. LL-37 alone (≤ 25 µg/ml) 
had no effect on cell death at this time point. Concomitant LL-37 treatment had no 
effect on the capacity of R-Roscovitine to induce cell death but significantly (p ≤ 
0.01) increased the proportion of necrotic cells in a dose-dependent manner with a 
reciprocal loss of apoptotic cells when compared with R-Roscovitine alone (Fig. 
3.13B). These data demonstrated no interaction with these direct modifiers of PMN 
apoptosis, but LL-37 induced apoptotic PMN secondary necrosis, relating in 
magnitude to the extent of induction of apoptosis. 
 
In addition, studies were performed to assess the impact of LL-37 (a well-
characterised anti-endotoxic agent [89]) on the anti-apoptotic effects of LPS in 
PMN [497]. LPS promoted PMN survival significantly (Fig. 3.13D), inhibiting 
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apoptosis without increasing necrosis. Concomitant incubation with LL-37 
inhibited this effect significantly in a dose-dependent manner (Fig. 3.13D). LL-37 
(5 µg/ml) blocked the pro-survival effects of LPS completely and significantly 
increased the proportion of dead cells that were necrotic (p ≤ 0.01) (Fig. 3.13C). 
However, the capacity of LL-37 to induce secondary necrosis was diminished 
significantly by LPS (p ≤ 0.001) (Fig. 3.13C). These data demonstrate LL-37-
mediated inhibition of the anti-apoptotic effects of LPS and suggest a mutually 
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Figure 3.13 LL-37 exposure of PMN in the presence of modifiers of apoptotic pathways. 
Freshly isolated human PMN were incubated with LL-37 (at the concentrations indicated) for 20 hr 
in the presence or absence of 20 ng/ml GM-CSF (A), for 6 hr in the presence or absence of 20 µM 
R-Roscovitine (B), or for 20 hr in the presence or absence of 500 ng/ml E.coli LPS (C and D). Cell 
death was examined by FACS analyses. Figures represent mean values + SEM for n ≥ 3 donors 
performed in triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s multiple 
comparison test comparing each treatment with control; *, p ≤ 0.05; **, p ≤ 0.01, for necrotic cells 
in LL-37-treated samples compared with controls without LL-37 in the presence of (A) GM-CSF, 
(B) R-Roscovitine, or (C) LPS; #, p ≤ 0.001, for necrotic (C) or viable (D) cells in LPS-treated 
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3.2.10. The effects of LL-37 on apoptotic PMN are not 
inhibited by the presence of Annexin V 
  
My data thus far suggested possible differences in apoptotic membranes, when 
compared to those of viable cells, enabled induction of membrane permeabilisation 
by LL-37. One clearly described change in apoptotic membrane is the 
externalisation of PS, which is usually resticted to the inner leaflet of cell 
membranes. In order to determine whether LL-37 may interact with PS, Annexin V, 
which has a high affinity to PS in the presence of physiological concentrations of 
calcium, was used to try to block such an interaction. Overnight untreated PMN 
were prepared to generate apoptotic PMN. These cells were then resuspended in 
HBSS, Annexin V buffer (which contained 5mM CaCl2) or Annexin V buffer 
containing Annexin V (diluated 1:2000), before a 10 min exposure pulse treatment 
of LL-37. Despite a trend towards diminished secondary necrosis, neither buffer 
containing high divalent ions nor Annexin V stain significantly inhibited the 
capacity of LL-37 to induce the secondary necrosis of apoptotic PMN (Fig. 3.14). 
The minor effects on the proportion of apoptotic cells observed appeared to be 
dependent upon the presence of higher concentrations of Ca2+, rather than 
inhibition by Annexin V. Although not conclusive, this experiment suggests that 
induction of secondary necrosis by LL-37 is not primarily due to a direct 
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Figure 3.14 The effect of LL-37 on apoptotic PMN is not inhibited by the presence of Annexin 
V. Fresh human peripheral blood PMN were isolated and incubated without LL-37 in the presence 
of 10% FCS for 20 hr. The overnight untreated PMN were then resuspended in HBSS, in the 
absence or presence of 5 mM CaCl2 (High Ca
2+ FACS buffer) or FACS buffer containing Annexin 
V FITC (dilute 1:2000 as for FACS staining) just before a 10 min exposure to pulse LL-37 and flow 
cytometric analyses. (A-C) FACS analysis was used to determine the percentage of apoptotic, 
necrotic, and viable cells. Figures indicate mean values + SEM for n = 3 for each condition in 
triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison 
test to compare control with samples exposed to LL-37 in different media conditions. *, p ≤ 0.05; 
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3.2.11. G-protein-coupled receptor and P2X7 receptor 
antagonists do not inhibit the capacity of LL-37 to 
induce secondary necrosis of PMN  
 
The modulatory effects of LL-37 on cell death have been proposed to be 
dependent on signalling through G-protein-coupled receptor FPRL-1 and the 
purinergic receptor P2X7R [20, 21]. In order to clarify if LL-37-induced secondary 
necrosis was a receptor-dependent or a membrane-perturbing event, antagonists of 
these known receptors were used. Fresh PMN were incubated with PTX (pertussis 
toxin, to inhibit G-protein-coupled receptors), WRW4 (specific inhibitor of FPRL-
1 [498]), oATP (oxidised ATP) or AZ-167 (specific inhibitors of P2X7 [499]) 30 
min before exposure to a concentration range of LL-37. The levels of cell death 
were subsequently determined after 20 hr incubation (Fig. 3.15). The inhibitors 
alone had no effects on PMN death compared to untreated control cells (data are 
not shown). Although there was a trend towards inhibition with oATP in apoptosis, 
none of these antagonists at the optimal concentrations significantly impaired the 
activity of LL-37 in inducing secondary necrosis. These data indicate that the 
capacity of promoting secondary necrosis is not a receptor-dependent phenomenon, 
and our collaborator in Dr. Johan Bylund’s laboratory further demonstrated a swift 
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Figure 3.15. LL-37-induced secondary necrosis of apoptotic PMN is not dependent on known 
receptors of LL-37. Fresh human peripheral blood PMN were isolated and incubated with 30 min 
10 µM WRW4, 100 µM oxidised ATP, 0.1 µM AZ-167, or 200 ng/ml PTX, followed by addition of 
5 µg/ml LL-37 or without LL-37 in the presence of 10% FCS for 20 hr. (A-C) FACS analysis was 
used to determine the percentage of apoptotic, necrotic, and viable cells. Figures indicate mean 
values + SEM for n = 3 for each condition in triplicate. Significance was assessed by one-way 
ANOVA with Bonferroni’s multiple comparison test to compare samples exposed to LL-37 alone 









                                                                                    
134 
                              
3.2.12. LL-37 also selectively permeabilises apoptotic 
Burkitt lymphoma cell line 
 
In order to test whether the induction of secondary necrosis of apoptotic cells 
was specific to PMN, or if it represented as a general mechanism acting on other 
cell types as well, a Burkitt lymphoma cell line Mutu I was used. Burkitt 
lymphoma cells display high baseline levels of apoptosis, a property that is 
retained constitutively in these tumor-derived cells, and can be further upregulated 
by irradiation. Irradiated Burkitt cells incubated for 4 hr displayed 60% apoptosis. 
When these highly apoptotic Burkitt cells were treated with LL-37 (5 µg/ml), they 
quickly became secondarily necrotic (Fig. 3.16). Thus the selective 
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Figure 3.16 LL-37 permeabilised apoptotic Burkitt lymphoma cells. Burkitt lymphoma cell line 
was irradiated and incubated for 4 hr in the presence of 10% FCS. Burkitt cells were then exposed 
to LL-37 for 10 min before flow cytometric analyses. (A-C) FACS analysis was used to determine 
the percentage of apoptotic, necrotic, and viable cells. Figures indicate mean values + SEM for n = 
3 for each condition in triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s 
multiple comparison test to compare control with samples exposed to LL-37 over a range of 
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3.2.13. LL-37-mediated induction of secondary 
necrosis is conserved in murine homologue 
mCRAMP and C-terminal partial peptides but not 
scrambled LL-37 peptide 
 
To examine the important characteristics of LL-37 for the capacity to induce 
secondary necrosis of PMN, FACS-based studies were performed using a 
scrambled LL-37 peptide (with conserved charge but altered amino acid sequence), 
the murine homologue mCRAMP, and a panel of sixteen 22-mer partial peptides 
spanning the sequence of LL-37 (a kind gift from Prof. Pieter Hiemstra) [501] 
(Table 3.2). Incubation of PMN with scrambled LL-37 peptide had no effect, 
whether exposed over 20 hr or only as a final 10-min pulse (Fig. 3.17). In contrast, 
PMN exposed to mCRAMP closely replicated the effects of LL-37 with significant 
induction of secondary necrosis (Fig. 3.18). Exposure to N-terminal 22-mer partial 
LL-37 peptides (from the peptide incorporating amino acids (aa) 1-22 through to 
that spanning aa 10-31) had no significant effects (Fig. 3.19). In contrast, C-
terminal partial peptides (from the peptide incorporating aa 11-32 through that 
spanning aa 16-37) induced significant secondary necrosis (p ≤ 0.01) but to a lesser 
extent than full-length LL-37 (Fig. 3.19). This identified a putative minimal core 
functional region for induction of secondary necrosis spanning aa 16-32. The 
effects of this panel of peptides showed no correlation with charge, which ranged 
from +3 to +6. These data demonstrate that the capacity to induce secondary 
necrosis is evolutionarily conserved between mouse and human cathelicidin, is not 
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primarily dependent on peptide charge, and is retained by C-terminal but not N-
terminal-truncated peptides of LL-37.  
 
Peptides Sequences 
N terminus--------------------------------------------C terminus 
Charge 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES +6 




Partial peptide LLGDFFRKSKEKIGKEFKRIVQ +4 
p1 LGDFFRKSKEKIGKEFKRIVQR +5 
Partial peptide GDFFRKSKEKIGKEFKRIVQRI +5 
Partial peptide DFFRKSKEKIGKEFKRIVQRIK +6 
Partial peptide FFRKSKEKIGKEFKRIVQRIKD +6 
Partial peptide FRKSKEKIGKEFKRIVQRIKDF +6 
Partial peptide RKSKEKIGKEFKRIVQRIKDFL +6 
Partial peptide KSKEKIGKEFKRIVQRIKDFLR +6 
Partial peptide SKEKIGKEFKRIVQRIKDFLRN +5 
Partial peptide KEKIGKEFKRIVQRIKDFLRNL +5 
Partial peptide EKIGKEFKRIVQRIKDFLRNLV +4 
 p2 KIGKEFKRIVQRIKDFLRNLVP +5 
Partial peptide IGKEFKRIVQRIKDFLRNLVPR +5 
Partial peptide GKEFKRIVQRIKDFLRNLVPRT +5 
Partial peptide KEFKRIVQRIKDFLRNLVPRTE +4 
p3 EFKRIVQRIKDFLRNLVPRTES +3 
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Figure 3.17 Scrambled LL-37 peptide has no secondary necrosis-inducing effect on apoptotic 
PMN. Fresh isolated human PMN were incubated in the presence of 10 % FCS with a range of 
concentrations of scrambled LL-37 peptide for 20 hr, or 10 min after 20 hr incubation in the 
absence of peptide (pulse); n = 3 donors performed in triplicate. Cell death was examined by FACS 
analyses as described. Figures represent mean values + SEM. Significance was assessed by one-
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Figure 3.18 Murine homologue mCRAMP closely replicates the effects of LL-37 with 
significant induction of secondary necrosis. Fresh isolated human PMN were incubated with a 
range of concentrations of mCRAMP peptide for 20 hr in the presence of 10% FCS. Cell death was 
examined by FACS analyses as described; n = 16 donors performed in triplicate. Figures represent 
mean values + SEM. Significance was assessed by one-way ANOVA with Bonferroni’s multiple 
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Figure 3.19 The capacity to induce PMN secondary necrosis is retained by C-terminal but not 
N-terminal-truncated peptides of LL-37. Fresh isolated human PMN were incubated with 5 
µg/ml partial LL-37 peptides from a panel of 16 overlapping 22-mers using N-terminal peptide (aa 
1-22), then peptide spanning aa 2-23, and so on through C-terminal peptide (aa 16-37) or full-length 
LL-37 for 20 hr in the presence of 10% FCS. Cell death was examined by FACS analyses as 
described; n = 3 donors performed in triplicate. Figures represent mean values + SEM. Peptides p1, 
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3.2.14. The property of induction of secondary necrosis 
is not a unique feature of cathelicidins 
 
In order to test whether the capability to induce secondary necrosis was specific 
to cathelicidins, another family of CHDP was evaluated. PMN were incubated with 
α-defensins (HNP1-4) purified from human PMN (a kind gift from Dr Ole 
Sorensen) or synthetic β-defensin HBD3 in the presence of 10% FCS for 20 hr. 
Interestingly, despite the shared features of these two subgroups of defensins (e.g. 
positive charges, 28-42 amino acid length, and containing three intramolecular 
disulfide bonds), only HBD3 had the capacity to induce secondary necrosis (Fig. 
3.20). As other effects of α-defensins can be inhibited by serum components [502, 
503], I also conducted the experiment in serum-free media. Incubation of PMN 
with α-defensin peptide had no effect, no matter whether exposed over 20 hr in the 
presence of serum or as a final 10 min pulse in serum free media (Fig. 3.21). I then 
confirmed that HNP1-4 were biologically active by testing their anti-endotoxic 
activity which is referred to later in this thesis (Fig. 4.17) and by demonstrating 
detection of the peptides with antibody in Western immunoblotting (data are not 
shown). Taken together, these results demonstrated that the capacity to induce 
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Figure 3.20 Human β-defensin HBD3 induces secondary necrosis of apoptotic PMN. Fresh 
isolated human PMN were incubated with a range of concentrations of HBD3 peptide for 20 hr in 
the presence of 10% FCS. Cell death was examined by FACS analyses as described; n = 3 donors 
performed in triplicate. Figures represent mean values + SEM. Significance was assessed by one-
way ANOVA with Bonferroni’s multiple comparison test comparing each treatment with control. *, 
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Figure 3.21 Human neutrophil peptides HNP1-4 did not induce secondary necrosis of 
apoptotic PMN. Fresh isolated human PMN were incubated with a range of concentrations of 
alpha-defensin HNP peptide for 20 hr in the presence of 10% FCS (A-C), or 10 min peptide 
exposure after 20 hr incubation in the absence of serum (pulse) (D-E); n = 3 donors performed in 
triplicate. Cell death was examined by FACS analyses as described. Figures represent mean values 
+ SEM. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison 
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3.2.15. LL-37-induced secondary necrosis of PMN can 
release granule contents. 
 
As shown by my data in earlier sections, LL-37 rapidly induced secondary 
necrosis of apoptotic PMN, and our collaborator demonstrated that LL-37 
selectively permeabilised plasma membrane of apoptotic PMN [500]. However, it 
was not known whether organelle membranes were similarly affected. To 
determine granule content release (or granule release) from LL-37-treated PMN, 
MPO (stored at the primary granules) levels in the cell supernatants was evaluated 
at 20 hr, under conditions in which secondary necrosis was significantly induced 
by LL-37 (Fig. 3.22). MPO release was not detected above background at 20 hr 
time point following exposure to ≤ 10 µg/ml LL-37 (concentrations at which 
substantial secondary necrosis occurred) or in response to scrambled LL-37. 
However, significant levels of MPO were observed in response to ≥ 25 µg/ml LL-
37 (p ≤ 0.01) at levels of around 40% of total MPO released by lysis with Triton X-
100 (Fig. 3.22). These data suggest that LL-37 at higher concentrations is not only 
able to permeabilise cell membrane, but is also able to destabilise granules and lead 
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Figure 3.22 LL-37-induced secondary necrosis of PMN can release granule contents. Isolated 
human PMN were incubated for 20 hr with a range of concentrations of LL-37 or 50 µg/ml 
scrambled LL-37 (scr50) in the presence of 10% FCS. The concentration of MPO in the 
supernatants was evaluated as a percentage of total MPO release after lysis of fresh control PMN 
using 0.1% Triton X-100. Significance was assessed by one-way ANOVA with Bonferroni’s 
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3.3. Discussion 
 
CHDP have been demonstrated to have multiple immunomodulatory capabilities. 
LL-37, a mature and functional CHDP, is a multifaceted modulator of innate 
immune responses, with properties including direct antimicrobial function, 
chemokine production, anti-endotoxin activity, and chemotaxis of inflammatory 
and immune cells [2, 5]. PMN are first-line innate immune cells and the regulation 
of their function, death, and removal is critical. Several studies have demonstrated 
that the direct effects of LL-37 on PMN, including enhancing their activity against 
pathogens [16, 17] and modulating their survival [20, 21]. At inflamed sites, 
increased concentrations of LL-37 and increased numbers of PMN are observed; 
thus, we hypothesised that LL-37 could modulate inflammation via effects on 
PMN cell death pathways.  
 
LL-37 has been reported to induce apoptosis in airway epithelial cells and 
keratinocytes, indicating its capacity to modulate cell death in innate effector cells 
[108, 111]. The antimicrobial capability of this peptide has been ascribed to its 
membrane pore-forming activity [504, 505], but eukaryotic cells are less 
susceptible to membrane attacks from LL-37 [2]. This is proposed to relate to 
differences in membrane composition [2]. It is well known that cells change the 
composition of their membranes during apoptosis, a process that is important in 
order to be recognised by phagocytes and ensure safe disposal. My data 
demonstrate that LL-37, and certainly other CHDP, can induce secondary necrosis 
of apoptotic PMN, altering the state of cell death. This alteration in PMN death 
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might provide another mechanism by which CHDP modulate inflammatory and 
immune responses.  
 
My data demonstrate that LL-37 rapidly induces secondary necrosis of apoptotic 
PMN. In order to confirm that the appearance of increased necrosis was not simply 
an artifact of loss of intact cells, total cell numbers were evaluated and showed 
there was not a substantial cell loss at the concentrations used in the experiments. 
In addition, in order to exclude the possibility of an interaction between Annexin V 
and the peptide which may skew results as decreasing apoptosis, our collaborators 
in Dr. Johan Bylund’s laboratory (University of Gothenburg) employed CD16 as a 
marker for PMN apoptosis rather than Annexin V. CD16 is a surface protein 
present on viable PMN and is lost upon apoptosis. They showed that only PMN 
negative for CD16 became necrotic after addition of LL-37, confirming that LL-37 
selectively targeted apoptotic cells [500].  
 
At inflamed sites, a variety of mediators can affect the life span of PMN [216, 
266]. GM-CSF or LPS has been demonstrated to prolong PMN survival whereas 
some pharmacological agents (eg. R-Roscovitine) effectively promote PMN 
apoptosis [216, 268]. Thus, these PMN survival factors or death signals were tested 
in the presence of LL-37 to estimate their net biological effects on human PMN 
death. The results support the hypothesis that LL-37 induces apoptotic PMN 
towards secondary necrosis, with the necrotic rates correlate to the extent of 
apoptosis. Combination of LPS and LL-37 (a well-characterised anti-endotoxic 
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agent [89]) demonstrate a mutually inhibitory effect on the modulation of PMN 
death, suggesting the antagonistic interaction between these two factors in vivo.    
 
It was proposed that LL-37-induced secondary necrosis was a serum-dependent 
event. LL-37 binds to at least one serum protein, and that this binding modifies its 
antibacterial and cytotoxic activities [107, 506]. In addition, for primary blood 
derived monocytes the presence of serum seems to be required for this peptide to 
activate MAPK, ERK1/2, and p38 [143]. In contrast, my data showed that LL-37-
induced secondary necrosis was not a serum-dependent event. Although the 
absence of serum in overnight incubation with LL-37 diminished the level of 
secondary necrosis of apoptotic cells, short, late stage pulse treatment studies 
demonstrated that serum presence was not necessary for LL-37-mediated 
secondary necrosis in PMN. Two possibilities may explain this phenomenon: 1) 
LL-37 could be more easily degraded in serum-free media; or 2) LL-37 could be 
internalised more rapidly in the absence of serum and localised intracellularly, as 
previously observed using biotinylated LL-37 [31]. In both cases lower levels of 
active LL-37 would be available in the media to induce secondary necrosis once 
apoptosis occurs. Although so far there are no data to prove or disprove my 
assumptions, experiments can be done by evaluating the concentrations and 
functions of residual LL-37 after overnight incubation in serum-free media, or 
using fluorescent LL-37 to localise the peptide while interacting with cells.  
 
Interestingly, the ability of LL-37 to induce secondary necrosis was not specific 
to apoptotic PMN, but also observed with a Burkitt lymphoma cell line and, by our 
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collaborators, primary natural killer (NK) cells [500]. These observations suggest 
that LL-37 might target a general membrane composition change in certain 
apoptotic cells, or receptor/ membrane protein the expression of which is altered by 
apoptosis in many diverse cell types. The fact that LL-37 selectively permeabilises 
membranes of apoptotic cells, which are nonfunctional and unable to transmit 
signals, diminishes the likelihood of specific active receptor signalling involvement. 
Experiments conducted with antagonists of known receptors of LL-37 also support 
this hypothesis. Apoptotic cells flip the negatively charged PS from the inner 
leaflet of the lipid bilayer to the outer leaflet. PS expression on the cell surface 
might promote susceptibility of apoptotic cells to the cationic LL-37. However, my 
data and that of our collaborators fail to support this hypothesis. Blocking PS by 
Annexin V did not inhibit the capability of LL-37 in the induction of secondary 
necrosis, nor did liposomes incorporating with PS confer any permeabilising 
activity of LL-37 [500]. It is possible that apoptotic membrane has other surface 
molecules than PS altered which may be recognised and targeted by LL-37. It 
could also be hypothesised that LL-37 interacts with outer membranes of both 
viable and apoptotic cells and temporarily disrupts them. The peptide can be 
removed from the membranes by internalisation in healthy cells with limited 
membrane damage whereas apoptotic cells are non-functional and unable to repair 
the disturbed membrane [500]. Taken together, the permeabilisation of apoptotic 
cells is unlikely to depend on LL-37 interaction with specific functional surface 
receptors or PS expression. 
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LL-37 and mCRAMP are structurally similar [44] and have a conserved capacity 
to induce secondary necrosis in apoptotic human PMN. In contrast, scrambled LL-
37 does not have secondary necrosis-inducing properties on apoptotic cells, 
suggesting that cationicity alone is not sufficient to confer this effect. Studies on 
the panel of partial peptides also show no correlation with positive charges and the 
capacity to induce secondary necrosis, but may correlate with peptide 
amphipathicity. However, defensins, although positively charged and amphipathic 
in structure, are not all capable of inducing secondary necrosis of apoptotic PMN; 
HBD3 had the capacity to induce secondary necrosis whereas HNP1-4 did not). 
Our collaborators evaluated the antibacterial/ immunomodulatory peptide Hp(2-20), 
a peptide that combines cationicity with an alpha-helical nature, and found that 
peptide was unable to permeabilise apoptotic leukocytes [500]. These findings 
show that the selective action described for LL-37 is not a general feature for 
cationic, alpha-helical, amphipathic antibacterial peptides [500]. Future research 
will hopefully unravel the structural determinants responsible for the 




Consistent with other recent reports, my data demonstrate that LL-37 
specifically induces secondary necrosis of apoptotic cells and may destroy the 
integrity of the plasma membrane [144, 500]. I also demonstrated LL-37-induced 
release of granule contents occurs, although only at higher peptide concentrations. 
These data suggest that LL-37-mediated secondary necrosis of apoptotic cells can 
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be a potent means of transferring the intracellular substances out to an extracellular 
location. Interestingly, lower concentrations of LL-37 do not lead to significant 
increases of granule content release, despite the induction of secondary necrosis. 
This may be due to decreased concentrations of LL-37 available intracelluarly for a 
given extracellular concentration, but could also possibly relate to differential 
membrane susceptibility. These observations suggest that during inflammation 
when recruited PMN become apoptotic and LL-37 is upregulated there may be 
massive PMN intracellular content release at affected sites. 
    
Apoptosis is viewed as a silent, physiological mechansim for removing PMN, 
without host damage or increasing inflammation, and contributing to the resolution 
of the inflammatory process. In contrast, necrosis is regarded as a pathological and 
inflammatory type of cell death. The membranes of necrotic cells are no longer 
intact and the cell contents are free to leak out to the extracellular milieu, causing 
tissue destruction and persistent inflammation [322]. Thus the impact of LL-37-
mediated secondary necrosis of apoptotic PMN on inflammatory responses was the 
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The impact of LL-37-induced secondary 
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4. The impact of LL-37-induced secondary 




Cell death by apoptosis, followed by efficient efferocytosis by professional 
phagocytes, is proposed to ensure safe cell removal without the release of harmful 
intracellular contents and to promote anti-inflammatory responses to enhance 
resolution [12]. In contrast, cell death by necrosis is proposed to be pro-
inflammatory. However, the effects of primary necrosis, as compared to secondary 
necrosis of apoptotic cells remain unclear. Although this axiom is widely accepted 
and applied to many experimental systems, there are still arguments against this 
oversimplified proposal [15]. It is clear that the mechanism of cell death do matter 
in determining ensuing biological responses, but more work is required to clearly 
clarify the inflammatory properties of different forms of cell death.  
 
I have demonstrated (in chapter 3) that human cathelicidin LL-37 is a potent 
inducer of secondary necrosis of apoptotic PMN. This observation raises several 
intriguing questions: does this LL-37-mediated secondarily necrosis of PMN affect 
their clearance by phagocytic cells, does this influence the consequent 
inflammatory responses, do these secondarily necrotic PMN release their 
intracellular constituents to alter the process of inflammation, and do these cells 
have any biological importance in real physiological or pathological conditions? In 
order to address these questions, the ingestion of dying PMN by primary human 
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monocyte-derived macrophage, and the consequences for inflammation, was used 




4.2.1. LL-37-induced secondary necrosis of apoptotic 
PMN does not affect efferocytosis by monocyte-
derived macrophages 
 
To determine whether MDM ingestion of dead PMN would be altered by LL-37-
mediated secondary necrosis, MDM phagocytosis of LL-37-treated and untreated 
PMN was studied by light microscopic enumeration (Fig. 4.1 & 4.2) and by FACS 
analyses. FACS method was validated by Dransfield et al. using a fluorescent 
chloromethyl dye that diffuses freely through plasma membranes to label the 
cytoplasm of cells [507] and phagocytic rate was determined by measuring 
ingestion of fluorescence-labelled PMN by MDM (Fig. 4.3 & 4.4). 
Dexamethasone-primed MDM which have previously been shown to have an 
increased capacity for apoptotic PMN ingestion [394], were used as positive 
control, to demonstrate that differences in the magnitude of ingestion could be 
evaluated using these methods. The data show significantly increased efferocytosis 
(p ≤ 0.05) by dexamethasone-primed MDM, but demonstrate that LL-37-induced 
secondary necrosis of PMN has no significant effects on the magnitude of PMN 
ingestion by MDM. 
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A) MDM+ PMN (20 hr untreated)                                 B) MDM+ PMN (20 hr LL-37 5 µg/ml-exposed) 
      
C) MDM+ PMN (20 hr LL-37 25 µg/ml-exposed)          D) Dexamethasone-treated MDM  
+ PMN (20 hr untreated) 
      
 
Figure 4.1 Representative images of phagocytosis (light microscopic enumeration). PMN were 
incubated for 20 hr, in the absence (A, D) or presence (B, C) of LL-37 at the stated concentrations 
and then incubated with MDM for 1 hr before four times of washing steps to remove noningested 
PMN. For positive control, hMDM were exposed to 1 µM Dexamethasone for 5 days before 
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Figure 4.2 LL-37-induced secondary necrosis of PMN does not affect rates of MDM 
phagocytosis (light microscopic enumeration). PMN were incubated for 20 hr, with or without 
LL-37 (or scrambled LL-37) at the stated concentrations and then incubated with MDM for 1 hr 
before removal of noningested PMN. Phagocytosis was assessed by light microscopy, counting the 
proportion of MDM peroxidase-positive cells (A, indicated by arrows). As a positive control, wells 
of adherent monocytes were also culture in the presence of 1 µM dexamethasone for 5 days to up-
regulate MDM phagocytosis of dead PMN. (A) representative image (B) mean + SEM for n = 3 
donors with each condition in duplicate. Significance was assessed by one-way ANOVA with 
Bonferroni’s multiple comparison post-tests comparing each treatment with control; *, p ≤ 0.05. 
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                         (A) MDM+ PMN (20 hr untreated) 
                            
                         (B) MDM+ PMN (20 hr LL-37 5 µg/ml-exposed) 
                           
                        (C) MDM+ PMN (20 hr LL-37 25 µg/ml-exposed) 
      
                             (D) Dexamethasone-treated MDM+ PMN (20 hr untreated) 
      
 
Figure 4.3 Representative figures of phagocytosis (FACS-based analyses). Dot plots represent 
MDM exposed to fluorescently-labelled PMN (left-sided panel). Histograms represent the 
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Figure 4.4 LL-37-induced secondary necrosis of PMN does not affect rates of MDM 
phagocytosis (FACS-based analyses). PMN were incubated for 20 hr, with or without LL-37 (or 
scrambled LL-37) at the stated concentrations and then incubated with MDM for 1 hr before 
removal of noningested PMN. Dexamethasone-treated MDM were used as positive controls. 
Phagocytosis was assessed by flow cytometric analyses, evaluating the proportion of MDM 
ingesting Cell Tracker Green-labelled PMN (A, B); mean + SEM for n ≥ 3 donors for each 
condition in duplicate (C). Significance was assessed by one-way ANOVA with Bonferroni’s 
multiple comparison test comparing each treatment with control; **, p ≤ 0.01. 
Fluorescently labelled PMN 
 
MDM having phagocytosed 
fluorescently labelled PMN 
 




Percentage of MDM having 
phagocytosed fluorescently labelled 
PMN 
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4.2.2. Uptake of PMN is not inhibited by blocking 
ανβ3/CD36/TSP system 
 
It has been well documented that several receptors are involved in phagocytosis 
of apoptotic PMN by MDM such as PSR, scavenger receptors, lectin-like receptors, 
CD44, and ανβ3/CD36/TSP complex [508]. The mechanisms of recognition of 
apoptosis are influenced by the activating status of macrophages, macrophages at 
different tissue, and the surrounding milieu. However, there are limited data about 
mechanisms by which late apoptotic or secondarily necrotic cells are phagocytosed. 
In order to determine whether LL-37-induced secondarily necrotic PMN and 
apoptotic PMN were phagocytosed by MDM using alternate pathways, inhibition  
of the ανβ3/CD36/TSP system was conducted chemically and using an inhibitory 
antibody as described in a previous report [435]. The tetrapeptide RGDS was used 
to block integrin ( vß3)
 binding, and a mouse anti-human CD36 were used to block 
CD36, with RGES and mouse IgG isotype antibody as negative controls. However, 
no effective inhibition of MDM ingestion of apoptotic PMN was observed (Fig. 
4.5), suggesting that there was a receptor redundancy in the process of clearance of 
dead cells. Thus, phagocytic mechanisms by which MDM ingest LL-37-mediated 
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Figure 4.5 ανβ3/CD36 inhibition does not alter uptake of dead PMN by MDM. MDM were 
pretreated with 1 mM RGDS or mouse anti-human CD36 (1:500) for 30 min before the addition of 
overnight incubated apoptotic PMN. As negative controls, 1 mM RGES and mouse anti-human IgG 
antibody (1:500) were used respectively. Cells were allowed to interact for 1 hr before removal of 
noningested PMN. Phagocytosis was assessed by light microscopy counting; data are shown as 
mean + SEM for n = 3 donors for each condition in duplicate. Significance was assessed by one-
wayANOVA with Bonferroni’s multiple comparison post-test comparing each treatment with 
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4.2.3. LL-37-induced secondarily necrotic PMN are 
not pro-inflammatory to phagocytosing MDM 
 
It is widely accepted that apoptotic cell death does not provoke inflammation, 
whereas necrotic cell death releases a variety of danger signals and stimulates a 
host inflammatory responses. To compare the effects of LL-37-induced secondarily 
necrotic human PMN on phagocytosing MDM, cytokine responses from 
macrophages were evaluated after 18 hr exposure to those PMN, which replicated 
the model used by Fadok et al. to characterise the inflammatory property of 
apoptotic PMN [13]. To separate any effect of residual, functional LL-37 in the 
media from the effects of the dead PMN and the effects of cell bodies from 
released soluble mediators and cellular contents, PMN were incubated for 20 hr at 
a range of concentrations of LL-37 (or scrambled LL-37) and then divided into 
three groups (Fig. 4.6): ①  peptide-treated/ untreated PMN which were 
resuspended in fresh serum-free media, ② unwashed peptide-treated/ untreated 
PMN in their original media (containing 10% FCS), and ③ supernatant from 
peptide-treated /untreated PMN (containing 10% FCS). The responses of MDM 
exposed to these three conditions were then evaluated and contrasted. MDM 
exposed to control apoptotic, LL-37-induced secondarily necrotic PMN, or the 
supernatants from these cells did not produce detectable levels of TNF-α, IL-6, IL-
10, (Fig. 4.7), IL-12p70, or IL-1β (data of IL-12p70 and IL-1β are not shown). 
There were no significant differences between responses to LL-37-treated and 
control untreated PMN. These data suggest that LL-37-induced secondarily 
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necrotic PMN are not pro-inflammatory to phagocytosing MDM, nor releasing 






Figure 4.6 Methods of measuring cytokine responses to MDM phagocytosis of dead PMN. 
Human PMN were incubated for 20 hr in the presence or absence of LL-37 or scrambled LL-37, 
then were divided into three groups to be added to unstimualted/ LPS-activated MDM: ① Peptide-
treated/ untreated PMN which were resuspended in fresh serum-free media, ② unwashed peptide-
treated/ untreated PMN in their original media (containing 10% FCS), and ③ supernatant from 
peptide-treated /untreated PMN (containing 10% FCS). Blank pattern represents serum-free media, 
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              ①+washed PMN              ②+PMN +sup                 ③+Supernatant 








































































































































































































Figure 4.7 LL-37-induced secondarily necrotic PMN are not pro-inflammatory for MDM. 
Human PMN were incubated for 20 hr in the presence or absence of LL-37 or scrambled LL-37 at 
the concentrations indicated, from which three preparations were made: ①  washed cells 
resuspended in serum-free media, ② unwashed in the IMDM + 10 % FCS media, or ③ 
supernatant from peptide-treated /untreated PMN. MDM were then incubated with these PMN. 
Alternatively, MDM were incubated for 18 hr without PMN (nc), in the presence or absence of 
fresh LL-37 as controls. Supernants were evaluated for cytokine responses. Column ① represents 
MDM incubated with washed cells resuspended in serum-free media, column ② shows MDM 
exposed to unwashed PMN in the IMDM + 10 % FCS original media, and column ③ reveals MDM 
exposed to supernatants from PMN (in original media containing 10% FCS). Significance was 
assessed by one-way ANOVA with Bonferroni’s multiple comparison test compared with MDM in 
the absence of PMN; data are shown as mean + SEM for n = 5 donors. 
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4.2.4. LL-37-induced secondarily necrotic PMN retain 
anti-inflammatory activity against LPS-stimulated 
MDM in serum-free media. 
 
Given the unexpected absence of pro-inflammatory activity of LL-37-induced 
secondarily necrotic PMN, the effects of these cells on activated MDM were then 
compared to that of anti-inflammatory apoptotic PMN. To determine the effect of 
secondarily necrotic PMN in the context of pro-inflammatory stimuli and MDM 
activation, MDM were exposed concomitantly to 10 ng/ml E. coli LPS (Fig. 4.8). 
MDM treated with LPS alone had significant TNF-α, IL-6, IL-10, and IL-8 
production, compared to untreated cells. Using method ① to replicate the previous 
study [13], this LPS-induced pro-inflammatory response (TNF-α, IL-6) was 
significantly diminished by the addition of control apoptotic PMN in serum-free 
media (p ≤ 0.01). In contrast to expectation, LL-37-induced secondarily necrotic 
PMN also significantly inhibited LPS-induced pro-inflammatory cytokine 
responses, and the effects were even potentiated under the conditions with the most 
induction of secondary necrosis (LL-37 25 µg/ml), with significantly greater 
inhibition of TNF-α (p ≤ 0.01). This demonstrates that extensive secondary 
necrosis of PMN, unexpectedly, retains anti-inflammatory property as apoptotic 
cells, and the anti-inflammatory effects are even more pronounced. Interestingly, in 
contrast, exposure of MDM to control untreated PMN in their original supernatant 
(method ②) had no effect on the LPS-induced production of TNF-α, IL-6, IL-10, 
and IL-8 by MDM and was essentially the same as exposure to supernatant alone. 
This suggests that some factor in the media, or the FCS, was able to inhibit the 
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anti-inflammatory effects of these apoptotic cells. However, exposure to unwashed, 
LL-37-treated PMN in their original supernatant did inhibit the LPS-induced 
production of TNF-α, IL-6, IL-10, and IL-8 by MDM. This could indicate that a 
factor released during secondary necrosis had an anti-inflammatory effect that was 
not inhibited in the manner observed for the apoptotic cell bodies. However, fresh 
LL-37 alone, added directly to LPS-stimulated MDM in the absence of PMN, was 
able to replicate this inhibitory effect, suggesting that the anti-endotoxic effects of 
residual functional LL-37 in the original supernatant may be responsible for the 
results observed in these later studies. Taken together, these data show that: 1) LL-
37-induced secondarily necrotic PMN are anti-inflammatory, 2) secondary necrosis 
induced by higher concentrations of LL-37 has more pronounced anti-
inflammatory effects, and 3) the anti-inflammatory effects of original supernatants 
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①+washed PMN              ②+PMN +sup                 ③+Supernatant 
































































































































































































































Figure 4.8 LL-37-induced secondarily necrotic PMN retain anti-inflammatory properties. 
Human PMN were incubated for 20 hr in the presence or absence of LL-37 or scrambled LL-37 at 
the concentrations indicated and then either washed and resuspended in serum-free media, or used 
unwashed in the original IMDM + 10% FCS original media. MDM were then incubated, with 
concomitant exposure to 10 ng/ml E. coli 0111:B4 LPS and PMN for 18 hr, or LPS without PMN 
(nc), in the presence or absence of fresh LL-37. Supernatants were evaluated for cytokine responses. 
Column ① represents MDM incubated with washed cells resuspended in serum-free media, column 
② shows MDM exposed to unwashed PMN in the IMDM + 10 % FCS original media, and column 
③ reveals MDM exposed to supernatants from PMN (in original media containing 10% FCS). 
Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison test; data 
are shown as mean + SEM for n = 10 donors (TNF-α); n = 5 donors (IL-6/IL-10/IL-8); *, p ≤ 0.05; 
**, p ≤ 0.01, ***, p ≤ 0.001, compared with MDM exposed to LPS in the absence of PMN; ##, p ≤ 
0.01; ###, p ≤ 0.001, compared with MDM exposed to control apoptotic PMN untreated with LL-37. 
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4.2.5. MDM do not die during the incubation with 
dead PMN or LL-37 peptide. 
 
Although it has been documented that LL-37 is not cytotoxic to MDM below the 
concentration of 250 µg/ml [25], the generalised reduction of cytokine responses in 
MDM exposed to LL-37-treated PMN (or LL-37) raised a question of whether 
MDM died during the process of phagocytosis or died during the incubation with 
LPS, apoptotic PMN, or secondarily necrotic PMN. MTT assay was conducted to 
assess cell viability. Although a trend was observed towards a small decrease in 
total viable cells when MDM were exposed to the PMN with the highest LL-37-
induced secondary necrosis, this was not significant nor of sufficient magnitude to 
account for the pronounced effects on cytokine production. These data indicated 
that there was no significant change in functional cell numbers in response to 
peptide or dead PMN over the incubation period (Fig. 4.9). These findings suggest 
that the observed anti-inflammatory effects can be attributed to the effect of active 
suppressive effects of apoptotic or secondarily necrotic PMN, components release 
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Figure 4.9 MDM do not die during the incubation with dead PMN or LL-37 peptide. Human 
PMN were incubated for 20 hr in the presence or absence of LL-37 at the concentrations indicated 
and used as washed cells resuspended in serum-free media (striped bars, PMN alone). MDM were 
then incubated with concomitant exposure to 10 ng/ml E. coli 0111:B4 LPS and PMN for 18 hr 
(black bars), or LPS without PMN (nc) in the absence/ presence of LL-37 (white bars). 
Supernatants were discarded followed by the addition of MTT reagent according to the 
manufacturer’s instructions (volume of media: MTT solution = 5:1). Absorbance at 490nm 








                                                                                    
169 
                              
4.2.6. Washing steps do not significantly alter the 
death modes of PMN. 
 
In order to evaluate whether the washing and resuspending steps applied to some 
of the PMN could damage the integrity of PMN cell membrane and diminish the 
number of intact cells, FACS analysis (with Annexin V and PI staining) was used 
to study washed and unwashed PMN. Absolute numbers of apoptotic, necrotic, and 
live cells were determined by multiplying the percentage of each group of cells 
(determined by FACS) by total cell number (assessed by nucleocounter). Data 
showed that the procedures of washing and resuspending did not have substantial 
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Figure 4.10 Washing steps do not have substantial effects on dead PMN. Human PMN were 
incubated for 20 hr in the presence or absence of LL-37 at the concentrations indicated and then 
were washed and resuspended once or twice in serum-free media. Cell death was assessed by FACS 
analyses of cells stained with Annexin V and PI (A). Total cell numbers were determined by 
nucleocounter (B). Absolute cell numbers of apoptotic, necrotic and AV-PI- cells were determined 
by multiplying percentages by total cell numbers (C); data are shown as mean + SEM for n=4 
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4.2.7. Short exposures of LPS-stimulated MDM to 
LL-37-induced secondarily necrotic PMN retain anti-
inflammatory effects.   
 
One of the potential problems with allowing the apoptotic PMN to remain in 
contact with the MDM for 18 hr was the possibility of ongoing secondary necrosis 
throughout the period of incubation that could influence the results. Although 
Fadok et al. claimed that dead PMN were still anti-inflammatory to phagocytosing 
MDM even incubated for 18 hr when most of cells were supposed to be 
secondarily necrotic  [13], experiments were conducted to confirm that. LPS-
activated MDM were allowed to phagocytose apoptotic or LL-37-induced 
secondarily necrotic PMN, or were incubated with serum-free media in the absence 
of PMN for 1 hr, after which time residual cells were removed by washing, 
followed by the addition of fresh serum-free media and the second dose of 10 
ng/ml LPS to ensure a continued activating pro-inflammatory stimulus. 
Supernatants were collected 17 hr after incubation to evaluate cytokine production. 
Although the total cytokine concentrations were significantly lower compared to 
18 hr incubation without washing steps (p ≤ 0.001), 1 hr of LPS-stimulated MDM 
to apoptotic or secondarily necrotic PMN decreased TNF-α production (Fig. 
4.11B). However, in contrast to the 18 hr continuous exposure, the potentiating 
anti-inflammatory effects of LL-37-mediated secondary necrosis of PMN (at LL-
37 25 µg/ml) were not observed in short exposure experiments (Fig. 4.11A vs. 
4.11B or 4.11C vs. 4.11D). These data demonstrate that only a brief exposure to 
dead PMN is sufficient to have anti-inflammatory effects, but raise the possibility 
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that the more pronounced effects of PMN previously incubated with high 
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Figure 4.11 Short exposure of LPS-stimulated MDM to LL-37-induced secondarily necrotic 
PMN remains anti-inflammatory effect. Human PMN were incubated for 20 hr in the presence or 
absence of LL-37 at the concentrations indicated, washed and resuspended in serum-free media. 
MDM were then incubated with 10 ng/ml E. coli 0111:B4 LPS for 1 hr, in the presence or absence 
(nc) of PMN. Noningested PMN were then removed followed by the addition of fresh media and 10 
ng/ml E. coli 0111:B4 LPS for another 17 hr (B, D), or PMN and LPS were left coincubated with 
MDM for a total of 18 hr (A, C). Supernatants were evaluated for cytokine responses. Significance 
was assessed by two-way ANOVA with Bonferroni’s multiple comparison test; n=5 donors; *, p ≤ 
0.05; **, p ≤ 0.01, compared with MDM exposed to LPS in the absence of PMN. Figure panel A & 
B demonstrated mean + SEM, whereas to correct for significant donor variation in absolute 
responses in these studies panels. C & D demonstrate the mean + SEM of the percentage of TNF-α 
production by MDM exposed to PMN, as a proportion of the total TNF-α production by activated 
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4.2.8. Serum inhibits the anti-inflammatory effects of 
apoptotic and LL-37-induced secondarily necrotic 
PMN. 
 
To determine whether the loss of inhibitory activity of apoptotic PMN observed 
with they were used in their original supernatant (Fig. 4.8), related to factors 
secreted into the media by the dying cells, or to the presence of serum, 20 hr 
incubated PMN were washed and then resuspened in fresh media with or without 
10% FCS. The anti-inflammatory properties of these cells were then evaluated 
against LPS-activated MDM. Apoptotic PMN completely lost their anti-
inflammatory properties in the presence of 10% FCS (Fig. 4.12). In addition, the 
presence of 10% FCS had a very significant impact on the anti-inflammatory 
properties of LL-37-induced secondarily necrotic PMN (Fig. 4.12), with only the 
most necrotic cells (with secondary necrosis induced by 25 µg/ml LL-37) retaining 
any significant anti-inflammatory effects in the presence of serum. This data 
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Figure 4.12 Serum inhibits the anti-inflammatory effects of apoptotic and LL-37-induced 
secondarily necrotic PMN. Human PMN were incubated for 20 hr in the absence or presence of 
LL-37 at the concentrations indicated. PMN were resuspened in X-vivo 10 media or X-vivo media 
with 10% FCS. MDM were exposed to these PMN with concomitant exposure to 10 ng/ml E.coli 
0111:B4 LPS for 18 hr. Activated MDM alone without PMN, in the presence or absence of serum 
were also studied as controls. Supernatants were evaluated for cytokine responses. Significance was 
assessed by two-way ANOVA with Bonferroni’s multiple comparison test; data are shown as mean 
+ SEM as a proportion of the total TNF-α production by activated MDM in the absence of PMN for 
each donor; n = 3 donors; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, compared with activated MDM 
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4.2.9. Partial LL-37 peptide-induced secondarily 
necrotic PMN are also anti-inflammatory to LPS-
activated MDM, irrespective of anti-endotoxic 
activity. 
 
In contrast to the original hypothesis, LL-37-induced secondarily necrotic PMN 
retain potent anti-inflammatory property. One possible confounding factor 
remaining in interpreting the data thus far could be that LL-37 has anti-endotoxic 
activity, and therefore any residual LL-37 remaining with the washed secondarily 
necrotic PMN could inhibit MDM activation and skew the result. Thus, three 22-
mer partial peptides from the partial peptide library, for which I have evaluated the 
capability to inducing secondary necrosis, were selected (Fig. 3.19). The anti-
endotoxic activity of these three peptides were characterised by TNF-α production 
by LPS-activated MDM exposed to these peptides (Fig. 4.13A white bars). N-
terminal peptide p1, which induced no PMN secondary necrosis (Fig. 3.19), also 
had no direct anti-endotoxic effect (Fig. 4.13A). C-terminal peptides p2 and p3 
induced significant PMN secondary necrosis (Fig. 3.19), but whereas p2 had direct 
anti-endotoxic effects, p3 did not have any significant anti-endotoxic properties 
(Fig. 4.13A). When 20 hr treated PMN in their original media were incubated with 
MDM concomitantly with LPS, their anti-inflammatory capacity clearly correlated 
with the anti-endotoxic properties of the peptide those PMN has been exposed to 
(Fig. 4.13A). Under these conditions, FCS in the original media inhibited the anti-
inflammatory effects of the cells, and residual functional peptide in the media 
appears to be responsible for the anti-inflammatory effects of full-length LL-37 
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and partial peptide p2. However, in contrast, when these same apoptotic or 
secondarily necrotic PMN incubated previously for 20 hr with these peptides, were 
resuspended in fresh serum-free media, these cells were all capable of mediating a 
significant inhibition of LPS-induced MDM TNF-α production, identical to 
untreated control apoptotic cells (Fig. 4.13B). These data demonstrated a) that no 
negligible functional residual peptide is carried over after washing the dead PMN, 
b) that peptide-induced secondarily necrotic PMN (here induced by LL-37, p2, or 
p3) had anti-inflammatory activity against LPS-stimulated MDM comparable to 
apoptotic PMN (controls or p1 treated), and c) that this inflammation-dampening 
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Figure 4.13 The anti-inflammatory properties of LL-37-induced secondarily necrotic PMN 
are independent of the anti-endotoxic activity of peptides. Human PMN were incubated for 20 
hr in the presence or absence of LL-37 (L) or partial peptides (p1, p2, or p3) at the concentrations 
indicated. PMN were washed and resuspended in X-vivo 10 media (B), or used unwashed in the 
IMDM +10% FCS media supernatant, in which they had been incubated overnight (A). MDM were 
incubated alone or with these PMN with concomitant exposure to 10 ng/ml E.coli 0111:B4 LPS for 
18 hr. LPS-activated MDM without PMN were also stuided, in the presence or absence of peptides, 
to evaluate direct anti-endotoxic activity of peptides (white bars in Fig A). Supernatants were 
evaluated for cytokine responses. Significance was assessed by one-way ANOVA with 
Bonferroni’s multiple comparison test; data are shown as mean + SEM for n = 4 donors; *, p ≤ 0.05; 
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4.2.10. LL-37-induced secondarily necrotic PMN are 
also anti-inflammatory to rhCD40L/INF-γ-activated 
MDM.  
 
To further confirm that the anti-inflammatory effects of LL-37-induced 
secondarily necrotic PMN were independent of the anti-endotoxic effects of the 
peptide, and had broader anti-inflammatory properties, rhCD40L and INF-γ 
treatment were used as an alternative activating signal for MDM (Fig. 4.14). LL-37 
had no significant capacity to directly inhibit the MDM-activating properties of 
this stimulus (Fig. 4.14A), and indeed showed a non-significant trend towards 
potentiating the activation at higher concentrations of LL-37. However, both 
apoptotic PMN and LL-37-induced secondarily necrotic PMN were capable of 
significantly inhibiting MDM activation (p ≤ 0.001), as assessed by pro-
inflammatory TNF-α cytokine production as the results observed in LPS-activated 
MDM. These results demonstrate equivalence with the results observed in LPS-
activated MDM, and further confirm that the anti-inflammatory effects of these 
LL-37-induced secondarily necrotic PMN are not dependent upon the anti-








                                                                                    
180 




























































Figure 4.14 LL-37-induced secondarily necrotic PMN are anti-inflammatory to 
rhCD40L/INF-γ-activated MDM. A) MDM were activated with 3 µg/ml rhCD40L +5 ng/ml 
rhINF-γ for 18 hr in the presence or absence of LL-37 at the stated concentrations. B) Human PMN 
were incubated for 20 hr in the absence or presence of LL-37 at the concentrations indicated. PMN 
were washed and resuspened in serum-free X-vivo 10 media. MDM were incubated with these 
PMN, with concomitant exposure to 3 µg/ml rhCD40L + 5 ng/ml rhINF-γ for 18 hr. Supernatants 
were evaluated for cytokine responses. Significance was assessed by one-way ANOVA with 
Bonferroni’s multiple comparison test; data are shown as mean + SEM as a proportion of the total 
TNF-α production by activated MDM in the absence of PMN for each donor, n = 3 donors; ***, p 
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4.2.11. LL-37-induced secondary necrosis of PMN can 
release cytoplasmic and granule contents. 
 
As previously described (Fig. 3.22), LL-37 at higher concentrations (> 25 µg/ml) 
can induce the release of PMN granule contents. MPO release was not detected 
above background at 20 hr time point following exposure to ≤ 10 µg/ml LL-37 
(concentrations at which substantial secondary necrosis occurred, Fig. 4.15D) or in 
responses to scrambled LL-37. However, LL-37 at higher concentrations (≥ 25 
µg/ml) induced release of MPO from azurophilic granules. In contrast, in 
collaboration with Dr. Robert Gray, we demonstrated that 20 hr PMN exposed to 5 
µg/ml LL-37, at which concentration substantial secondary necrosis was induced 
as evaluated by PI permeability, induced significant increase of a cytoplasmic 
protein calprotectin release (p ≤ 0.05) (Fig. 4.15A). These data suggest that LL-37 
at lower concentration (< 10 µg/ml) can permeabilise cell plasma membrane, 
leading to the leakage of cytoplasmic contents, whereas LL-37 at higher 
concentration (>25 µg/ml) not only breaks up cytoplasmic membrane but also 
permeabilises granules. In addition to evaluating granule content release at 20 hr 
(when secondary necrosis was significantly induced by LL-37, but negligible in 
control cells), I evaluated the effect after 38 hr incubation to include full period of 
incubation of PMN in the MDM stimulation assay (Fig. 4.15C). In contrast to 20 hr 
incubation, PMN cultured for 38 hr have increased MPO release, even under 
control conditions. This is to be expected given the extent of necrosis by this 
timepoint, even in the control cells. Indeed the level of secondary necrosis 
observed at 38 hr was equivalent in all the samples irrespective of peptide 
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treatment (Fig. 4.15E). Intriguingly, LL-37 at higher concentration (≥ 25 µg/ml) 
significantly induced significantly greater MPO release at 38 hr (p ≤ 0.01) than 
control cells, even although the necrotic rate was equivalent, as assessed by FACS 
study (Fig. 4.15E). These data indicate that higher concentrations of LL-37 are able 
to destabilise granules and lead to the release of their intracellular contents. 
Whereas, untreated apoptotic cells, despite gradually undergoing secondary 
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Figure 4.15 LL-37-induced secondary necrosis of PMN can release cytoplasmic and granule 
contents. A) Isolated human PMN were incubated for 20 hr without or with exposure to LL-37 at 
concentrations stated in the presence of 10% FCS. The concentration of calprotectin in the 
supernatant was evaluated by ELISA by Dr. R. Gray. B-E) Isolated human PMN were incubated 
for 20 hr or 38 hr over a range of concentrations of LL-37 or scrambled LL-37 (scr50). The 
concentrations of MPO in the supernatant were evaluated as a percentage of total MPO release 
after lysis of fresh control MPO using 0.1% Triton X-100 (B, C). PMN death was also assessed by 
FACS analysis (D, E). Significance of protein release was assessed by one-way ANOVA with 
Bonferroni’s multiple comparison test; data are shown as mean + SEM for n = 4 donors 
(calprotectin), or n = 7 donors (MPO); *, p ≤ 0.05 **, p ≤ 0.01, compared with untreated control 
PMN. 
     0              5             25 
                LL-37 µg/ml 
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4.2.12. “Freeze-and-thaw-induced” primary necrotic 
PMN are anti-inflammatory to phagocytosing MDM. 
 
Necrotic cells are generally considered to pose a danger to the immune system, 
resulting in pro-inflammatory responses. Since secondary necrosis of PMN were 
anti-inflammatory in my system, the contrasting inflammatory potential of primary 
necrotic PMN compared to apoptotic PMN as previously proposed [457], was 
investigated. Freeze-and-thaw-induced primary necrotic PMN were incubated with 
LPS-stimulated MDM in the absence or in the presence of 10% FCS. In contrast to 
our original expectation, primary necrotic PMN were anti-inflammatory both in 
serum-free and in serum-present media (Fig. 4.16). The data are compatible to a 
study published recently in which dying and necrotic PMN were found to be anti-
inflammatory secondary to the release of anti-inflammatory peptide α-defensins 
[387]. Apoptotic, LL-37-mediated secondarily necrotic, and freeze-thaw-induced 
primary necrotic PMN were therefore all anti-inflammatory to phagocytosing 
MDM in this in vitro system, suggesting that the inflammatory consequences of 
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Figure 4.16 Primary necrotic PMN are anti-inflammatory to activated MDM both in the 
absence or presence of serum. Fresh human PMN were suspended in IMDM in the absence of 
serum (A, C) or in the presence of 10% FCS (B, D). PMN were frozen and thawed for 3 cycles to 
induce primary necrosis. MDM were then incubated with these primary necrotic PMN with 
concomitant exposure to 10 ng/ml E.coli 0111:B4 LPS for 18 hr. Activated MDM without PMN 
(nc), in the presence or absence of serum, were also studied as controls. Supernatants were 
evaluated cytokine responses. Data were presented as raw TNF-α concentrations (A, B) and as 
percentages of TNF-α production by activated MDM (C, D); data are shown as mean + SEM for n 
≥ 12 donors. Significance was assessed by Student’s t-test compared with activated MDM in the 
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4.2.13. The activity of α-defensins is inhibited by serum 
components, whereas LL-37 retains its anti-endotoxic 
property in the presence of serum.  
 
HNP, cathelicidins, and other PMN granule components are expected to be 
released during the process of granule membrane permeabilisation in necrosis. 
Whether these components, released from necrotic PMN, could be responsible for 
effects observed, was unknown. Thus the anti-inflammatory activity of HNP and 
LL-37 were evaluated in the presence or absence of serum. Both of peptides have 
potent anti-endotoxic activity in the absence of serum (Fig. 4.17A, C). However, 
unlike LL-37, for which anti-endotoxic function was retained in the presence of 
serum (Fig. 4.17D), the anti-endotoxic effects of HNP were inhibited by unknown 
serum factors (Fig. 4.17B). These findings suggest that both HNP and LL-37 
possess anti-endotoxic capability while demonstrating that this activity is serum-
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Figure 4.17 The activity of α-defensins is inhibited by serum components, whereas LL-37 
retains its anti-endotoxic property in the presence of serum. MDM were untreated/ treated with 
5 µg/ml HNP (A, B) or LL-37 (C, D) concomitantly exposure to 10 ng/ml E.coli 0111:B4 LPS for 
18 hr in the absence (A, C) or presence of 10% FCS (B, D). Untreated MDM and peptide-exposed 
MDM were also studied. Supernatants were evaluated cytokine responses; n = 3 donors. 
Significance was assessed by two-way ANOVA; data are shown as mean + SEM; *, p ≤ 0.05; ***, 
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4.2.14. Thioglycollate-elicited sterile peritonitis induces 
PMN influx. 
 
LL-37-induced secondary necrosis of apoptotic PMN is not pro-inflammatory in 
in vitro studies, thus the question arose of whether secondarily necrotic PMN are 
anti-inflammatory in vivo. The thioglycollate-induced sterile peritonitis mouse 
model was chosen as a well-characterised model, with significant PMN influx, in 
which the effects of LL-37 on these recruited PMN would be investigated. In order 
to establish this model, mice were intraperitoneally injected with 0.5 ml 10% 
thioglycollate or PBS as control, and peritoneal lavages were performed, either 3 hr 
or 24 hr after initial thioglycollate injection. PMN in peritoneal lavage were 
assessed by FACS to determine the percentage of cells expressed Ly6G, a specific 
protein expressed on mouse peripheral PMN. Data revealed that thioglycollate 
effectively induced PMN influx at 3 hr and 24 hr, providing an acute inflammatory 
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             (A) PBS 3hr 
   
             (B) Thioglycollate 3hr 
   
             (C) PBS 24hr 
   
 (D) Thioglycollate 24hr 
   
Figure 4.18 Representative FACS plots. Dot plots represent cell population selected for analysis 
(left-sided panel). Histograms represent the percentage of cell with positive Ly6G expression 
(Green graph) and antibody isotype control (red graph) (right-sided panel). 
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Figure 4.19 Thioglycollate induces PMN influx in sterile peritonitis model. Six to eight week 
old Balb/c mice were injected intraperitoneally with 0.5 ml 10% thioglycollate or PBS as control, 
and the peritoneal lavages were performed after 3 hr and 24 hr. Total cell numbers were counted by 
nucleocounter and the percentages of PMN in peritoneal fluids were assessed by FACS. PMN 
numbers were then determined by multiplying total cell numbers by percentages of PMN; data are 
shown as mean + SEM for n ≥ 4. Significance was assessed with Student t-test to compare PBS and 
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4.2.15. LL-37 is anti-inflammatory during sterile 
thioglycollate-induced peritoneal inflammation 
 
In order to evaluate the effects of LL-37 on the induction of PMN influx during 
sterile inflammation, 25 µg/ml LL-37 was injected simultaneously with 0.5 ml PBS 
or 0.5 ml 10% thioglycollate to mouse peritoneum. Three hours after injection, 
peritoneal lavages were performed and the number of PMN in peritoneal fluids was 
evaluated. As report in the literature [19], LL-37 had chemotactic property, 
demonstrating 2-3 fold greater peritoneal lavage total cell and PMN counts in LL-
37 + PBS-injected mice, when compared to PBS-only mice (although this did not 
reach statistical significance). Interestingly, in contrast, LL-37 diminished PMN 
influx in thioglycollate-induced peritonitis (even though this did not reach 
statistical significance) (Fig. 4.20), demonstrating its anti-inflammatory properties. 
In addition, LL-37 significantly inhibited pro-inflammatory cytokine (IL-6 and 
MCP-1) production (p ≤ 0.05), and diminished TNF-α production in 
thioglycollate-mediated inflammation (Fig. 4.21). These data demonstrate complex 
in vivo anti-inflammatory immunomodulatory functions of LL-37, with modulation 








                                                                                    
192 






























































Figure 4.20 LL-37 modulates inflammatory cell numbers in vivo during thioglycollate-induced 
inflammation. Six to eight week old Balb/c mice were intraperitoneally injected with 0.5 ml 10% 
thioglycollate or 0.5 ml PBS in the presence or absence of 25 µg/ml LL-37 (12.5 µg peptide in 0.5 
ml PBS or thioglycollate as mentioned). The peritoneal lavages were performed 3 hr after injection. 
Total cell numbers were counted by nucleocounter (A) and the number of PMN was determined by 
FACS and total cell number (B); data are shown as mean + SEM for n = 6 mice. Significance was 
assessed with two-way ANOVA with Bonferroni’s multiple comparison tests, compare mice with 
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Figure 4.21 LL-37 inhibits pro-inflammatory cytokine production during thioglycollate-
induced sterile inflammation. Six to eight week old Balb/c mice were injected intraperitoneally 
with 0.5 ml 10% thioglycollate or 0.5 ml PBS in the presence or absence of 25 µg/ml LL-37 (12.5 
µg peptide in 0.5 ml volume). The peritoneal lavages were collected 3 hr after injection and 
cytokine production was evaluated by CBA analysis; data are shown as mean + SEM for n = 6 mice. 
Significance was assessed with two-way ANOVA with Bonferroni’s multiple comparison tests, 
compared mice with or without LL-37 exposure under the same reagent injection (PBS/ 
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4.2.16. LL-37-induced secondarily necrotic PMN are 
anti-inflammatory in vivo. 
 
LL-37-mediated secondary necrosis of apoptotic PMN is not pro-inflammatory 
in vitro, and PMN exposed to higher concentrations of LL-37 have even more 
pronounced anti-inflammatory effects. To determine the inflammatory impacts of 
the secondary necrosis of PMN in inflammation in vivo, overnight incubated 
apoptotic human PMN, LL-37-induced secondarily necrotic PMN, or control 
media were administered in thioglycollate-elicited sterile peritonitis or PBS-
injected mice. Three hours after injection peritoneal cells were harvested and 
analysed by FACS. Consistent with in vitro findings, apoptotic and LL-37-induced 
secondarily necrotic cells were anti-inflammatory in thioglycollate-induced 
peritonitis, demonstrating a trend towards inhibition of PMN influx (Fig. 4.22) and 
significantly inhibiting TNF-α production (Fig. 4.23) (p ≤ 0.05). However, in these 
studies the effects of apoptotic and LL-37-induced secondarily necrotic cells were 
largely comparable. These data indicate that in sterile inflammation, secondarily 
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Figure 4.22 LL-37-induced secondarily necrotic PMN diminish PMN influx in thioglycollate-
induced sterile peritonitis. Six to eight week old Balb/c mice were injected intraperitoneally with 
apoptotic human PMN, LL-37 (25 µg/ml)-induced secondarily necrotic PMN, or media 
concomitantly with 0.5 ml 10% thioglycollate or 0.5 ml PBS. The peritoneal lavages were collected 
3 hr after injection. Total cell numbers were counted by nucleocounter (A) and PMN numbers were 
determined by FACS and total cell number (B); data are shown as mean + SEM for n = 4 mice. 
Significance was assessed with two-way ANOVA with Bonferroni’s multiple comparison post-tests 
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Figure 4.23 LL-37-induced secondarily necrotic PMN are anti-inflammatory in thioglycollate-
induced sterile peritonitis. Six to eight week old Balb/c mice were injected intraperitoneally with 
apoptotic human PMN, LL-37 (25 µg/ml)-induced secondarily necrotic PMN, or media 
concomitantly with 0.5 ml 10% thioglycollate or 0.5 ml PBS, and mice without PMN injection were 
used as controls. The peritoneal fluids were collected 3 hr after injection and cytokines were 
evaluated by CBA analysis; data are shown as mean + SEM for n = 4 mice. Significance was 
assessed with two-way ANOVA with Bonferroni’s multiple comparison post-tests used to compare 
mice with and without PMN injection under the same conditions (PBS/ thioglycollate); *, p ≤ 0.05; 
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4.3. Discussion 
 
In comparison to the well characterised effects of apoptosis, studies on death by 
secondary necrosis are still scarce. Although secondary necrosis has been 
implicated as a major pathogenic mechanism in several inflammatory disorders 
[509], the biological significance of this cell death remains unclear. I have 
demonstrated that LL-37, a multi-faceted modulator of inflammation and immune 
responses, is a potent inducer of PMN secondary necrosis. Given the conventional 
views, in which apoptosis is regarded as anti-inflammatory while necrosis is 
considered as a pro-inflammatory event, were true, LL-37-mediated secondary 
necrosis of PMN was expected to be pro-inflammatory in nature. However, my 
data contrast with these initial expectations, suggesting that the inflammatory 
consequences determined by the various modalities of cell death are more 
complicated than initially proposed. 
 
It was proposed that different forms of cell death affected the efficiency of 
phagocytosis, with phagocytes may recognising and ingesting dead cells by 
different mechanisms, dependent upon their mode of death. My data fail to support 
this assumption, demonstrating similar phagocytic rates by MDM in uptake of 
apoptotic and secondarily necrotic PMN. Two methods were used to ensure the 
accuracy of assessment. Although it is noted that microscopy-based enumeration 
has generally lower phagocytic rates than FACS-based assessment (probably due 
to the extra washing steps in the former method removing the MDM having 
phagocytosed the most PMN, and the potential inclusion of adherent, but not 
                                                                                    
198 
                              
internalised PMN by FACS), the overall uptake is consistent, irrespective of the 
induction of secondary necrosis. The possibility that MDM may use different 
mechanisms to engulf apoptotic and secondarily necrotic PMN can not be excluded 
by this experimental approach, but these data suggest the possibility that apoptotic 
PMN induced to undergo secondary necrosis in response to LL-37 are recognised 
by the same mechanisms as apoptotic PMN.  
 
In addition, it should be noted that the influences of LL-37 itself on the process 
of phagocytosis could not be ruled out. In phagocytic studies, MDM were 
incubated with LL-37-mediated secondarily necrotic PMN with concomitant 
exposure to the original cultured media containing residual peptide. As the 
presence of cationic amino acids can inhibit recognition mechanisms of 
macrophages [510], LL-37, which is a peptide with positive charges, may inhibit 
the cell clearance. On the other hand, Davidson et al. demonstrated that LL-37 
could significantly enhanced phagocytosis by professional phagocytes [159]. 
However, in the absence of discernable differences in my studies, I would conclude 
that apoptotic PMN induced to secondary necrosis by LL-37 do not alter the 
efficiency of phagocytosis, possessing similar clearance rates compared with 
apoptotic cells. 
 
In keeping with the pioneer study, phagocytosis of apoptotic PMN (in contrast to 
immunoglobulin G-opsonised apoptotic cells) actively inhibited the production of 
TNF-α, IL-10, and IL-8 by MDM. However, in contrast to initial expectations, 
ingestion of LL-37-induced secondarily necrotic PMN was not a pro-inflammatory 
                                                                                    
199 
                              
event, and did not promote the pro-inflammatory cytokine release. Furthermore, 
these secondarily necrotic PMN were actively anti-inflammatory, and the anti-
inflammatory effects were enhanced in response PMN with the most extensive 
secondary necrosis.  These data suggest functional equivalence, irrespective of 
membrane integrity, of apoptotic PMN and LL-37-induced secondarily necrotic 
PMN in this system, with an additional anti-inflammatory effect dependent upon 
secondary necrosis induced by high concentrations of LL-37. 
 
The exact mechanism by which dead PMN inhibit the activation of MDM is still 
unknown. Previous reports suggested the possible role of anti-inflammatory 
cytokines TGF-β1 and IL-10 in suppression of inflammatory responses [13, 459]. 
However, other studies suggested that cell contact was the main determinant of 
anti-inflammatory consequence [462, 463]. Although my experiments do not 
specifically address the importance of these mediators and cell interaction in 
inflammation-dampening results, it is clear that this peptide can modulate 
inflammatory responses by altering the mode of PMN death.  
 
Short exposure of MDM to apoptotic or LL-37-induced secondarily necrotic 
PMN was sufficient to dampen pro-inflammatory reaction. However, the 
potentiated anti-inflammatory responses of secondary necrosis in 18 hr continuous 
exposure were not observed in short exposure. In conjunction with my 
observations on LL-37-mediated granule content release, this suggest that 
secondary necrosis induced by higher concentrations of LL-37 results in steady 
releases of anti-inflammatory granule contents, whereas short exposure to the dead 
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cells does not allow this extra anti-inflammatory reinforcement. The data also 
suggest that from the earliest stages after engulfment MDM produce mediators to 
promote their later cytokine production, with removal of these mediators resulting 
in diminished total cytokine production.  
 
Unknown serum factors were found to inhibit the anti-inflammatory effects of 
apoptotic PMN and secondarily necrotic PMN (to a variable extent, dependent 
upon the concentrations of LL-37 used to induce secondary necrosis), probably 
through blocking the undefined anti-inflammatory activity of cellular components 
(eg. cell membrane, cytoplasmic proteins, granule contents) or of mediators 
released from dead cells (eg. cytokines). As serum contains abundant proteins 
which function as opsonins [422, 462, 511-513], bridging molecules, binding 
proteins, and proteases, it can be expected that the presence of serum can alter cell 
engulfment, degrade the activity of soluble mediators, inhibit anti-inflammatory 
molecules, and modulate the eventual inflammatory outcomes. To further 
characterise the inhibitory factors of serum, fractionated serum could be used in the 
future to identify key proteins influencing the inflammatory results of dead PMN.  
 
The anti-inflammatory effects of LL-37-induced secondary necrosis could have 
been the result of the anti-endotoxic effects of residual LL-37 in the media, or even 
residual peptide retained on PMN membranes. Partial peptide with poor anti-
endotoxic capability and CD40L/INF-γ were used to exclude these possibilities. 
Although recent data revealed that LL-37 could also inhibit cellular responses to 
INF-γ in monocytic cells, showing suppression of cell activation and pro-
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inflammatory cytokine production [514], my results did not support these 
observations. LL-37 peptide did not inhibit pro-inflammatory cytokine production, 
by CD40/INF-γ-stimulated MDM, but LL-37-induced secondary necrosis of 
apoptotic PMN did have anti-inflammatory effects. The data indicate that LL-37-
altered PMN death possess modulatory activities of inflammation which is 
independent of the anti-endotoxic property of the peptide.   
 
In contrast to original expectations, freeze-and-thaw-induced necrosis of PMN 
was not pro-inflammatory in my studies, an observation which was also reported 
by Fadok et al. although their results were inconsistent [13]. Although Fadok et al. 
later demonstrated that necrotic PMN could stimulate production of cytokines such 
as IL-8, TNF-α, and IL-10 by phagocytosing macrophages through releasing pro-
inflammatory proteases [269], using separation of necrotic PMN into membrane 
and soluble fractions, they showed that the PMN membranes behaved like 
apoptotic cells. In addition, the authors demonstrated that late apoptotic PMN 
released very little elastase and the anti-inflammatory effects of the membrane 
could predominate over pro-inflammatory properties [269].  
 
Another report indirectly supports the anti-inflammatory property of necrotic 
PMN, showing that necrotic PMN do not release pro-inflammatory mediator 
HMGB1, in contrast to apoptotic cells from as most tumour cell lines [515]. These 
disparities in studies of the inflammatory impacts of necrosis may be due to 
variations in the necrotic cell preparation and the unique properties of specific cell 
types used. As mentioned above, PMN can release anti-inflammatory peptides 
                                                                                    
202 
                              
during death [387], which may explain why this type of cell has an anti-
inflammatory propensity, regardless of the mode of cell death. Also, it may be 
possible that apoptotic process degrades pro-inflammaotry PMN proteases such as 
elastase, and oxidises pro-inflammatory mediators, such as HMGB-1 [353, 354], 
but preserves the activity of anti-inflammatory peptides, resulting in the tendency 
to inhibiting inflammation of late apoptotic/ secondarily necrotic PMN. 
 
During the process of inducing secondary necrosis by LL-37, PMN which were 
exposed to higher concentrations of LL-37 release greater amount of granule 
contents (eg. HNP, LL-37), which may enhance their anti-inflammatory effects. 
This proposal is supported by recent work from Dr. Mohini Gray’s group, 
demonstrating the anti-inflammatory potential of necrotic PMN, and that α-
defensins in the membrane-free fraction of necrotic PMN are potent anti-
inflammatory mediators, in the absence of serum [387]. Interestingly, in keeping 
with my data, inhibition of the effects of α-defensins in these membrane-free 
fractions from necrotic PMN completely inhibited the anti-inflammatory properties 
against INFγ/CD40L (agsinst which stimulus α-defensins have potent activity), but 
only partially inhibited the anti-inflammatory effects against LPS. This suggests a 
primary role for α-defensins against the former stimulus, but roles for both LL-37 
and α-defensins against the latter stimulus. However, my studies demonstrate that 
the activity of HNP is inhibited by the presence of serum, and only PMN releasing 
the greatest amount of granule contents (and therefore the most “serum resistant” 
LL-37) retained the anti-inflammatory capability in the presence of serum. The 
induction of granule content release from secondarily necrotic PMN and primary 
                                                                                    
203 
                              
necrotic PMN provide a reasonable hypothesis for their potent anti-inflammatory 
property. 
 
However, studies increasingly demonstrate that the anti-inflammatory impact of 
apoptosis is dominant over the pro-inflammatory effect of necrosis [448, 462, 463]. 
It is technically challenging to separate dead cells into pure populations for 
studying, however, such mixtures should reflect real inflammatory conditions, in 
which we can expect the existence of mixed populations of dead cells. 
Nevertheless, according to this hypothesis, the anti-inflammatory properties of 
mixtures of apoptotic and LL-37-induced secondarily necrotic PMN (as found in 
my experimental system), might be predicted to be equivalent to the anti-
inflammatory effects of even a minority of apoptotic cells. Although this could 
provide a possible explanation for the apparent equivalence of apoptotic and 
secondarily necrotic PMN, such a hypothesis would not explain the enhanced anti-
inflammatory properties of the most secondarily necrotic PMN. 
 
Irrespective, the anti-inflammatory nature of LL-37-induced secondarily necrotic 
PMN, which raises another interesting question: is LL-37-induced secondary 
necrosis immunogenic? In addition to macrophages, DC are another type of APC 
with specific response to dying cells. In vivo observations suggest that there is a 
balance between macrophage- and dendritic cell-mediated clearance of dead cells. 
Macrophages may maintain homeostasis by promote the silent disposal of dying 
cells, whereas clearance by dendritic cells favours an immune responses [458, 484]. 
LL-37-modulated PMN death may have significant impacts on immune responses 
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once phagocytosed by DC or non-professional phagocytes. Cancer research reveals 
that post-apoptotic tumors are more immunogenic than early apoptosis and DC 
have higher efficiency to cross-present them [516], while others state that only 
certain extent of necrosis can release DC maturation factor and post-apoptotic cells 
behave more like early-apoptotic cells [14]. The immunogenicity of LL-37-
mediated secondary necrosis may acquire physiological significances but was 
beyond the scope of this thesis.  
 
The sterile peritonitis model demonstrates that LL-37-induced secondary 
necrosis is anti-inflammatory in vivo, as predicted by in vitro data. This model 
system induces inflammatory responses with a swift PMN influx. Although the 
model is too simple to reflect complexity of specific disease states, in which many 
mediators are concomitantly present, it provides interesting initial confirmation of 
the in vitro observations. Although cell death was evaluated to determine whether 
injection of LL-37 could induce secondary necrosis of recruited apoptotic mouse 
PMN, the rates of apoptosis detectable were too low (data are not shown) to 
address this question. Thus, human PMN exposed to LL-37 were used as a 
secondarily necrotic PMN stimulus. My data showed that LL-37-induced 
secondarily necrotic PMN behaved in an anti-inflammatory manner comparable to 
that of apoptotic PMN in the mouse peritonitis model, the possibility that cells 
from different species will result in different inflammatory responses cannot be 
ruled out.  
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Under physiological conditions, PMN undergo spontaneous apoptosis and are 
swiftly removed by phagocytes, probably minimising the number of apoptotic cells 
available for LL-37-induced secondary necrosis. However, under pathological 
conditions, with excessive neutrophilia, apoptosis can be facilitated by the presence 
of pathogens or cytokines, with the additionally delayed clearance [509]. Under 
these conditions, LL-37 may induce secondary necrosis of PMN with anti-
inflammatory, protective consequences. However, it is possible that the release of 
other PMN factors could have deleterious consequences in this scenario, with the 
balance of effects therefore unknown. More in vivo studies are therefore required 
in the future, promoting extensive neutrophilia, and inducing massive apoptosis (eg. 
Fas ligand, R-Roscovitine, bacterial metabolites) to overload the clearance capacity, 
and inducing secondary necrosis by LL-37 (or its homologue mCRAMP) to better 




LL-37-induced secondary necrosis of human PMN is anti-inflammatory in vitro 
and in vivo, dampening the pro-inflammatory cytokine production. However, LL-
37-induced secondary necrosis has the potential to induce the release of potentially 
harmful granule contents, which could have deleterious consequences for the host, 
particularly in chronic disease states. Further understanding of the biological 
significance of secondary necrosis in physiological or pathological conditions will 
assist the establishment of novel strategies to modulate inflammatory responses in 
diseases and promote the resolution of inflammation. 
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In addition to the capability of modulating cell death, CHDP possess other 
immunomodulatory functions including anti-endotoxic activity and modulation of 
cytokine responses in immune effector cells [5]. These key properties of CHDP 




5.2.1. The anti-endotoxic and anti-inflammatory 
properties of CHDP 
 
5.2.1.1. LL-37 inhibits pro-inflammatory cytokine 
production by MDM in response to TLR3 or TLR4 
agonist.  
 
LL-37 has been shown to bind LPS (a TLR4 agonist) with high affinity and has 
potent anti-endotoxic activity [89]. To evaluate the influences of LL-37 on innate 
immunity through other TLRs, the cytokine responses of MDM exposed to a panel 
of TLR agonists were studied in the presence or absence of LL-37, added 
concomitantly. In order to evaluate the downstream pathways through which LL-
37 affected TLR signalling, cytokines characteristic of responses from separate 
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pathways were evaluated. TNF-α, which can be upregulated through both MyD88 
dependent signalling and via TRIF pathway (MyD88-independent pathway) was 
contrasted with IP-10 production, an interferon-regulated protein which mainly 
depends on the TRIF pathway (Fig. 1.1) [121].  
 
Data showed that TLR1/2 (Pam3CSK4), TLR2 (HKLM), TLR3 (poly I:C 
LMW), TLR4 (E. coli K12 LPS), TLR5 (S. typhimurium Flagellin), TLR6/2 
(FSL1), TLR8 (ssRNA) and TLR9 (ODN2006) agonists all effectively activated 
MDM, resulting in significantly increased  TNF-α production (p ≤ 0.05) (Fig. 5.1). 
The addition of LL-37 significantly inhibited the pro-inflammatory cytokine 
production by MDM in response to TLR3 and TLR4 agonists only (Fig. 5.1C & 
5.1D). Given that TLR3 signals exclusively through TRIF, TLR4 uses both TRIF 
and MyD88-dependent signaling, and other TLR primarily uses MyD88-dependent 
signaling [118, 124, 517], these data raise the possibility that the inhibitory effects 
may be primarily on the TRIF pathway.  
 
Significant IP-10 responses were only induced by TLR3 and TLR4 agonists, as 
expected based on their use of TRIF signalling (Fig. 5.2C & 5.2D). However, LL-
37 did not inhibit TLR3 or TLR4-induced IP-10 production (Fig. 5.2C & 5.2D), 
indicating that the inhibitory effects were not simple blockade of the TRIF pathway, 
and may not affect the interferon-regulated responses. However, we could not 
exclude the possibility that LL-37 had selective direct affinity/ interactions with, 
different agonists, accounting for some of these observations [131]. These data 
suggest that LL-37 selectively inhibits certain components of TLR signalling 
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pathways, with cytokine specific results. However, further studies are clearly 
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Figure 5.1 LL-37 inhibits pro-inflammatory cytokine production by MDM in response to 
TLR3 or TLR4 agonist. MDM were incubated with a panel of TLR agonists (TLR1/2: Pam3CSK4 
0.1 µg/ml; TLR2: HKLM 108 cells/ml; TLR3: Poly (I:C) LMW 10 µg/ml; TLR4: LPS 10 ng/ml; 
TLR5 :Flagellin 10 ng/ml; TLR6/2: FSL1 1 ng/ml; TLR7: Imiquimod 0.25 µg/ml; TLR8: ssRNA40 
0.25 µg/ml; TLR9: ODN2006 5µM ) in the absence or presence of 5 µg/ml LL-37 in media with 
10% FCS for 18 hr. Supernatants were evaluated for TNF-α responses by ELISA. Significance was 
assessed by two-way ANOVA with Bonferroni’s multiple comparison test; data are shown as mean 
+ SEM for n = 5 donors; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, compared with untreated MDM; 
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Figure 5.2 LL-37 does not directly inhibit TRIF pathway. MDM were incubated with a panel of 
TLR agonists (TLR1/2: Pam3CSK4 0.1 µg/ml; TLR2: HKLM 108 cells/ml; TLR3: Poly (I:C) LMW 
10 µg/ml; TLR4: LPS 10 ng/ml; TLR5 :Flagellin 10 ng/ml; TLR6/2: FSL1 1 ng/ml; TLR7: 
Imiquimod 0.25 µg/ml; TLR8: ssRNA40 0.25 µg/ml; TLR9: ODN2006 5µM ) in the absence or 
presence of 5 µg/ml LL-37 in media with 10% FCS for 18 hr. Supernatants were evaluated for IP-
10 production by ELISA. Significance was assessed by two-way ANOVA with Bonferroni’s 
multiple comparison test; data are shown as mean + SEM for n = 5 donors; *, p ≤ 0.05, compared 
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5.2.1.2. HBD3 (human β-defensin 3) has anti-endotoxic 
activity. 
 
The role of LL-37 as an anti-endotoxic agent is well described, but defensins 
have been less clearly characterised in this area. HBD3 is a β-defensin with a broad 
spectrum of microbicidal property, which also induces secondary necrosis of 
apoptotic PMN (Fig. 3.20). In order to evaluate whether HBD3 has anti-endotoxic 
activity similar to that observed for LL-37, LPS-induced pro-inflammatory 
cytokine responses were studied in MDM exposed concomitantly to HBD3 (or LL-
37 as a positive control). Data showed that HBD3 and LL-37 had similar capacities 
to reduce pro-inflammatory cytokine responses in LPS-stimulated MDM in the 
absence (Fig. 5.3A) and in the presence of serum (Fig. 5.3B), suggesting that both 
of the peptides have anti-endotoxic capacity. The anti-endotoxic effects of these 
two peptides were not sensitive to the presence of serum, although LPS-induced 
MDM responses were much greater in the presence of serum. This observation 
implies that these two CHDP have overlapping immunomodulatory functions and 
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Figure 5.3 HBD3 (human β-defensin 3) has anti-endotoxic activity. MDM were incubated with 
5 µg/ml LL-37 or 5 µg/ml HBD3 with concomitant exposure to 10 ng/ml E.coli 0111:B4 LPS for 
18 hr in the absence (A) or presence (B) of 10% FCS. Untreated MDM and peptide-exposed MDM 
were also studied as controls. Supernatants were evaluated for TNF-α responses by ELISA. 
Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison test; data 
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5.2.2. Stimulation of cytokine release 
 
5.2.2.1. LL-37 triggers IL-1β release from LPS-primed 
monocytes through P2X7 receptor-independent 
pathway. 
 
Elssner et al demonstrated that LL-37 induced IL-1β release from LPS-primed 
monocytes through P2X7 receptor [29]. However, in collaboration with Dr. David 
Brough (University of Manchester), the Davidson lab has determined that LL-37 
can promote IL-1β release from LPS-primed murine bone marrow-derived 
monocytes from P2X7 receptor deficient mice, suggesting an alternative 
mechanism (data not shown). In order to further investigate this capacity of LL-37 
in human cells, LPS-primed primary human monocytes were stimulated with LL-
37, ATP or nigericin (the latter two compounds being knwon secondary signals in 
IL-1β processing and release), and the production of activated IL-1β was 
determined. Purinergic receptor inhibitors, oATP, KN-62, and a novel P2X7 
antagonist AZ-167 (a kind gift from Dr Keith Findlayson, University of Edinburgh) 
were utilised to clarify the involvement of P2 receptors. In addition, a potent 
caspase-1 inhibitor (YVAD-CHO), with YVAD as the specific recognition 
sequence for caspase-1, was exploited to try to define the role of caspase-1 in IL-
1β processing in primed monocytes exposed to these secondary signals.  
 
In agreement with previous reports, LL-37 increased IL-1β release from LPS-
primed monocytes, as assessed by measuring the concentrations of total IL-1β (full 
length and cleaved forms) in supernatants by ELISA (Fig. 5.4A). However, this 
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increase could not be inhibited by specific P2X7 receptor antagonists KN-62 and 
AZ-167. In contrast, the IL-1β release was significantly blocked by oATP, 
described as a P2X7-inhibitor by Elssner et al. [29], but recently described as being 
a nonspecific P2 receptor antagonist [518], (Fig. 5.4B), suggesting that the 
induction of secretion was not via P2X7 receptor. In contrast to the induction of IL-
1β release by nigericin, LL-37-mediated IL-1β release was not observed to be 
dependent on the activation of caspase-1, with no effect observed from the addition 
of caspase-1 inhibitor on IL-1β secretion in LL-37-stimulated monocytes (Fig. 
5.4B). However, caspase-1 inhibitor did not significantly reduce IL-1β release 
from ATP-stimulated monocytes in these studies as expected, raising the 
possibility that this inhibitor was poorly functional or that optimal concentrations 
had not been reached. As expected, the effects of ATP could be inhibited by either 
nonspecific P2 receptor antagonist or P2X7 receptor antagonists (Fig. 5.4D), while 
nigericin acted as an potassium ionophore disrupting membrane potential and 
triggering IL-1β release via caspase-1 activation [379], and could not be blocked 
by purinergic receptor antagonists, but was sensitive to caspase-1 inhibition (Fig. 
5.4F). Western immunoblotting was also conducted to analyse the maturation of 
IL-1β in supernatants and cell lysates and the activation of caspase-1 in cell lysates. 
Consistent with the ELISA data, LL-37, ATP, or nigericin did not induce IL-1β 
release from unprimed monocytes, but did promote mature IL-1β secretion by 
LPS-primed monocytes (Fig. 5.5A), albeit at very much lower levels when LL-37 
was used as a second signal. In cell lysates, monocytes exposed to LPS alone, also 
had increased expression of proIL-1β as expected, but no cleaved IL-1β was 
observed in these cells (Fig. 5.5B). The activation of caspase-1 (10 kDa or 20 kDa) 
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was found in LPS-primed monocytes exposed to ATP or nigericin, while there was 
no active casapse-1 detected in LPS-primed monocytes exposed to LL-37 (Fig. 
5.5C). In summary, these data demonstrate that LL-37, like ATP and nigericin, 
promote IL-1β release from LPS-primed monocytes, but indicate that the 
mechanism is independent of P2X7 receptor and raising questions about the role of 
caspase-1. 
 
5.2.2.2. LL-37 does not promote other pro-inflammatory 
cytokine release from LPS-primed monocytes. 
 
To clarify whether LL-37-mediated promotion of cytokine release in LPS-
primed monocytes was specific to IL-1β, TNF-α concentrations from the same 
samples were evaluated. Data revealed that LPS effectively activated monocytes, 
resulting in the increase of TNF-α. However, the subsequent addition of LL-37, 
ATP, nigericin, purinergic receptor antagonists, or caspase-1 inhibitor did not alter 
TNF-α response by monocytes (Fig. 5.6), indicating that LL-37, ATP, and 
nigericin specifically functioned as the second signals to promote IL-1β processing 
and release from monocytes. 
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Figure 5.4 LL-37, ATP, and nigericin (NG) trigger IL-1β release from LPS-primed monocytes. 
Freshly isolated PBMC were purified by CD14 magnetic bead positive selection. CD14 positive 
monocytes were then stimulated with 10 ng/ml E.coli 0111:B4 LPS for 3 hr in IMDM +10 %FCS, 
followed by 1 hr LL-37 50 µg/ml (A), ATP 5 mM (C), NG 0.5 µM (E) stimulation concomitant 
with exposure to P2 receptor antagonists (oATP 900 µM; KN-62 1 µM; AZ-167 0.1 µM) or 
caspase-1 inhibitor (“Capi” 10 µM) (B, D, and F). Untreated monocytes and monocytes exposed to 
single stimulation of LL-37, ATP, or nigericin were also studied as controls. Supernatants were 
evaluated for IL-1β release by ELISA. Significance was assessed by two-way ANOVA (IL-1β, A, 
C, and E) or one-way ANOVA (B, D, and F) with Bonferroni’s multiple comparison test; data are 
shown as mean + SEM for n ≥ 6 donors; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, compared with 
LPS-primed monocytes; ###, p ≤ 0.001, compared with monocytes exposed to LPS and secondary 
stimulus in the absence of inhibitors (expressed as a ratio due to donor variation in absolute levels).  
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A) Supernatants, IL-1β 
LPS      -         +          -         +        -         +         -      + 
LL-37  -          -          +        +         -         -         -       - 
ATP     -          -          -         -         +        +         -       - 
NG       -          -          -         -         -         -         +      +  
     
           1         2         3         4        5       6        7      8    
 
B) Monocyte cell lysates, IL-1β 
LPS      -         +          -         +        -         +         -      + 
LL-37  -          -          +        +         -         -         -       - 
ATP     -          -          -         -         +        +         -       - 
NG       -          -          -         -         -         -         +      +  
 
              1        2        3         4         5        6        7       8  
  
C) Monocyte cell lysates, caspase-1 
LPS      -         +          -         +        -         +         -      + 
LL-37  -          -          +         +        -         -         -       - 
ATP     -          -          -         -         +        +         -       - 
NG       -          -          -         -         -         -         +      +  
 
               1        2         3        4        5         6       7       8   
Figure 5.5 Representative images of Western immunoblotting for IL-1β and caspase-1. (A) 
Supernatants from monocytes were analysed using anti-IL-1β antibody. (B & C) Cell lysates were 
analysed using anti-IL-1β antibody (B) or anti-caspase-1 antibody (C). Lane 1: Untreated 
monocytes; lane 2: LPS-primed monocytes; lane 3: LL-37-stimulated monocytes; lane 4: LL-37-
stimulated LPS-primed monocytes; lane 5: ATP-stimulated monocytes; lane 6: ATP-stimulated 
LPS-primed monocytes; lane 7: nigericin-stimulated monocytes; lane 8: nigericin-stimulated LPS-
primed monocytes. 
Precursor IL-1β (31 kDa) 
Mature IL-1β (17 kDa) 
Precursor IL-1β (31 kDa) 
Mature IL-1β (17 kDa) 
Procaspase-1 (45 kDa) 
Caspase-1 (20 kDa) 
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Figure 5.6 LL-37 does not promote other pro-inflammatory cytokine release from LPS-
primed monocytes. CD14 positive monocytes were stimulated with 10 ng/ml E.coli 0111:B4 LPS 
for 3 hr in IMDM +10 %FCS, followed by 1 hr LL-37 50 µg/ml (A), ATP 5 mM (C), NG 0.5 µM 
(E) stimulation concomitant with exposure to P2 receptor antagonists (oATP 900 µM; KN-62 1 µM; 
AZ-167 0.1 µM) or caspase-1 inhibitor (“Capi” 10 µM) (B, D, and F). Untreated monocytes and 
monocytes exposed to single stimulation of LL-37, ATP, or nigericin were also studied as controls. 
Supernatants were evaluated for TNF-α release by ELISA. Significance was assessed by two-way 
ANOVA (A, C, and E) or one-way ANOVA (B, D, and F) with Bonferroni’s multiple comparison 
test; data are shown as mean + SEM for n = 3 donors; ***, p ≤ 0.001, compared with untreated 
monocytes; ###, p ≤ 0.001, compared with monocytes exposed to LPS and secondary stimulus in 
the absence of inhibitors (expressed as a ratio due to donor variation in absolute levels).  
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5.2.2.3. IL-1β responses are not the results of monocyte 
death/ lysis. 
 
Previous studies have found that the release of processed IL-1β takes place 
before there is significant cell death, which can occur after the formation of a non-
selective pore by repeated or prolonged stimulation of P2X7 receptor [519]. 
Nevertheless, to clarify whether the release of IL-1β resulted from cytolytic cell 
death, an MTT assay was performed to evaluate monocyte viability after 
stimulation with LPS and secondary stimuli. Data showed that none of these 
stimuli significantly altered viability of cells (Fig. 5.7), indicating that the release 
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Figure 5.7 IL-1β responses are not the results of monocyte death/ lysis. CD14 positive 
monocytes were stimulated with 10 ng/ml E.coli 0111:B4 LPS for 3 hr in IMDM +10 %FCS, 
followed by 1 hr LL-37 50 µg/ml (A), ATP 5 mM (B), NG 0.5 µM (C) stimulation concomitant 
with exposure to P2 receptor antagonists (oATP 900 µM; KN-62 1 µM; AZ-167 0.1 µM) or 
caspase-1 inhibitor (“Capi” 10 µM). Untreated monocytes were also studied as controls. 
Supernatants were discarded followed by the addition of MTT reagent (volume of media: MTT 
solution = 5:1). Absorbance at 490nm wavelength was measured 1 hr after incubation. Significance 
was assessed by one-way ANOVA with Bonferroni’s multiple comparison test compared with 
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5.2.2.4. LL-37 promoted proIL-1β release from LPS-
primed monocytes. 
 
To determine whether the IL-1β released in these studies was the mature form or 
inactive precursor form, the proform IL-1β in supernatants was evaluated using a 
specific ELISA. Triton X100-lysed activated monocytes were used as a positive 
control for the release of substantial amounts of precursor proform IL-1β. 
Interestingly, both LL-37 and nigericin, promoted extensive release of proIL-1β 
(Fig. 5.8).  However, studies by Western immunoblotting did not detect substantial 
proIL-1β release in supernatants of LPS-primed monocytes exposed to LL-37 (Fig. 
5.5). This discrepancy may be due to the different sensitivity of antibodies from 
two different manufactures to detect mature or precursor form of IL-1β, which 
made it more difficult to interpret the data. Although there are still unsolved 
problems to delineate the mechanism by which LL-37 induces IL-1β release, the 
data on proIL-1β measured by ELISA raise the possibility that LL-37 may function 
similar to nigericin: perturbing the cell membrane and inducing the secretion of 
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Figure 5.8 LL-37 and nigericin trigger precursor IL-1β release from LPS-primed monocytes. 
CD14 positive monocytes were stimulated with 10 ng/ml E.coli 0111:B4 LPS for 3 hr in IMDM 
+10% FCS, followed by 1 hr LL-37 50 µg/ml, ATP 5 mM, or nigericin 0.5 µM exposure. Untreated 
monocytes and 0.1% Triton X-lysed LPS-primed monocytes were studied as negative and positive 
control, respectively. Supernatants were evaluated for proIL-1β release by ELISA. Data were 
presented as ratio of pro-IL-β released by cells as a proportion of the Triton-treated positive control 
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5.2.2.5. Human monocyte-derived macrophages have 
diminished LL-37-induced IL-1β release compared 
with fresh monocytes. 
 
LL-37 was shown to trigger IL-1β secretion from LPS-primed monocytes. In 
order to determine whether this peptide has similar effects on differentiated 
macrophages, studies were conducted in MDM. Exposure to LL-37, or positive 
controls ATP or nigericin, was used as a secondary signal to trigger IL-1β release 
from LPS-primed MDM. Similar to the results of observed in monocytes, ATP and 
nigericin induced IL-1β release, albeit at much lower concentrations (Fig. 5.9B & 
5.9C). In contrast to monocytes, LL-37 could not promote IL-1β secretion from 
LPS-activated macrophages (Fig. 5.9A). These data raise the possibility that an as 
yet undefined receptor involved in LL-37-induced IL-1β release exists and is 
differentially expressed on these cell types, or that these two monocytic cells may 
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Figure 5.9 MDM have diminished IL-1β release compared with fresh monocytes. MDM were 
stimulated with 10 ng/ml E.coli 0111:B4 LPS for 3 hr in IMDM +10 %FCS, followed by 1 hr LL-
37 50 µg/ml (A), ATP 5 mM (B), NG 0.5 µM (C) stimulation. Untreated MDM and MDM exposed 
to single stimulation of LL-37, ATP, or nigericin were also studied as controls. Supernatants were 
evaluated for IL-1β release by ELISA. Significance was assessed by two-way ANOVA with 
Bonferroni’s multiple comparison test; data are shown as mean + SEM for n = 3 donors; ***, p ≤ 
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5.3. Discussion 
 
CHDP have been shown to have multiple immunomodulatory properties and 
play critical roles in host defence. Here we further investigated these modulatory 
functions of CHDP in immune effector cells, demonstrating anti-inflammatory 
effects in response to TLR agonists and inhibiting pro-inflammatory cytokine 
production. In contrast, CHDP can also promote certain cytokine release in TLR-
primed immune cells, indicating their pleiotropic roles in regulating inflammatory 
responses. 
 
Previous studies have demonstrated that LL-37 can modulate inflammatory 
responses by affecting TLR signalling. For example, LL-37 has been reported to 
selectively neutralise the pro-inflammatory response to the TLR2, TLR4, and 
TLR9 ligands in human monocytic cells, THP-1, probably through directly acting 
on NF-κB and MAPK pathway [89, 131, 136]. However, the exact mechanism by 
which LL-37 inhibits pro-inflammatory cytokine responses to TLR ligands remains 
unclear. My study investigated cytokine responses which were dependent on 
MyD88 or TRIF pathways to differentiate the inhibiting effects of LL-37 on TLR 
signals. It is known that production of the pro-inflammatory cytokines TNF-α and 
IL-6 after LPS stimulation is regulated by both TLR-MyD88-dependent and TLR-
MyD88-independent signalling pathways that result in the activation of NF-κB and 
p38, JNK, and p42/44 ERK MAPKs. Transcription of the CXCL10 (IP-10) gene 
downstream of TLR agonists is exclusively regulated by the TLR-MyD88-
independent signalling pathway via interferon production [517]. Both TLR3 and 
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TLR4 agonists, which utilise the TRIF pathway, significantly induced IP-10 
production as expected but LL-37 could not block this response, indicating that the 
inhibiting effect of LL-37 was not simply blocking TRIF-dependent signalling, and 
may not affect the interferon-regulated responses. LL-37 may have selective 
affinity/ interaction with different agonists, resulting in the inhibition of certain 
TLR signalling pathways. Taken together, LL-37 does not directly inhibit TRIF 
signalling pathways and further studies are required to clarify at which point of 
signalling pathway LL-37 has its inhibitory effects. 
 
Similarly to LL-37, HBD3 demonstrates potent anti-endotoxic properties in the 
presence or absence of serum. These two peptides, although belong to different 
families of CHDP (cathelicidin and defensin, respectively), have overlapping 
immunomodulatory functions, including inducing secondary necrosis of apoptotic 
PMN and inhibiting activation of MDM in vitro. This observation may suggest the 
redundancy, of these two peptides in vivo, or that they may have additive, or even 
synergistic, roles in immunomodulation. Indeed, emerging evidence reveals that 
these two peptides are present simultaneously throughout the body at epithelial 
barriers. At these sites they may significantly contribute to host defence against 
pathogens, but could also play detrimental roles in chronic inflammatory 
conditions [520]. Future studies are required to determine the interactions of these 
peptides in physiological and pathological conditions. 
 
LL-37 can also stimulate pro-inflammatory cytokine release [29]. Some reports 
using other CHDP, suggest that some of these peptides may act as P2X7 agonists, 
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ionophores, or bacterial toxins, to induce pore formation on plasma membrane of 
cells, triggering inflammasome-mediated caspase-1 activation and IL-1β release 
[365, 379, 521, 522]. However, the exact mechanism is not fully characterised. It is 
well-known that LL-37, like most of CHDP, can insert into the membrane through 
their amphipathic propensity, which may eventually generate a perturbation of cell 
membrane and allow certain mediator leakage. LL-37 can also modulate the 
activities of receptors, transiting channel-gated receptor to pore formation [523], 
which may enhance the secretion of intracellular mediators. However, further work 
is needed to better characterise the mechanism by which LL-37 stimulate IL-1β 
cytokine release. 
 
Elssner et al. demonstrated that LL-37 promoted IL-1β secretion by LPS-primed 
monocytes through P2X7R-dependent pathway. However, Dr. David Brough 
(University of Manchester) showed that LL-37 could promote IL-1β release from 
LPS-primed murine bone marrow-derived monocytes from P2X7 receptor deficient 
mice, suggesting an alternative mechanism. Consistent with Dr. Brough’s finding, 
my data revealed that LL-37-induced IL-1β release could not be inhibited by 
specific P2X7 receptor antagonists, suggesting the induction of secretion was not 
via P2X7 receptor. Additionally, given that the activity was proposed to be 
dependent on P2X7 receptor, it would be anticipated that LPS-primed macrophages 
would demonstrate greater IL-1β release in response to LL-37, as a consequence of 
their greater P2X7 receptor expression on the cell surface [524]. In contrast to this 
assumption, my results showed that LPS-stimulated macrophages were less 
responsive to LL-37 than LPS-primed monocytes. Other studies also revealed 
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similar results, showing that macrophages had diminished IL-1β production 
compared with monocytes [525, 526]. Using fresh human blood monocytes and 
monocyte-derived macrophages, the study indicated that there is a differential 
requirement for processing and releasing IL-1β in these two different monocytic 
cells [525]. Different cell types are equipped with distinct machinery (e.g. the 
components of inflammasome) for IL-1β process and release. which may explain 
the discrete responses of these two cell types [527]. 
 
My data demonstrated that LL-37 induced IL-1β release by LPS-primed 
monocytes. Both mature form and precursor form of IL-β were detected by 
different experimental approaches (Western immunoblotting and specific proIL-1β 
ELISA, respectively). However, the underlying mechanisms by which LL-37 
mediate IL-1β release remain unclear. The involvement of caspase-1 in this 
process was not fully studied. It has been shown that IL-1β can be released by two 
distinct pathways: the well-known caspase-1 cascade mediating release of 
processed IL-1β, and a calcium-independent, caspase-1-independent release of pro-
IL-1β [527]. Future work is required to determine the activation of caspase-1, 
either by FLICA probe which enters cells and binds active caspase-1 enzyme with 
fluorescence, or by studying the response of monocytes from caspase-1 knockout 
mice.  
 
Although the precursor form of IL-1β is biologically inactive [373], extracellular 
proteases than the intracellular activated caspase-1 can also mediate pro-IL-1β 
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processing. For example, protease-3 and elastase from PMN granules and proteases 
released from pathogens have been reported to contribute to the processing of IL-
1β precursor into an active cytokine [369, 373, 528]. It is proposed that during 
pathophysiological conditions of inflammation or infection when monocytes are 
stimulated with pro-inflammatory cytokines or TLR ligands (eg. LPS), LL-37 can 
promote the release of mature and precursor forms of IL-1β by an undefined 
mechanism. Proteases released from recruited PMN or LL-37-mediated 
secondarily necrotic PMN may trigger the extracellular processing of proIL-1β into 
the active form. LL-37 released from PMN can further potentiate the release of this 





 CHDP possess the capability of modulating inflammatory response, to inhibit 
pro-inflammatory cytokine production by interfering with TLR signaling in MDM, 
and to promote IL-1β secretion of activated monocytes. These observations 
indicate that CHDP play a complex role during inflammation, and tuning their 
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6. Conclusion and future work 
 
PMN are important innate immune cells packed with toxic substances that allow 
effective microbial killing. PMN are rapidly recruited to sites of inflammation, 
where they play a key role in innate immune responses, before undergoing 
spontaneous apoptosis. This mode of cell death maintains their intact plasma 
membrane, preventing release of their cytotoxic contents, and promotes the 
resolution of inflammation. In contrast, necrotic PMN, which lose their cell 
membrane integrity, have been proposed to release their harmful intracellular 
substances, resulting in sustained inflammatory responses.  
 
In this thesis I have demonstrated that the human cathelicidin LL-37 is a potent 
inducer of secondary necrosis in apoptotic PMN. The specific membrane 
alterations that make these apoptotic cells susceptible to permeabilisation remain 
unclear, but it is likely independent of known LL-37 receptors [500]. Whether, the 
interaction of LL-37 and apoptotic PMN is through a mechanism that differs from 
the interaction of LL-37 and live PMN, or simply has different consequences for 
cells in these different states remains unknown. Interestingly, although LL-37 can 
induce secondary necrosis in other apoptotic cell types (NK cells and Burkitt’s 
lymphoma), it has not been reported to permeabilise apoptotic cells in all 
circumstances. Indeed, LL-37 can induce apoptosis in certain cell types, such as 
lung epithelial cells and Jurkat T leukemia [20, 108, 529], but did not further 
induce these apoptotic cells into secondary necrosis. Which specific property of 
                                                                                    
233 
                              
apoptotic cells determines the susceptibility to LL-37-induced secondary necrosis 
requires further studies.  
 
The secondary necrosis-inducing property of LL-37 is conserved in the murine 
homologue mCRAMP, and is also retained in C-terminal fragments of the peptide. 
I have also demonstrated that HBD3 also possesses this property. The effect is 
neither dependent primarily on peptide charge (with no effects seen for a 
scrambled peptide, N-terminal partial peptides, and α-defensins HNP1-4 with 
positive charge), nor is dependent on alpha-helical structure (with no effects seen 
for Hp(2-20) with α-helical nature). A greater propensity of forming amphipathic 
structure, a critical character for the direct microbicidal effects of CHDP [530], 
may however be related to the capability of inducing secondary necrosis. Future 
research is required to unravel the structure determinants responsible for the 
permeabilisation of apoptotic cells. 
 
In contrast to initial expectations, LL-37-mediated secondary necrosis does not 
affect PMN ingestion by human monocyte-derived macrophages and is not pro-
inflammatory. Indeed the anti-inflammatory effects of apoptotic PMN on activated 
macrophages are retained, and even enhanced, by LL-37-induced secondarily 
necrotic PMN, and are independent on the anti-endotoxic activity of LL-37. 
Exposure to a concentration of LL-37 sufficient to induce PMN granule content 
releases, was necessary to generate potentiating the anti-inflammatory effects of 
the dead cells, suggesting a key role for the release of more anti-inflammatory 
PMN granule contents. Although the components released from secondary necrotic 
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PMN have not been well characterised, my data, and that of Dr Mohini Gray’s 
group support this hypothesis, demonstrating that α-defensins in the membrane-
free fraction of necrotic PMN have potent anti-inflammatory effects in the absence 
of serum [387]. Since the activity of α-defensins is inhibited by unknown serum 
factors, only PMN induced to maximal release of granule contents, including the 
most “serum-resistant” LL-37 (eg. secondary necrosis induced by higher 
concentrations of LL-37 or primary necrosis) retain their anti-inflammatory effects 
in the presence of serum. In addition to inhibiting the anti-inflammatory effects of 
α-defensins, undefined serum components may interact with secondarily necrotic 
PMN and engage alternative clearance pathways, resulting in altered inflammatory 
consequences. Studies by using fractionated serum to isolate important components 
which are involved in cell engulfment, such as complement components and 
immunoglobulins, or proteases which can degrade soluble mediators, may help 
address this question.  
 
In vivo, a murine sterile peritonitis model confirmed elements of the findings 
from my in vitro studies, demonstrating anti-inflammatory effects of LL-37-
mediated secondarily necrotic PMN, that were comparable to apoptotic PMN. 
Although the experiments were too simple to reflect the complexity of 
inflammatory diseases, with the interplay between numerous factors, they provided 
an initial confirmation of the in vitro observations. More in vivo studies are 
required to better characterise the biological significance of LL-37-induced 
secondary necrosis at inflamed sites and their interaction with pathogens, cytokines, 
peptides, and immune effector cells. In addition, although LL-37-induced 
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secondary necrosis of apoptotic PMN is anti-inflammatory to MDM, it is still 
unknown whether these cells are immunogenic or immunosuppressive to DC. The 
immune properties of secondarily necrotic PMN may have physiological 
significances, bridging innate immune cells to adaptive immune responses, and 
merit further investigation. 
 
Clinical observations evaluating secondary necrosis in certain chronic disorders 
[509], suggesting that secondarily necrotic PMN may not exclusively serve an anti-
inflammatory role. It is noteworthy that LL-37 also promotes PMN granule content 
release, which has the potential to induce the release of toxic intracellular 
substances and could have deleterious consequence of the host, particularly in 
chronic disease status. Additional in vivo experiments, and more clinical studies 
are necessary to determine the association of secondary necrosis with the 
pathogenesis of inflammatory disorders. 
 
In addition to modulating cell death of PMN, CHDP have multiple modulatory 
functions in other immune effector cells. The anti-inflammatory capability of 
peptides has been demonstrated in response to a variety of TLR stimuli although 
the exact mechanisms remain unclear. It is likely that CHDP directly interact with 
TLR ligands or function on signalling pathways in immune cells, selectively 
inhibiting pro-inflammatory responses. On the other hand, LL-37 promotes 
specific pro-inflammatory cytokine IL-1β secretion by TLR-primed immune cells 
though undefined mechanisms. These findings indicate the pleiotropic roles of 
CHDP in immune system. Neither exclusively acting as a pro-inflammatory factor 
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nor as a purely anti-inflammatory mediator, CHDP modulate inflammatory 
responses in multiple aspects through complex mechanisms, to alter the balance of 
the inflammatory response, and thus the outcome.  
 
In conclusion, I have demonstrated that the human cathelicidin LL-37 is a potent 
inducer of secondary necrosis of apoptotic PMN, with the potential to alter the 
consequent inflammatory responses. The data provide novel insight into the effects 
of PMN death, suggesting that LL-37-induced secondary necrosis of apoptotic 
PMN, in contrast to previous dogma, is not pro-inflammatory to MDM, and can 
even potentiate anti-inflammatory effects on activated MDM. In vivo murine sterile 
peritonitis studies have confirmed these data, demonstrating anti-inflammatory 
effects of secondarily necrotic PMN. However, LL-37-induced secondary necrosis 
has the potential to induce the release of potentially harmful granule contents, 
which may have detrimental consequences for the host. In addition to modulating 
cell death, CHDP possess other immunomodulatory capabilities to alter 
inflammatory responses and cytokine production, indicating some of the critical 
regulatory roles of this peptide in immune system. It is anticipated that further 
advancements in our understanding of the multiple modulatory mechanisms of 
CHDP in innate and adaptive immune responses in the future, will help inform the  
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Human b-defensin 3 has immunosuppressive activity
in vitro and in vivo
Fiona Semple1, Sheila Webb1, Hsin-Ni Li2, Hetal B. Patel3,
Mauro Perretti3, Ian J. Jackson1, Mohini Gray2, Donald J. Davidson2
and Julia R. Dorin1
1 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh EH4
2XU, Scotland, UK
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b-defensins are antimicrobial peptides with an essential role in the innate immune
response. In addition b-defensins can also chemoattract cells involved in adaptive
immunity. Until now, based on evidence from dendritic cell stimulation, human b defen-
sin-3 (hBD3) was considered pro-inflammatory. We present evidence here that hBD3 lacks
pro-inflammatory activity in human and mouse primary M/. In addition, in the presence
of LPS, hBD3 and the murine orthologue Defb14 (but not hBD2), effectively inhibit TNF-a
and IL-6 accumulation implying an anti-inflammatory function. hBD3 also inhibits CD40/
IFN-c stimulation of M/ and in vivo, hBD3 significantly reduces the LPS-induced TNF-a
level in serum. Recent work has revealed that hBD3 binds melanocortin receptors but we
provide evidence that these are not involved in hBD3 immunomodulatory activity. This
implies a dual role for hBD3 in antimicrobial activity and resolution of inflammation.
Key words: Anti-inflammatory . cAMP . Defensin . TNF-a
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Introduction
b-defensins are broad spectrum, cationic, antimicrobial peptides.
They are expressed predominantly at mucosal surfaces and believed
to be important components of innate immunity although their
precise in vivo role has not been clarified [1]. Human b-defensins
are a multigene family and the main cluster on chromosome 8p23
has been shown to be copy number variable [2]. Increased copy
number in humans is associated with psoriasis and decreased copy
number with Crohn’s disease, suggesting involvement in these
autoimmune diseases [3, 4]. Human b defensin-3 (hBD3) is one of
the most cationic of the b-defensins with broad spectrum, salt
insensitive, antimicrobial activity [5]. It is highly expressed in
psoriatic skin and the reproductive tract [6, 7]. Defensins have been
considered pro-inflammatory as their expression increases in
response to TLR ligands, TNF-a, IL-1b, IFN-g and PMA, and
following infection or injury [5, 8, 9]. In addition, they have been
shown to chemoattract CD4 T cells and immature dendritic cells
through CCR6, suggesting that they link innate and adaptive
immunity [10]. hBD3 and 4 also chemoattract monocytes and Mf
[8, 11], and hBD3 has been shown to activate monocytes and
myeloid dendritic cells through TLR-1/2 by inducing expression of
co-stimulatory molecules and NF-kB [12]. Recently, human
a-defensins present in neutrophil granules have been shown to
display anti-inflammatory properties [13].
In this paper we show that hBD3 does not induce TNF-a or IL-6 in
Mf and in fact has potent anti-inflammatory effects on both human
and mouse primary Mf. The anti-inflammatory effect was also
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evident in vivo and in the THP-1 human monocytic cell line and
RAW264.7 mouse Mf cell line. hBD3 effectively inhibited the
inflammatory effects of both LPS and CD40 ligand (CD40L). Recently
it has been shown that hBD3 can interact with melanocortin recep-
tors in vitro [14] and a dominant mutation in this gene in dogs and
arctic wolves is causative for black coat colour [15]. Despite mela-
nocortin 1 receptor (MC1R) and melanocortin 3 receptor (MC3R)
being expressed on Mf and having known immunomodulatory
activity, we show here that these receptors do not mediate the novel,
potent anti-inflammatory effect displayed by hBD3.
Results and discussion
hBD3 is anti-inflammatory in vitro
In contrast to the assumed pro-inflammatory effect of hBD3
summarised above, we show here that synthetic hBD3 inhibits
production of TNF-a by the human myelomonocytic cell line
THP-1 in a concentration-dependent manner (Fig. 1A). The effect
was maximal at 2.5mg/mL, and comparable in magnitude to the
cationic antimicrobial peptide LL37, which is a known immuno-
modulatory peptide [16–18]. This same effect was also evident
using human peripheral blood monocyte derived Mf (Fig. 1B).
Treatments did not affect cell viability as MTT assay measurements
were comparable between treated cells and untreated controls.
Addition of hBD3 to the mouse Mf cell line RAW264.7 also
led to inhibition of TNF-a and IL-6 production (Fig. 1C and D). In
our experimental settings hBD3 did not induce TNF-a or IL-6, in
contrast to the recent report that this defensin activates mono-
cytes and myeloid dendritic cells via TLR1/2, up-regulating the
co-stimulatory molecules CD80, CD86 and CD40 [12]. We
observe our anti-inflammatory effect with 5mg/mL (1 mM) of
synthetic hBD3 by directly measuring the attenuation of
pro-inflammatory cytokine production, whereas Funderburg
et al observe their effects on co-stimulatory molecules with 20 mg/
mL of recombinant hBD3 (and do not measure pro-inflammatory
cytokines). We did, however, observe a slight increase in TNF-a
with hBD3 at 10 mg/mL but only in RAW264.7 cells (Fig. 1D), not
primary Mf or THP-1 cells, suggesting that in specific cells at
higher concentrations of hBD3 there may also be a pro-inflam-
matory effect of hBD3.
The anti-inflammatory effect of both hBD3 and the mouse
orthologue Defb14 [19] was observed in mouse primary BM-derived
Mf (BMDM), reducing the TNF-a response to LPS (Fig. 1E). hBD2
was not an effective suppressor of the TNF-a response to LPS in
mouse cells (Fig. 1E), whereas hBD3 was more effective than LL37
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Figure 1. hBD3 down-regulates cytokine production in response to the TLR4 agonist LPS in human and mouse Mf. (A) THP-1 monocyte cell line,
(B) human monocyte-derived Mf, (C and D) RAW264.7 mouse Mf cell line and (E) BMDM from CBA mice were exposed to b-defensin or control
peptides at 5mg/mL, in the presence or absence of LPS for 18 h in serum-free media. TNF-a (or IL-6) in the supernatant was measured by ELISA, n 5 6
donors for the human primary cells, n 5 3 THP-1, n 5 3 RAW264.7 and n 5 3 mouse BMDM (from three separate mice). Figure shows means7SEM,
significance assessed by two-way ANOVA, po0.001, po0.01 was calculated by comparing LPS plus peptide to LPS alone. (F) TNF-a levels in
supernatant in BMDM from different mouse strains, treated with hBD3 or LL37 at indicated concentrations, with and without LPS for 18 h, n 5 3.
Statistical comparisons are between LPS alone versus LPS with peptide in each strain, po0.001, po0.01, po0.05.
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30% amino acid similarity to hBD3, which may explain lack of anti-
inflammatory effects. Conversely, Defb14, which is 64% identical to
hBD3 [20], did demonstrate anti-inflammatory activity.
The anti-endotoxic effects of LL37 have been shown to be partly
due to direct binding of LL37 to LPS [16, 21]. It has previously been
shown that hBD3 does not inhibit endotoxin binding in a Limulus
assay [22] and we confirmed this finding (Supporting Information)
to demonstrate similar endotoxin activity in the presence and
absence of hBD3. However, the Limulus assay is not a direct
measure of LPS-hBD3 binding; so we also investigated hBD3 effects
after LPS stimulation of cells. Figure 2A shows that TNF-a levels
were significantly reduced even when hBD3 was added to Mf 1 h
after LPS. This suggests that even if hBD3 binds LPS to some extent,
most of the hBD3 inhibitory effect is occurring downstream of TLR4
activation by LPS.
Further evidence that hBD3 is endowed with general anti-
inflammatory properties is shown in Fig. 2B. Stimulation with
IFN-g and CD40L results in Mf activation and increased TNF-a, but
here we show that hBD3 inhibited this pro-inflammatory cytokine
response in mouse BMDM. This effect was also evident in C3H/HeJ
Mf, which lack functional TLR4, demonstrating that hBD3 is not
simply inhibiting stimulation by endotoxin contamination. The
anti-inflammatory effect was not evident when cells were exposed
to PAM3CSK4 a TLR1/2 agonist (Fig. 2C). This suggests that hBD3
has an effect on signalling molecules that are used by TLR4 and
CD40 but not TLR1/2. This differs from LL-37, which has been
shown to inhibit pro-inflammatory responses via both TLR4 and
TLR1/2. [16]. As TLR4 and TLR1/2 signalling both involve MyD88
it is possible that hBD3 is affecting components of the non-MyD88
pathway (such as TRAM and TRIF) downstream of TLR4.
hBD3 is anti-inflammatory in vivo
Next, we wished to see whether hBD3 could reduce the
accumulation of TNF-a in mice following exposure to LPS. We
injected 16 mg/kg LPS into male Balb/c mice with and without
10 mg of hBD3 and measured serum TNF-a levels 1 h later. We
found that the group injected with hBD3 and LPS had
significantly reduced levels of TNF-a compared with mice
receiving LPS alone (Fig. 2D). This result demonstrates that
hBD3 inhibits LPS-stimulated TNF-a production in vivo as well as
in vitro. The extent of inhibition afforded by hBD3 was
comparable to that conferred by 1 mg IL-10, which protects mice
from endotoxic shock [23], so hBD3 may provide similar
protection.
Melanocortin receptors are not involved in hBD3
anti-inflammatory function
hBD3 is a promiscuous ligand which interacts with CCR6 and
another unknown Mf receptor [14, 24]. In addition, Candille
































untr LPS 0 5 15 30 60


























































Figure 2. Dissection of hBD3 anti-inflammatory function and in vivo effects of hBD3. (A) The mouse Mf cell line RAW 264.7 was exposed at various
times up to 1 h with LPS before treatment with hBD3, followed by 18 h incubation. The inhibitory effect was still evident at all time points (n 5 2,
po0.05). (B) BMDM from different mouse strains were activated with CD40L (5 mg/mL) and IFN-g (5 ng/mL) (CI) with and without hBD3 for 18 h.
TNF-a levels in supernatants were measured. BMDM were prepared from at least three separate mice for each strain. Statistical comparisons are
between agonist alone versus agonist with hBD3 within each strain, po0.01 by two-way ANOVA. (C) TNF-a levels in supernatant in BMDM from
different mouse strains, treated with hBD3 at indicated concentrations, with and without Pam3Csk4 for 18 h, n 5 3. (D) Balb/c male mice were
injected i.p. with 16 mg/kg LPS with or without 10 mg hBD3 in 200 mL saline. After 1 h animals were killed and exsanguinated and serum TNF-a
measured. Figure shows means7SEM and comparison between LPS alone (n 5 18) and LPS with hBD3 (n 5 21) is statistically different p 5 0.032 by
unpaired t-test.
Eur. J. Immunol. 2010. 40: 1073–1078 Immunomodulation 1075
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
alters hair colour in transgenic mice via binding to murine MC1R
[14]. We tested whether hBD3 might mediate its anti-inflammatory
effect through MC1R or MC3R, as these receptors are expressed in
Mf, and the known ligand a-melanocortin stimulating hormone is
an anti-inflammatory mediator [25]. The absence of either receptor
has also been reported to influence the response to inflammatory
agents [26, 27]. We tested the naturally defective Mc1r mutant
mouse strain (recessive yellow Mc1re) [28] and an Mc3r knockout
mouse [29]. We found no statistically significant difference between
the ability of hBD3 to reduce TNF-a levels following stimulation of
TLR4 or CD40 in BMDM from WT controls or mutant mice (Fig. 3A
and B). This demonstrates that the anti-inflammatory properties of
hBD3 are not mediated by MC1R or MC3R.
hBD3 Anti-inflammatory effect is not mediated by
IL-10 or cAMP
IL-10 is a well-known anti-inflammatory cytokine that inhibits co-
stimulatory molecule expression on Mf and limits the production
of pro-inflammatory cytokines and chemokines [30]. We inves-
tigated the ability of hBD3 to induce IL-10 in BMDM and
established that IL-10 levels were not altered by hBD3 in the
presence or absence of LPS (Fig. 3C), suggesting that the hBD3
anti-inflammatory effect is not mediated by IL-10.
cAMP is an important controller of the innate immune system,
with a wide range of functions including up-regulation of IL-10
and reduction of TNF-a [31]. Using the membrane permeable
cAMP analogue, 8-Bromoadenosine-cAMP (8Br-cAMP), we
examined similarities between cAMP and hBD3 anti-inflamma-
tory activity. TNF-a levels induced by LPS were markedly reduced
by 8Br-cAMP or hBD3 alone, however a combination of 8Br-
cAMP and hBD3 reduced TNF-a levels further. This effect was
evident at low concentrations of hBD3, where hBD3 alone shows
minimal inhibition of TNF-a (Fig. 3D). Similarly induction of
IL-10 by 8Br-cAMP was inhibited by hBD3 (Fig. 3C). These results
suggest that cAMP and hBD3 act through distinct mechanisms.
Concluding remarks
In conclusion, hBD3 is a potent inhibitor of the accumulation of
pro-inflammatory cytokines TNF-a and IL-6, secreted in response
to the TLR4 agonist LPS and following activation with CD40L.
This effect was not due to direct peptide binding of LPS and was
not mediated through the anti-inflammatory receptors MC1R or
MC3R. In support of this finding hBD3 anti-inflammatory action
was independent of cAMP levels and not controlled by an
increase in IL-10. In addition, administration of hBD3 to mice
reduced LPS-induced serum levels of TNF-a, indicating that hBD3
may be important in controlling inflammation and septic shock.
The copy number variation of b-defensins at the 8p23 cluster may
lead to subtle variation in expression levels in the human
population [2]. Up-regulation of hBD3 is critical to antimicrobial
activity in the epithelia; however, the novel hBD3 functions
presented here suggest a role in the resolution of inflammation,






































































































Figure 3. hBD3 anti-inflammatory effect does not act through MC1R or MC3R and has mechanisms distinct from cAMP. BMDM from (A) MC1R
mutant and (B) MC3R mutant were stimulated with LPS alone or LPS in combination with hBD3 or DefB14 (5mg/mL) or (B only) CD40/IFN-g (CI) alone
or in combination with hBD3 as described. After 18 h, concentrations of TNF-a in the supernatants were measured, n 5 3. Statistical comparisons
are between LPS alone versus LPS with peptide in each strain, po0.001, po0.01 by two-way ANOVA. BMDM from Balb/c mice were cultured with
LPS (50 ng/mL) in the presence of 8Br-cAMP (100 mM) and decreasing concentrations of hBD3, as shown, for 18 h. Concentrations of (C) IL-10 and
(D) TNF-a in the supernatants were measured by ELISA.
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Materials and methods
Reagents
Ultra pure LPS from E. coli 0111:B4, Pam3CSK4 and IFN-g were
purchased from InvivoGen (San Diego, USA), pertussis toxin,
polymixin B and 8Br-cAMP (B7880) from Sigma Dorset, UK and
QCL-1000s Endpoint Chromogenic LAL Assay from Lonza Group,
Basel, Switzerland. Mouse CD40L was kindly provided by Dr. David
Gray (University of Edinburgh). hBD3 (GIINTLQKYYCRVRGGR-
CAVLSCLPKEEQIGKCSTRGRKCCRRKK) and hBD2 (GIGDPVTCLKS-
GAICHPVFCPRRYKQIGTCGLPGTKCCKKP) were purchased from
Peptides International Louisville, USA and are oxidised so the
disulfide connectivities are of the canonical b-defensin arrangement
[32]. Defb14 (FLPKTLRKFFCRIRGGRCAVLNCLGKEEQIGIRCSNS-
GRKCCRKKK) and LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLR-
NLVPRTES) were synthesized as previously described [20, 33].
Cells and mice
RAW264.7 cells were maintained in DMEM (GIBCO Paisley, UK)
and THP-1 cells in RPMI containing 10% FBS, essential amino
acids and antibiotics. Balb/c, CBA and C57 Black/6 mice were
obtained from Charles River (UK) and Mc1r e/e and Mc3r KO
mutants were bred in-house. C3H/HeJ OlaHsd-Tlr4 mutants and
C3H/HeN controls were obtained from Harlan Laboratories, UK.
Primary Mf were generated from femur BM and grown in DMEM
containing 10% FBS and 20 ng/mL M-CSF (R&D Systems,
Abingdon, UK) for 7 days. Cells were seeded at 1.25 105 into
48-well plates and grown without growth factor for 24 h prior to
treatment. Replicate experiments were done with separate Mf
preparations from at least three mice for each experiment.
Human PBMC preparation
Human venous blood was collected according to Lothian
Research Ethics Committee approvals ]08/S1103/38, using
sodium citrate anticoagulant (Phoenix Pharma, Gloucester,
UK), and cells were separated by Dextran sedimentation,
followed by discontinuous, isotonic Percoll gradient centrifuga-
tion as previously described [33]. PBMC were incubated at
4 106/mL in IMDM (PAA Laboratories, Somerset, UK) at 371C,
5% CO2, for 1 h. Non-adherent cells were removed and adherent
monocytes cultured for 6 days in IMDM with 10% autologous
serum to generate monocyte-derived Mf.
Cell treatment and ELISA
Cells were treated with LPS (50 ng/mL), Pam3CSK4 (100 ng/mL),
CD40L (3mg/mL) IFN-g (5 ng/mL), hBD3, Defb14, LL-37, 8Br-
cAMP (at concentrations shown) or combinations of these as
described, in serum free media then incubated at 371C, 5% CO2 for
18 h. Supernatants were collected and centrifuged to remove
particulate debris. Levels of TNF-a, IL-6 and IL-10 in the
supernatants were measured using human or mouse DuoSet ELISA
(R&D Systems) according to the manufacturer’s instructions. Cell
viability was measured using TACS
TM
MTT assay (R&D Systems).
LPS delivery in vivo
Balb/c male mice (5–8 wk) were injected with 16 mg/kg of LPS
(approx. 200mg/mouse) with or without 10 mg of hBD3 in 200 mL
of PBS. After 1 h mice were killed by cervical dislocation,
exsanguinated and serum TNF-a levels measured by ELISA. All
experiments were covered by Project License PPL 60/3787
granted by the Home Office under the Animal Scientific
Procedures Act 1986, and locally approved by the University of
Edinburgh Ethical Review Committee.
Statistical analysis
GraphPad Prism 5 statistical software was used to determine
statistical significance. One or two-way ANOVA with Bonferroni’s
multiple comparison post-tests were performed. Where appro-
priate, statistical significance was determined by an unpaired
t-test using GraphPad software. For all statistical analyses po0.05
was considered significant. Values are expressed as mean7SEM.
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ABSTRACT
Cathelicidins are CHDP with essential roles in innate
host defense but also more recently associated with
the pathogenesis of certain chronic diseases. These
peptides have microbicidal potential and the capacity
to modulate innate immunity and inflammatory pro-
cesses. PMN are key innate immune effector cells with
pivotal roles in defense against infection. The appropri-
ate regulation of PMN function, death, and clearance is
critical to innate immunity, and dysregulation is impli-
cated in disease pathogenesis. The efferocytosis of ap-
optotic PMN, in contrast to necrotic cells, is proposed
to promote the resolution of inflammation. We demon-
strate that the human cathelicidin LL-37 induced rapid
secondary necrosis of apoptotic human PMN and iden-
tify an essential minimal region of LL-37 required for
this activity. Using these LL-37-induced secondary ne-
crotic PMN, we characterize the consequence for
macrophage inflammatory responses. LL-37-induced
secondary necrosis did not inhibit PMN ingestion by
monocyte-derived macrophages and in contrast to
expectation, was not proinflammatory. Furthermore,
the anti-inflammatory effects of apoptotic PMN on acti-
vated macrophages were retained and even potenti-
ated after LL-37-induced secondary necrosis. How-
ever, this process of secondary necrosis did induce the
release of potentially harmful PMN granule contents.
Thus, we suggest that LL-37 can be a potent inducer of
PMN secondary necrosis during inflammation without
promoting macrophage inflammation but may mediate
host damage through PMN granule content release un-
der chronic or dysregulated conditions. J. Leukoc. Biol.
86: 891–902; 2009.
Introduction
PMN are important first-line innate immune cells, which are
mobilized rapidly in response to infection and injury. How-
ever, the arsenal of products used by PMN to destroy microbes
is also potentially deleterious to host cells. Appropriate regula-
tion of PMN influx, activation, death, and removal is therefore
critical, and dysregulation of these processes has been impli-
cated in the pathogenesis of chronic lung diseases [1, 2].
PMN have a short half-life and undergo spontaneous apop-
tosis. This programmed and regulated form of cell death en-
ables recognition, ingestion, and removal by macrophages or
DCs, a process involving multiple receptors and adaptors [3].
Efferocytosis (the uptake of apoptotic cells) can protect the
host from the release of toxic PMN intracellular contents and
induce anti-inflammatory and immunosuppressive effects.
These include dampening the LPS-induced, proinflammatory
cytokine response and enhancing anti-inflammatory responses
by macrophages [4–6]. These processes, in addition to an ac-
tive switch in the lipid mediators generated to the production
of lipoxins, resolvins, and protectins [7], can stimulate the res-
olution of inflammation. However, in the absence of efferocy-
tosis, apoptotic PMN will undergo secondary necrosis with loss
of membrane integrity. Although necrosis is typically regarded
as proinflammatory [1], the effect of PMN secondary necrosis
on inflammation and the mechanisms of clearance of these
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cells are relatively poorly understood. Further understanding
of these issues is of great significance to evaluate the impact of
delayed PMN clearance in the resolution of inflammation.
The survival and death of PMN can be modulated signifi-
cantly by the inflammatory milieu, including cytokines such as
TNF- and GM-CSF, TLR agonists (e.g., LPS), and bacterial
products (e.g., pyocyanin) [8], in addition to potential thera-
peutic modulators [9]. The human CHDP (also known as anti-
microbial peptide) LL-37 can also modulate PMN death pathways
in vitro [10, 11]. We have demonstrated that LL-37 promotes
PMN necrosis at the expense of apoptosis [10]. However, the
mechanisms involved and the consequences for inflammation
remain to be determined.
CHDP are key evolutionarily conserved components of in-
nate host defense systems, which are being modified and de-
veloped as novel, antimicrobial therapeutic agents. The two
major CHDP families in vertebrates are defensins and catheli-
cidins. LL-37 is the predominant, mature cationic peptide frag-
ment of the sole human cathelicidin hCAP-18, which is found
at high concentration in neutrophil specific granules and is
cleaved to its active form by proteinase-3 [12, 13]. LL-37 is also
produced by epithelial cells from a variety of tissues in re-
sponse to infectious and inflammatory stimuli and is expressed
by macrophages and other leukocytes [14]. In addition to di-
rect microbicidal potential, LL-37 has a broad range of immu-
nomodulatory functions including antiendotoxic activity and
chemotactic function, modulation of chemokine and cytokine
responses, promotion of cell wound-healing and angiogenesis,
modulation of DC differentiation and function, and the capac-
ity to modulate cell death pathways [10, 11, 15–27]. In vivo
evidence in humans and mice supports a critical role in innate
defense [28–31], hCAP-18/LL-37 concentration in BALF is
increased significantly in human lung infections [32], and
overexpression of LL-37 in the murine lung enhanced the
clearance of infection [33]. However, increased levels of
hCAP-18/LL-37 have also been associated with and implicated
in chronic disease processes [34–36]. Thus, despite a funda-
mental role in innate defense, dysregulated control of LL-37
may be detrimental to the host. The key immunomodulatory
properties that contribute to the physiological role of LL-37 in
host defense and how these might contribute to disease patho-
genesis when dysregulated remain unresolved.
We hypothesized that LL-37-induced necrosis of PMN could
alter efferocytosis and the nature of the subsequent inflamma-
tory response and could lead to the release of potentially dam-
aging PMN intracellular contents. To examine the role of LL-
37-induced PMN necrosis on the inflammatory response, we
characterized the dynamics of LL-37-induced PMN necrosis
before evaluating the effect of LL-37-induced PMN necrosis on
efferocytosis and macrophage inflammatory responses and the
consequences for release of PMN intracellular contents.
MATERIALS AND METHODS
Reagents
rhGM-CSF was purchased from Research Diagnostics Inc. (Flanders, NJ,
USA). R-Roscovitine was supplied by A. G. Scientific (San Diego, CA,
USA). Ultra-pure LPS from the Escherichia coli 0111:B4 strain was pur-
chased from InvivoGen (San Diego, CA, USA). Dexamethasone was pur-
chased from Organon Laboratories Ltd. (Cambridge, UK). rhCD40L
and IFN- were purchased from PeproTech ED Ltd. (London, UK).
LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) and
mCRAMP (GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ) were syn-
thesized by N-(9-fluorenyl) methoxycarbonyl chemistry at the Nucleic
Acid/Protein Service Unit at the University of British Columbia (Canada), as
described previously [10]. Peptides were purified by reverse-phase HPLC and
were at least 98% pure. The concentration of the peptides in solution was de-
termined by amino acid analysis. Scrambled LL-37 (RSLEGTDRFPFVRLKN-
SRKLEFKDIKGIKREQFVKIL) was purchased from CSS-Albachem Ltd. (Glads-
muir, Scotland, UK), and the panel of 16 overlapping 22-mer partial LL-37
peptides (from N-terminal peptide LLGDFFRKSKEKIGKEFKRIVQ through to
C-terminal peptide EFKRIVQRIKDFLRNLVPRTES) was synthesized by Jan W.
Drijfhout at Leiden University Medical Center (The Netherlands) as described
previously [37]. Peptides were dissolved in endotoxin-free water (Sigma-Al-
drich, Poole, UK) and stored at –20°C until further use. All reagents were
tested using a LAL kinetic-quantitative chromogenic LAL assay (Cambrex,
Walkersville, MD, USA) to ensure they were free of endotoxin and reconsti-
tuted in endotoxin-free water.
Isolation of human blood neutrophils
Human venous blood was collected according to Lothian Research Ethics
Committee approval #08/S1103/38 or #1702/95/4/72 using sodium citrate
anticoagulant (Phoenix Pharma Ltd., Gloucester, UK), and cells were sepa-
rated by Dextran sedimentation, followed by discontinuous, isotonic Percoll
gradient centrifugation as described previously [10]. Granulocytes were
washed in PBS without calcium or magnesium (PAA Laboratories, Somer-
set, UK) and resuspended in IMDM (PAA Laboratories) with 10% FCS
(Biosera, East Sussex, UK). Purity was assessed by morphological criteria
using cytocentrifuge preparations and FACS analyses and antibodies against
human CD16 (Caltag-Medsystems Ltd., Towcester, UK) and CD66b (BD
Biosciences, San Diego, CA, USA) to distinguish PMN from eosinophils
and against CD14, CD4, CD8, and CD19 (Caltag-Medsystems Ltd.). Granu-
locyte purity of 98% was yielded by this method, and granulocytes were
typically 95–98% PMN. However, high eosinophil donors were also studied,
demonstrating no significant effect of eosinophil number on LL-37-induced
secondary necrosis of apoptotic PMN. Total cell number was assessed by
hemacytometer counts and by NucleoCounter YC-100 (ChemoMetec,
Allerød, Denmark) automated cell number counting.
Assessment of PMN death
Freshly isolated PMN were incubated at 37°C, 5% CO2, at 5  10
6/ml in IMDM
with 10% (v/v) FCS in the presence of LL-37, GM-CSF, R-Roscovitine, LPS,
mCRAMP, scrambled LL-37, or partial LL-37 peptides at the stated concentrations
or in control media in triplicate over the time periods detailed. To induce primary
necrosis, freshly isolated cells were heated at 65°C for 30 min. Cell death was as-
sessed by light microscopic evaluation of apoptotic morphology as described [10]
and also by examining cells stained at 4°C with FITC-labeled AV (Roche Applied
Sciences, West Sussex, UK), diluted 1:2000 in HBSS with 5 mM CaCl2, and 3
g/ml PI (Invitrogen Ltd., Paisley, UK) for flow cytometric evaluation using a
FACSCalibur, counting 10,000 cells, and analyzed using FloJo software (TreeStar
Inc., Ashland, OR, USA). High concentrations of LL-37 can lead to a complete
loss of cells from analysis [10, 38]. To evaluate this accurately, the concentration-
dependent induction of necrosis was determined by FACS, and the total detect-
able PMN numbers were determined using a NucleoCounter YC-100 (Chemo-
Metec) after 20 h culture over a range of LL-37 concentrations (25 g/ml). An
approximate EC50  3.8 g/ml was determined for LL-37-induced necrosis, and
LL-37 10 g/ml (2 M) was found to induce a significant and concentration-
dependent loss in total detectable cell number (total cell number as a proportion
of control sample81%5% at 20 h, LL-37 10 g/ml; P0.01; n20). In con-
trast, incubation with 5 g/ml LL-37 did not result in a significant decrease,
although a degree of cell loss was observed sometimes. LL-37 was therefore used
at 5 g/ml for further studies examining LL-37-mediated modulation of PMN
cell death.
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TEM
Freshly isolated PMN were incubated with or without 5 g/ml LL-37 for
20 h, as described above, centrifuged at 250 g for 5 min at room tempera-
ture, and resuspended gently in 1 ml 2.5% glutaraldehyde (Sigma-Aldrich)
in 0.1 M sodium cacodylate buffer, pH 7.3 (Sigma-Aldrich), for 1 h. Cells
were washed in three 10-min changes of 0.1 M sodium cacodylate and post-
fixed in 1% osmium tetroxide in 0.1 M sodium cacodylate for 45 min be-
fore three 10-min changes of 0.1 M sodium cacodylate. Samples were then
dehydrated in 50%, 70%, 90%, and 100% normal grade acetones before
two 10-min changes in analar acetone and embedded in Araldite resin. To-
luidine blue-stained sections (1 m) were previewed before 60 nm ultra-
thin sections were cut from selected areas, stained in uranyl acetate and
lead citrate, and then viewed in a Philips CM120 transmission electron mi-
croscope (FEI UK Ltd., Cambridge, UK). Images were taken on a Gatan
Orius charged-coupled device camera (Gatan UK, Oxon, UK).
Western immunoblotting
Freshly isolated PMN were incubated as described above over a range of
LL-37 concentrations. At Time 0 h or after 20 h, cells were washed with
PBS without Ca2 and Mg2, and proteins were extracted using Mamma-
lian Protein Extraction Reagent (Pierce/Perbio Science UK, Cheshire, UK)
containing 30 l/ml HaltTM protease inhibitor cocktail, 30 l/ml HaltTM
phosphatase inhibitor cocktail, 10 l/ml EDTA solution (all Pierce/Perbio
Science UK), 30 M pepstatin (Sigma-Aldrich), and 10 M lactacystin (Cal-
biochem/Merck Biosciences Ltd., Nottingham, UK). Total protein concen-
trations were determined by bicinchoninic acid assay (Pierce/Perbio Sci-
ence UK). Equivalent total protein (20 –50 g) was resolved in Pierce
Precise gels (Pierce/Perbio Science UK) transferred to Immun-Blot
polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules,
CA, USA) and immunoblotting performed as described [10] with anti-hu-
man cleaved caspase-3 rabbit polyclonal antibody and reprobed with anti-
pan-actin antibody (both Cell Signaling Technology, Beverly, MA, USA) for
protein loading correction via densitometric analysis using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
Phagocytic studies
Human PBMC were isolated by isotonic Percoll gradient centrifugation as
described above and incubated at 4 106/ml in IMDM at 37°C, 5% CO2,
for 1 h. Nonadherent cells were removed and adherent monocytes cul-
tured for 5–7 days in IMDM and 10% autologous serum to generate MDM.
For light microscopic analyses of phagocytosis, PMN were incubated previ-
ously for 20 h, with or without LL-37 (or scrambled LL-37) at the stated
concentrations (as described above), and the level of apoptosis was assessed
as described. PMN (2.5106; 2.5:1 ratio of PMN:MDM) were overlaid
onto HBSS-washed MDM monolayers for 1 h at 37°C. MDM were then
washed gently four times with IMDM to remove noningested PMN and
fixed with 2.5% paraformaldehyde (Sigma-Aldrich) for 10 min. PMN MPO
was stained with 0.1 mg/ml dimethoxybenzidine (Sigma-Aldrich) and
0.03% (v/v) H2O2 (Sigma-Aldrich) before analysis by light microscopy,
counting at least 200 MDM in five randomly selected fields of view to evalu-
ate the proportion of MDM-containing peroxidase-positive cells, with n  2
replicates/experiment. Only MDM that had engulfed PMN clearly were
scored as positive. For flow cytometric analyses of phagocytosis, freshly iso-
lated PMN were stained with Cell Tracker Green (Molecular Probes, Eugene,
OR, USA) at 37°C for 20 min, according to the manufacturer’s instructions,
and then washed twice with PBS before incubation for 20 h in the presence or
absence of LL-37, as described. The effects of LL-37 were not altered by Cell
Tracker Green staining (data not shown). MDM were exposed to PMN as
described above, but after 1 h incubation, cells were detached and col-
lected using 0.05% trypsin/0.02% EDTA solution (Cambrex). Samples were
analyzed by FACSCalibur as described previously [39], with n  2 repli-
cates/experiment. The number of Cell Tracker Green-positive events in the
macrophage gate (based on forward- and side-scatter) represented the
number of macrophages that had ingested PMN and was evaluated as a
proportion of total number of MDM. As a positive control, wells of adher-
ent monocytes were also cultured in the presence of 1 M dexamethasone
for 5 days, a process demonstrated previously to up-regulate MDM phagocy-
tosis of dead PMN [40].
MDM cytokine production
Freshly isolated PMN at 5  106/ml were incubated for 20 h in the pres-
ence or absence of LL-37, scrambled LL-37, or partial LL-37 peptides p1
(LLGDFFRKSKEKIGKEFKRIVQ), p2 (KIGKEFKRIVQRIKDFLRNLVP), or
p3 (EFKRIVQRIKDFLRNLVPRTES) at the concentrations indicated in 10%
FCS as described above. Samples (1 ml) were collected and each split in
two, and half of each sample was centrifuged at 230 g before collection of
the supernatant and resuspension of the cells in 0.5 ml X-vivo 10 media
(Lonza Biologics, Slough, UK), with or without 10% FCS. Washed MDM,
with or without concomitant exposure to 10 ng/ml E. coli 0111:B4 LPS or 3
g/ml rhCD40L/5 ng/ml rhIFN-, were then incubated at 37°C, 5% CO2,
for 18 h with 0.5 ml PMN in fresh X-vivo 10, PMN in the original IMDM
with 10% FCS, IMDM with 10% FCS supernatant collected from overnight-
incubated PMN, or media alone. MDM alone and PMN alone in the pres-
ence of absence of LPS and/or LL-37 were also studied as controls. Super-
natants were collected, centrifuged at 230 g for 6 min to remove cells and
particulate debris, and then stored in aliquots at –70°C. The concentrations
of TNF-, IL-6, IL-10, IL-12p70, and IL-1 in the supernatants were mea-
sured using BD Cytometric Bead Array human inflammation kits with a BD
FACSArray (BD Biosciences) or Human TNF- DuoSet ELISA (R&D Sys-
tems, Minneapolis, MN, USA), according to the manufacturer’s instruc-
tions.
MPO release
Freshly isolated PMN were incubated with different concentrations of
LL-37 or scrambled peptide for 20 h as described above, centrifuged at 230
g for 6 min, and placed immediately on ice, and the supernatants were col-
lected. To detect MPO, 100 l supernatant samples (used neat or diluted
in PBS) were incubated in the dark for 20 min at room temperature with
100 l substrate solution (1:1 mixture of H2O2 and tetramethylbenzidine;
R&D Systems), followed by addition of 50 l 2 N H2SO4 stop solution and
colorimetric analyses at 450 nm using a microplate reader. The concentra-
tion of MPO in the supernatants was evaluated as a percentage of MPO
release after complete lysis of fresh control PMN using 0.1% Triton X-100
(Sigma-Aldrich).
Statistical analysis
GraphPad Prism 5 statistical software was used to determine statistical sig-
nificance. One-way or two-way ANOVA with Bonferroni’s multiple compari-
son post-tests or Student’s t-tests was performed as appropriate. P  0.05
was considered significant. Values are expressed as mean  sem.
RESULTS
LL-37 induces the rapid secondary necrosis of
apoptotic PMN
We and others [10, 11] have demonstrated that the propor-
tion of apoptotic (AVPI–) cells detected in an in vitro model
of spontaneous apoptosis of human PMN was decreased signif-
icantly when cells were cultured with LL-37. The most prom-
inent consequence of this was an increased proportion of
necrotic (AVPI) PMN [10]. To carefully characterize LL-
37-induced, necrotic PMN, with which to examine the conse-
quences for macrophage inflammatory responses, a large donor
pool (n28 different donors) was evaluated. This demonstrated
the concentration-dependent capacity of LL-37 to promote PMN
necrosis significantly at the expense of apoptosis, with no signifi-
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cant impact on the proportion of live (AV–PI–) cells at 5
g/ml LL-37 using FACS (Fig. 1A) and morphological analy-
ses. LL-37-induced necrotic PMN were observed to be similar
to “late apoptotic” cells observed in control samples at 20 h,
with less-severe loss of membrane integrity than primary necro-
sis induced by heat treatment of cells (Fig. 1B). TEM was used
to confirm the capacity of LL-37 to promote PMN necrosis
after 20 h incubation when compared with control cells (Fig.
1, C and D).
We have demonstrated previously that LL-37 was not lytic to
PMN [10]. Furthermore, no significant necrosis was observed
at 0, 1, 4, or 6 h (ref. [10], and data not shown). However,
significant (P0.001) induction of necrosis was observed at
12 h (data not shown) and thereafter, occurring at time-points
at which substantial apoptosis was observed. In keeping with
recent publications [38, 41], this suggested prior induction of
apoptosis may be necessary and that LL-37 might induce sec-
ondary necrosis. To confirm this in our model system, PMN
were exposed to early or late pulses of LL-37. PMN incubated
with LL-37 (5 g/ml) for 4 h, followed by washing and incu-
bation in control media for 16 h, had proportions of apopto-
tic, necrotic, and live cells identical to untreated controls (data
not shown). In contrast, 20 h incubation of cells in control
media, followed by exposure to LL-37 for just 10 min before
FACS analyses, completely replicated the dose-dependent ef-
fect of 20 h incubation with LL-37 (Fig. 1E), demonstrating
that LL-37 induced a rapid secondary necrosis of apoptotic
PMN without affecting live cells.
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Figure 1. Induction of PMN ne-
crosis by LL-37. (A–D) Freshly
isolated human PMN were incu-
bated for 20 h over a range of
LL-37 concentrations before
analyses. Primary necrosis was
induced by heating at 65°C for
30 min. Cell death was exam-




positive), and live (FITC-AV-
negative, PI-negative) cells were
enumerated. Figures represent
mean values  sem for n  28
different donors for each condition, performed in triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison
test comparing each treatment with control; **, P  0.01; ***, P  0.001. (B) Representative FACS plots. (C and D) Representative TEM images
of (C) untreated, apoptotic PMN and (D) PMN exposed to 5 g/ml LL-37. Arrows indicate examples of necrotic PMN. (E) Freshly isolated hu-
man PMN were incubated for 20 h over a range of LL-37 concentrations (20 h samples) or incubated for 20 h in the absence of LL-37 followed
by exposure to a range of LL-37 concentrations for 10 min (pulse samples) before FACS analyses of apoptotic, necrotic, and live cells. Panels rep-
resent mean values  sem for n  3 donors performed in triplicate. Significance was assessed by two-way ANOVA with Bonferroni’s post-test; **,
P  0.01; ***, P  0.001, compared with untreated control.
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Interaction of LL-37 with known modulators of PMN
apoptosis
To investigate whether LL-37 can interact with and modulate
the effects of known modifiers of PMN apoptosis pathways,
cells were incubated with LL-37 in the presence or absence of
GM-CSF (a PMN survival factor [42]) or R-Roscovitine (a cy-
clin-dependent kinase inhibitor and inducer of PMN apoptosis
[9]). GM-CSF reduced PMN apoptosis significantly at 20 h,
increasing the proportion of live cells with no effect on necro-
sis (Fig. 2A). Concomitant treatment with 5 g/ml LL-37 had
no effect on the capacity of GM-CSF to promote cell survival
but significantly (P0.05) increased the proportion of necrotic
cells with a reciprocal loss of apoptotic cells when compared
with GM-CSF alone (Fig. 2A). R-Roscovitine induced PMN apop-
tosis significantly at 6 h with minimal necrosis (Fig. 2B). LL-37
alone (25 g/ml) had no effect on cell death at this time-
point. Concomitant LL-37 treatment had no effect on the ca-
pacity of R-Roscovitine to induce cell death but significantly
(P0.01) increased the proportion of necrotic cells in a dose-
dependent manner with a reciprocal loss of apoptotic cells
when compared with R-Roscovitine alone (Fig. 2B). These data
demonstrate no interaction with these direct modifiers of PMN
apoptosis, but LL-37 induced secondary necrosis, relating in
magnitude to the extent of induction of apoptosis.
In addition, studies were performed to assess the impact of
LL-37 (a well-characterized antiendotoxic agent [15]) on the
antiapoptotic effects of LPS in PMN [43]. LPS promoted PMN
survival (Fig. 2C) significantly, inhibiting apoptosis without
inducing necrosis (Fig. 2D). Concomitant incubation with
LL-37 inhibited this effect significantly in a dose-dependent
manner. LL-37 (5 g/ml) blocked the pro-survival effects of
LPS completely and significantly increased the proportion of
dead cells that were necrotic (P0.01). However, the capacity
of 5 g/ml LL-37 to induce secondary necrosis was diminished
significantly by LPS (P0.001). These data demonstrate LL-37-
mediated inhibition of the antiapoptotic effects of LPS and
suggest a mutually inhibitory interaction with LPS diminishing
LL-37-induced secondary necrosis.
LL-37-mediated induction of secondary necrosis is
conserved in mCRAMP and C-terminal partial
peptides and is not primarily charge-dependent
To examine the important characteristics of LL-37 for the ca-
pacity to induce secondary necrosis, FACS-based studies were
performed using a scrambled LL-37 peptide (with conserved
charge but altered amino acid sequence), the murine homo-
logue mCRAMP, and a panel of sixteen 22-mer partial pep-
tides spanning the sequence of LL-37 [37]. Incubation of
PMN with scrambled LL-37 had no effect, whether exposed
over 20 h or as a final 10-min pulse (Fig. 3A). In contrast,
mCRAMP exposure closely replicated the effects of LL-37 with
significant, dose-dependent induction of secondary necrosis
(Fig. 3B). Exposure to N-terminal 22-mer partial LL-37 pep-
tides (from the peptide incorporating aa 1–22 of LL-37
through that spanning aa 10–31) had no significant effects
(Fig. 3C). In contrast, C-terminal partial peptides (from the
peptide incorporating aa 11–32 through that spanning aa 16–
37) induced significant secondary necrosis (P0.01) in the
absence of effects on live cells but to a lesser extent than full-
length LL-37. This identified a putative minimal core func-
tional region for induction of secondary necrosis spanning aa
16–32. The effects of these peptides showed no correlation
with charge, which ranged from 3 to 6. These data demon-
strate that the capacity to induce PMN secondary necrosis is
evolutionarily conserved between mouse and human cathelici-
din, is not primarily dependent on peptide charge, and is re-
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Figure 2. LL-37 exposure of PMN in the presence of modifiers of apoptotic pathways. Freshly
isolated human PMN were incubated with LL-37 (at the concentrations indicated) for 20 h in
the presence or absence of 20 ng/ml GM-CSF (A), for 6 h in the presence or absence of 20 M
R-Roscovitine (B), or for 20 h in the presence or absence of 500 ng/ml E. coli LPS (C and D).
Cell death was examined by FACS analyses. Figures represent mean values  sem for n  3 do-
nors performed in triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s
multiple comparison test comparing each treatment with control; *, P  0.05; **, P  0.01, for
necrotic (A, B, and D) or viable (C) cells in LL-37-treated samples compared with controls with-
out LL-37 in the presence of (A) GM-CSF, (B) R-Roscovitine, or (C) LPS; #, P  0.001, for necrotic
(D) or viable (C) cells in LPS-treated samples compared with controls without LPS in the compara-
ble concentration of LL-37.
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LL-37-induced secondary necrosis of apoptotic PMN
does not inhibit macrophage efferocytosis
To determine whether macrophage ingestion of dead PMN
was altered by LL-37-mediated secondary necrosis, ingestion of
LL-37-treated PMN was studied using MDM by light micro-
scopic enumeration (Fig. 4A). Confirmatory studies were per-
formed using FACS analyses of MDM to determine ingestion
of labeled PMN (Fig. 4B). In both studies, positive control
dexamethasone-primed macrophages (shown previously to
have increased capacity for apoptotic PMN ingestion [40])
were used. LL-37-mediated induction of secondary necrosis
had no significant effects on the magnitude of PMN ingestion
by MDM, even at 25 g/ml LL-37 (a concentration at which
80% of dead cells are necrotic [10]).
LL-37-induced secondarily necrotic PMN do not
induce proinflammatory macrophage responses
The interaction of apoptotic PMN and macrophages can in-
duce anti-inflammatory macrophage responses and inhibit
LPS-induced proinflammatory cytokine responses [5]. In con-
trast, necrotic cells are suggested to induce proinflammatory
responses [44]. To examine the effects of LL-37-mediated
PMN secondary necrosis, MDM cytokine responses to these
cells were evaluated at 18 h after exposure. To separate the
effects of any residual, functional LL-37 in the media from the
effects of the dead PMN and of the cell bodies from the cellu-
lar contents released from secondarily necrotic cells, PMN
were incubated for 20 h at a range of concentrations of LL-37,
and MDM were then exposed to LL-37-treated PMN, resus-
pended in fresh serum-free media, unwashed LL-37-treated
PMN in their original media, supernatant from LL-37-treated
PMN alone, or media without PMN as a control.
MDM exposed to control apoptotic PMN, PMN incubated
for 20 h with LL-37 (25 g/ml), or the supernatants from
these cells did not produce detectable levels of TNF-, IL-6,
IL-10, IL-12p70, or IL-1 (Fig. 5, and data not shown), and
there were no significant differences between responses to LL-
37-treated and control apoptotic PMN. These data suggest that
LL-37-induced secondarily necrotic PMN are not proinflamma-
tory to macrophages nor release effective, proinflammatory
contents into the supernatant.
LL-37-induced secondarily necrotic PMN have anti-
inflammatory effects on macrophages
To determine the effect of these cells in the context of proin-
flammatory stimuli, MDM were exposed concomitantly to 10
ng/ml E. coli LPS. Treatment of MDM with LPS alone stimu-
lated significant production of TNF-, IL-6, and IL-10 (but not
IL-12p70 or IL-1). In keeping with previous reports [5], the
LPS-induced proinflammatory response was reduced by the
addition of control apoptotic PMN in serum-free media with
significant inhibition (P0.01) of TNF- and IL-6 (Fig. 6A).
However, these control apoptotic cells had no significant effect
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Figure 3. Peptide specificity in the
induction of PMN secondary ne-
crosis. Freshly isolated human
PMN were incubated with (A) a
range of concentrations of scram-
bled LL-37 peptide for 20 h, or
for 10 min after 20 h incubation
in the absence of peptide (pulse);
n  3 donors performed in tripli-
cate; (B) a range of concentra-
tions of mCRAMP peptide; n 
16 donors performed in tripli-
cate; or (C) 5 g/ml partial
LL-37 peptides from a panel of
16 overlapping 22-mers using N-
terminal peptide (aa 1–22), then
peptide spanning aa 2–23, and so
on through C-terminal peptide
(aa 16 –37) or full-length LL-37;
n  3 donors performed in tripli-
cate. Peptides p1, p2, and p3 are
identified. Cell death was exam-
ined by FACS analyses as de-
scribed. Figures represent mean
values  sem. Significance was
assessed by one-way ANOVA with
Bonferroni’s multiple comparison
test comparing each treatment
with control; **, P  0.01; ***,
P  0.001.
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variation). Contrary to expectation, when PMN, incubated pre-
viously for 20 h with LL-37 to induce secondary necrosis, were
resuspended in fresh, serum-free media and used, these cells
also inhibited LPS-induced TNF- and IL-6 responses. The ef-
fect of cells incubated previously with 5 g/ml LL-37 to in-
duce secondary necrosis was not significantly different than
control apoptotic cells (Fig. 6A). However, significantly greater
inhibition of LPS-induced TNF- (P0.01) was observed in
response to cells incubated previously with 25 g/ml LL-37
(Fig. 6A), in which the largest induction of secondary necrosis
is evident. In addition, in contrast to control apoptotic cells, a
trend toward diminished, LPS-induced MDM IL-10 responses
was observed in response to these secondarily necrotic cells
(Fig. 6A). Exposure of MDM to control apoptotic PMN in
their original supernatant (Fig. 6B) had no effect on the LPS-
induced production of TNF-, IL-6, or IL-10 by MDM and was
essentially the same as exposure to the supernatant alone
(data not shown). In contrast, exposure to unwashed, LL-37-
treated PMN in their original supernatant did inhibit the LPS-
induced production of TNF- (P0.001), IL-6 (P0.05), and
IL-10 by MDM (Fig. 6B). This effect could be replicated using
supernatants alone (data not shown) but was not observed us-
ing cells treated with scrambled LL-37 (Fig. 6B). In addition,
fresh LL-37, added directly to LPS-stimulated MDM in the ab-
sence of PMN, was able to replicate this inhibitory effect (Fig.
6B), indicating that the antiendotoxic effects of remaining,
active LL-37 in the original supernatant may be responsible for
the results observed in these latter studies. To determine
whether the loss of inhibitory activity of dead PMN in their
original supernatant related to cellular products or serum
within the original media, 20 h PMN, washed and resuspended
in fresh serum-containing media, were used. These cells (con-
trol and LL-37-treated) lost the capacity to inhibit LPS-induced
MDM TNF- production (Fig. 7A), implicating an unidentified
serum-factor and demonstrating that washed, LL-37-treated cells
did not have sufficient residual LL-37 to be directly antiendo-
toxic.
To confirm that the anti-inflammatory effects of LL-37-in-
duced secondarily necrotic PMN were independent of the anti-
endotoxic effects of the peptide, rCD40L and rIFN- treat-
ment was used to activate MDM, rather than LPS. Control-
apoptotic and LL-37-induced secondarily necrotic PMN were
capable of significantly (P0.001) inhibiting the resultant
TNF- production (Fig. 7B).
In addition, the impact of three 22-mer partial LL-37 pep-
tides was evaluated. N-terminal peptide p1 induced no PMN
secondary necrosis (Fig. 3C) and had no direct antiendotoxic
effects when applied to LPS-treated MDM (Fig. 7C). C-termi-
nal peptides p2 and p3 induced significant PMN secondary
necrosis (Fig. 3C), but whereas p2 had direct, significant anti-
endotoxic effects (P0.05), p3 did not (Fig. 7C). When PMN,
incubated previously for 20 h with these peptides, were resus-
pended in fresh serum-free media, these cells were all capable
of mediating a significant (P0.01) inhibition of LPS-induced
MDM TNF- production, identical to control cells (Fig. 7D).
However, when used in their original media, the effects of
these cells replicated the direct, antiendotoxic capacity of the
peptide with which they had been treated (Fig. 7C).
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Figure 4. Macrophage phagocytosis of LL-37-induced secondarily ne-
crotic PMN. PMN were incubated previously for 20 h, with or without
LL-37 (or scrambled LL-37) at the stated concentrations, and then
incubated with hMDM for 1 h before removal of noningested PMN.
Phagocytosis was assessed by (A) light microscopy, counting the pro-
portion of MDM peroxidase-positive cells; n  3 donors for each con-
dition and n  2 replicates/experiment; or (B) flow cytometric analy-
ses, evaluating the proportion of MDM ingesting Cell Tracker Green-
stained PMN; n  3 donors for each condition, with n  2 replicates/
experiment. As a positive control, wells of adherent monocytes were
also cultured in the presence of 1 M dexamethasone for 5 days to
up-regulate MDM phagocytosis of dead PMN. Significance was assessed
by one-way ANOVA with Bonferroni’s multiple comparison test com-
paring each treatment with control; *, P  0.05; **, P  0.01.
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Figure 5. LL-37-induced second-
arily necrotic PMN are not proin-
flammatory for macrophages. Hu-
man PMN were incubated for 20 h
in the presence or absence of
LL-37 or scrambled LL-37 at the
concentrations indicated and used
unwashed in the IMDM  10% FCS
media supernatant, in which they
had been incubated. hMDM were
incubated with these PMN or incu-
bated without PMN (nc) in the pres-
ence or absence of LL-37 or 10
ng/ml E. coli 0111:B4 LPS as a posi-
tive control. Supernatants were eval-
uated for cytokine responses.
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These data demonstrate the effect of residual peptide in the
original media, show that functional peptide is not carried
over in washed cells, and demonstrate that these dead PMN
can inhibit LPS-induced MDM cytokine production, irrespec-
tive of the degree of peptide-induced secondary necrosis. These
data demonstrate that the inhibition of activated MDM proin-
flammatory cytokine production mediated by apoptotic PMN is
not inhibited and may even be enhanced by LL-37-mediated
induction of secondary necrosis of these apoptotic PMN.
Furthermore, the intracellular contents released by these
cells are not actively proinflammatory or can be inhibited
by the effects of LL-37.
LL-37-mediated secondary necrosis can induce the
release of PMN granule contents
To determine the effect of LL-37-induced secondary necrosis
of apoptotic PMN on the azurophilic (primary) granules, the
release of MPO in response to LL-37 was quantified at 20 h.
MPO release was not detected above background for this time-
point following exposure to 10 g/ml LL-37 (concentrations
at which substantial secondary necrosis occurred) or in re-
sponse to scrambled LL-37 (Fig. 8). However, significant levels
of MPO were observed in response to 25 g/ml LL-37
(P0.01) at levels approaching 40% of total MPO released by
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Figure 7. The anti-inflammatory properties LL-37-induced, secondarily necrotic PMN are independent of peptide antiendotoxic activity. Human
PMN were incubated for 20 h in the presence or absence of LL-37 or partial peptides p1, p2, or p3 at the concentrations indicated. PMN were
resuspended in X-vivo 10 media with 10% FCS (A), resuspended in serum-free X-vivo 10 media (B and D), or used unwashed in the IMDM 
10% FCS media supernatant, in which they were incubated overnight (C). MDM were incubated with these PMN, with concomitant exposure to
10 ng/ml E. coli 0111:B4 LPS (A, C, and D) or 3 g/ml rhCD40L  5 ng/ml rhIFN- (B) for 18 h. Activated MDM without PMN, in the presence
or absence of peptides, were also studied as controls and to evaluate direct antiendotoxic activity. Supernatants were evaluated for cytokine re-
sponses. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison test; n  3 donors; *, P  0.05; **, P  0.01; ***,
P  0.001, compared with activated MDM in the absence of PMN under the same conditions.
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Figure 6. LL-37-induced secondarily ne-
crotic PMN retain anti-inflammatory prop-
erties. Human PMN were incubated for
20 h in the presence or absence of LL-37
or scrambled LL-37 at the concentrations
indicated. PMN were resuspended in se-
rum-free X-vivo 10 media (A) or used un-
washed in the IMDM  10% FCS media
supernatant, in which they were incubated
overnight (B). MDM were incubated with
these PMN, with concomitant exposure to
10 ng/ml E. coli 0111:B4 LPS for 18 h. LPS-
treated MDM without PMN, in the pres-
ence or absence of LL-37, were also studied
as controls. Supernatants were evaluated for
cytokine responses. Significance was as-
sessed by one-way ANOVA with Bonferro-
ni’s multiple comparison test; n  9 donors
(TNF-); n  5 donors (IL-6/IL-10); *, P 
0.05; **, P  0.01; ***, P  0.001, com-
pared with MDM exposed to LPS in the
absence of PMN under the same condi-
tions; ##, P  0.01; ###, P  0.001, com-
pared with MDM exposed to control apo-
ptotic PMN untreated with LL-37.
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lysis with Triton X-100. These data suggest that although LL-
37-induced secondary necrosis of apoptotic PMN does not lead
directly to the release of granule contents over this time scale,
higher concentrations of LL-37 are able to destabilize granules
and lead to the release of their potentially damaging contents.
DISCUSSION
PMN are key cells of the innate immune system. The appropri-
ate regulation of PMN function, death, and clearance is criti-
cal to effective control of inflammation, and dysregulation of
these processes has been implicated in disease pathogenesis.
Cell death by apoptosis, followed by efferocytosis by profes-
sional phagocytic cells, is proposed to enable safe PMN re-
moval without the release of harmful intracellular contents to
inhibit proinflammatory responses and to promote anti-inflam-
matory responses to enhance resolution [3]. In contrast, cell
death by necrosis (whether primary necrosis or secondary ne-
crosis of apoptotic PMN that have not been cleared) is pro-
posed to be proinflammatory. We demonstrate that the human
cathelicidin LL-37 is a potent inducer of secondary necrosis in
PMN, which have undergone prior apoptosis, and evaluate the
impact of this process on macrophage inflammatory responses.
We demonstrate that the ingestion of LL-37-induced second-
arily necrotic PMN was not a proinflammatory event. This pro-
cess did not promote the release of proinflammatory cytokines
by macrophages and was indistinguishable from the macro-
phage response to apoptotic cells. Furthermore, these second-
arily necrotic PMN were actively anti-inflammatory, demon-
strating that the capacity of apoptotic PMN to inhibit LPS-in-
duced proinflammatory cytokine production by macrophages
was undiminished by LL-37-induced secondary necrosis. In-
deed, this anti-inflammatory effect was actually enhanced in
response to PMN with the most extensive secondary necrosis.
Although the anti-inflammatory activity of unwashed, LL-37-
treated apoptotic PMN was a result of the antiendotoxic prop-
erties of the remaining, functional LL-37 in the supernatant,
washed cells retained the anti-inflammatory capacity of control
apoptotic cells, even after treatment conditions (25 g/ml
LL-37 for 20 h) in which 80% of dead PMN have undergone
secondary necrosis [10]. These data suggest functional equiva-
lence, irrespective of membrane integrity, of apoptotic PMN
and LL-37-induced secondarily necrotic cells in this system. A
previous report has demonstrated potential functional domi-
nance of apoptotic cells over primary necrotic cells [45]. We
cannot exclude a dominant role for the remaining membrane-
intact apoptotic cells in our system. However, the significantly
enhanced anti-inflammatory effects induced by PMN, with the
greatest proportion of secondary necrosis, indicate that the
anti-inflammatory activity of apoptotic PMN can in fact be po-
tentiated by LL-37-induced secondary necrosis. Whether this
applies to PMN necrosis induced in other ways and the mecha-
nisms involved remains to be determined. However, exposure
to a concentration of LL-37, sufficient to induce PMN granule
content release, appeared to be necessary to generate second-
ary necrosis capable of potentiating the anti-inflammatory ef-
fects. This indicates that induction of necrosis per se is not
sufficient and implicates a possible role for the release of en-
dogenous LL-37 or other anti-inflammatory agents from PMN
granules. Irrespective, it is clear that LL-37-induced secondary
necrosis did not compromise the anti-inflammatory effects of
the dead cells nor confer proinflammatory properties on
them. Furthermore, any proinflammatory mediators released
by secondarily necrotic PMN into the supernatant were unable
to initiate or potentiate macrophage production of the cyto-
kines studied in the presence of LL-37.
Whereas apoptosis has been viewed as anti-inflammatory and
inducing immune-tolerance, necrosis has been considered a
proinflammatory and immunogenic form of cell death. How-
ever, recent studies have suggested that this axiom is oversim-
plified [46]. Apoptotic Jurkat T cells are reported to be
equally potent in modulating macrophage MAPK pathways,
irrespective of membrane integrity [47], and the membranes
of apoptotic and primary necrotic PMN have been shown to
inhibit TNF- production by activated macrophages [44]. In
addition, apoptosis can neutralize potential intracellular dan-
ger signals, such as high-mobility group box-1 protein, via
caspase-activated mitochondrial reactive oxygen species pro-
duction [48]. Thus, the release of intracellular contents from
apoptotic cells having undergone secondary necrosis may not
be equivalent to the proinflammatory contents of primary ne-
crotic cells, an hypothesis that would be compatible with our
data.
We demonstrate that LL-37-induced PMN secondary necro-
sis had no impact on the magnitude of ingestion of dead PMN
by macrophages, consistent with previous reports [44, 45]. Ef-
ferocytosis is a complex process with multiple receptors and
adaptors proposed [3], independent from the anti-inflamma-
tory effects initiated by apoptotic cells [49]. We cannot ex-
clude the possibility that the mechanism of ingestion of these
secondary necrotic PMN and apoptotic PMN may be different,
but comparable levels of uptake suggest that LL-37-mediated
induction of PMN secondary necrosis in vivo would not inhibit
the clearance of dead PMN.
Irrespective of the impact of secondary necrosis on the
clearance of dead PMN or macrophage cytokine responses,
the loss of PMN membrane integrity presents the additional
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Figure 8. LL-37-induced secondary necrosis of PMN can release gran-
ule contents. Isolated human PMN were incubated for 20 h with a
range of concentrations of LL-37 or 50 g/ml scrambled LL-37
(sc50). The concentration of MPO in the supernatants was evaluated
as a percentage of total MPO release after lysis of fresh control PMN
using 0.1% Triton X-100. Significance was assessed by one-way ANOVA
with Bonferroni’s multiple comparison test; n  7 donors; **, P 
0.01, compared with untreated PMN.
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threat of the release of harmful intracellular contents, includ-
ing granule contents such as neutrophil elastase, cathepsin G,
MPO, and gelatinase [50]. In contrast to previous TEM-based
observations [38], our data demonstrate that high concentra-
tions of LL-37 induced the release of MPO from the azuro-
philic granules. Interestingly, this was not observed at lower
LL-37 concentrations, at which significant induction of second-
ary necrosis was observed nevertheless. This suggests that LL-
37-induced secondary necrosis did not disrupt granule integ-
rity per se but that high concentrations of LL-37 (10 g/ml)
had the capacity to damage granule membranes in addition to
apoptotic outer membranes. The consequences of such an ef-
fect in a rapidly resolving acute infection may contrast with
those in a chronic inflammatory process associated with high
levels of LL-37. Indeed, increased hCAP-18/LL-37 concentra-
tions in cystic fibrosis lung disease (detected at up to 15
g/ml in BALF from patients without recent infectious exacer-
bation) were correlated with increased lung damage [34], and
raised pulmonary LL-37 levels are associated with bronchiolitis
obliterans syndrome in the recipients of lung transplants [36].
In addition, LL-37 has been proposed recently to contribute to
the pathogenesis of psoriasis [35], and the concentration of
hCAP-18/LL-37 was reported to be 1.5 mg/ml in psoriatic
skin lesions [51]. These estimates of in vivo peptide concentra-
tions do not take into account the recent observation that the
ratio of active LL-37 to full-length precursor hCAP-18 varied
considerably between donors in the inflamed lung [36]. Nev-
ertheless, at these concentrations, extensive induction of sec-
ondary necrosis of apoptotic PMN, with the release of PMN
granule contents, could be generated by exposure to LL-37 in
vivo. Thus, the potentially detrimental effects of LL-37-medi-
ated induction of PMN secondary necrosis could have signifi-
cance in chronic disease processes.
The potential consequences of PMN granule release may be
of particular significance for the ongoing development of
CHDP as therapeutic agents for infectious and inflammatory
diseases. A greater knowledge of the capacity of these peptides
to modulate inflammation and the peptide attributes that con-
fer them will have important implications. We have demon-
strated recently that the capacity of LL-37 to induce secondary
necrosis of apoptotic cells is not specific to PMN [41] and now
additionally define a core functional region and describe inter-
action with other modifiers of cell death.
We demonstrate that LL-37-induced secondary necrosis of
PMN occurred rapidly, within minutes of exposure of an apop-
totic PMN to the peptide. The specific membrane alterations
that make these apoptotic cells acutely susceptible to damage
by LL-37 and the nature of this interaction remain unclear,
but the process has been proposed recently to be energy-inde-
pendent [38] and independent of known LL-37 receptors
[41]. Our data demonstrate that this property was conserved
in the murine ortholog mCRAMP, and the effect was not de-
pendent primarily on peptide charge (with no effects seen for
a scrambled sequence peptide with the same charge) and was
retained partially by C-terminal, but not N-terminal partial
LL-37 peptides. These latter studies, using truncated partial
peptides, shown previously to be poorly antiendotoxic [37],
identified a minimal core-functional region for induction of
secondary necrosis by LL-37, spanning aa 16–32. This may in-
dicate an important motif or be related to the more amphi-
pathic nature of the peptides spanning this region. Interest-
ingly, the region 17–32 has been identified previously as the
core antimicrobial region [52]. This suggests a possible conser-
vation of mechanism between the direct microbicidal effects of
LL-37, for which amphipathicity is critical [52], and the capac-
ity to induce PMN secondary necrosis. However, it is notewor-
thy that whereas core LL-37 peptide 17-32 had enhanced mi-
crobicidal function compared with full-length LL-37, our par-
tial peptides had diminished capacity to induce secondary
necrosis. This has important implications for the development
of therapeutic peptides and in consideration of the possible in
vivo activities of shorter-form cleavage products of hCAP-18,
identified previously in the skin [53]. Further study of our par-
tial peptides will enable dissection of the various properties of
LL-37.
In conclusion, we demonstrate that the human cathelicidin
LL-37 is a potent inducer of secondary necrosis of apoptotic
PMN, with the potential to alter the profile of PMN cell death
at sites of infection and inflammation. Our data give novel in-
sights into the potential effects of PMN secondary necrosis,
suggesting that LL-37-mediated secondary necrosis of PMN
does not have proinflammatory effects on macrophages and
can even potentiate the anti-inflammatory effects of efferocyto-
sis. These data challenge the prevailing model that although
apoptotic cells are anti-inflammatory to macrophages, necrotic
cells (whether primary or secondary necrosis) are inherently
proinflammatory. This has particular importance for the de-
layed clearance of the apoptotic cell hypothesis for chronic
inflammation and implications for novel, anti-inflammatory
strategies being developed based on our understanding the
mechanisms controlling the resolution of inflammation. How-
ever, we also demonstrate that LL-37-induced secondary necro-
sis has the potential to induce the release of potentially harm-
ful granule contents, which could have deleterious conse-
quences for the host, particularly in chronic disease states. We
demonstrate that this induction of secondary necrosis by LL-37
is not primarily charge-dependent, is partially retained by C-
terminal partial peptides, and is conserved in the murine or-
tholog. Further understanding of this mechanism and its phys-
iological significance will assist the appropriate modification of
synthetic analogs as novel therapeutics, illuminate possible
roles in the pathogenesis of chronic disease, and advance our
understanding of the impact of different cell death processes
in the promotion and resolution of inflammation.
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LL-37 is a cationic host defense peptide that is highly expressed during acute inflammation and that kills
bacteria by poorly defined mechanisms, resulting in permeabilization of microbial membranes. High concen-
trations of LL-37 have also been reported to have cytotoxic effects against eukaryotic cells, but the peptide is
clearly capable of differentiating between membranes with different compositions (eukaryotic versus bacterial
membranes). Eukaryotic cells such as leukocytes change their membrane composition during apoptotic cell
death, when they are turned into nonfunctional but structurally intact entities. We tested whether LL-37
exerted specific activity on apoptotic cells and found that the peptide selectively permeabilized the membranes
of apoptotic human leukocytes, leaving viable cells unaffected. This activity was seemingly analogous to the
direct microbicidal effect of LL-37, in that it was rapid, independent of known surface receptors and/or active
cell signaling, and inhibitable by serum components such as high-density lipoprotein. A similar selective
permeabilization of apoptotic cells was recorded for both NK cells and neutrophils. In the latter cell type,
LL-37 permeabilized both the plasma and granule membranes, resulting in the release of both lactate
dehydrogenase and myeloperoxidase. Apoptosis is a way for inflammatory cells to die silently and minimize
collateral tissue damage by retaining tissue-damaging and proinflammatory substances within intact mem-
branes. Permeabilization of apoptotic leukocytes by LL-37, accompanied by the leakage of cytoplasmic as well
as intragranular molecules, may thus shift the balance between pro- and anti-inflammatory signals and in this
way be of importance for the termination of acute inflammation.
The cathelicidins form a large family of microbicidal, cat-
ionic host defense peptides found in all mammalian species
examined so far, including humans, cows, pigs, rabbits, sheep,
mice, monkeys, and horses (60). Only one human cathelicidin,
human cationic antimicrobial protein 18 (hCAP-18; unproc-
essed form), or LL-37 (the predominant, mature antibacterial
form), has been isolated. LL-37 is mainly expressed by neutro-
phils and epithelial cells during acute inflammation. LL-37 is
stored as a propeptide in the specific granules of neutrophils.
Upon neutrophil activation, the proform is cleaved enzymati-
cally by proteinase 3 to the active form during degranulation
toward the extracellular compartment (49). The concentration
of LL-37 can be severely increased at sites of inflammation,
and levels up to about 15 to 25 g/ml have been reported in
bronchoalveolar lavage fluid from infants with pulmonary in-
fections as well as from cystic fibrosis patients (14, 45); even
higher levels (over 1 mg/ml) has been reported from psoriatic
skin lesions (40).
LL-37 was originally identified as a cationic microbicidal
peptide due to its ability to specifically permeabilize prokary-
otic membranes (1, 16, 31); it possesses direct microbicidal
activity against bacteria, fungi, and enveloped viruses (5, 33).
Very high concentrations of LL-37 have also been reported to
have cytotoxic effects against eukaryotic cells in vitro (28). The
microbial killing mechanism is dependent on the membrane-
active properties of the peptide, which has the ability to inter-
act with both the inner and the outer membranes of gram-
negative bacteria (22). The mode of action for the direct
microbicidal activity of host defense peptides has not been
determined conclusively, but the leading hypothesis is that
these peptides are membrane active and have the ability to
break the integrity of bacterial cell membranes more or less
selectively over eukaryotic membranes (47). Bacterial mem-
branes are composed of phospholipids different from those of
eukaryotic cell membranes, with the bacterial membranes be-
ing more negatively charged than their eukaryote counterparts.
The presence of surface molecules other than phospholipids,
e.g., lipopolysaccharide (LPS; an outer membrane component
of gram-negative bacteria), is also of importance to the overall
negative charge of bacterial membranes. This negative charge
is, in part, believed to be a determinant for the interaction with
cationic peptides and gives the peptides selectivity for the mi-
crobial membranes (37).
Lately, LL-37 has been shown to have immunomodulatory
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properties, in addition to its microbicidal potential (10), and is
also capable of activating various immune cells; thus, it pos-
sesses a functional dualism that is also displayed by certain
other cationic peptides (7, 13, 51, 58). Among the numerous
immunomodulatory actions displayed by LL-37, chemoattrac-
tion and the induction of chemokine release from leukocytes,
the stimulation of angiogenesis, and the binding and neutral-
ization of bacterial LPS can be found (9). LL-37 has been
shown to be highly upregulated under inflammatory condi-
tions, particularly those involving the skin, e.g., psoriasis (20,
40). During inflammation, it is of vital importance that the
activities of the cells involved are tightly regulated. Many in-
flammatory leukocytes, especially neutrophils, are packed with
a variety of cytotoxic substances aimed at microbial killing, and
if these substances reach the extracellular environment in an
uncontrolled fashion, the risk of tissue destruction and sus-
tained inflammation are increased (25, 56). One important
means of ridding the system from potentially harmful intracel-
lular constituents is by apoptosis of the inflammatory cells,
followed by phagocytic clearance of the corpse by viable
phagocytes (34, 44). Apoptosis is often called the physiological,
programmed form of cell death, characterized by the lack of
proinflammatory actions and the minimization of damage to
surrounding cells and tissue. Apoptotic cells are nonfunctional
but, importantly, carry an intact cell membrane that prevents
the uncontrolled leakage of intracellular molecules (25). De-
spite the integrity of the apoptotic cell membrane, its surface-
exposed molecule composition differs substantially from that
of the membranes of viable cells. One prominent example of
surface changes relates to phospholipids. In viable cells, an
uneven distribution of phospholipids between the two leaflets
of the double-sided membrane is maintained by an energy-
dependent process that keeps the negatively charged phospha-
tidylserine (PS) on the inside. In a nonfunctional apoptotic
cell, the PS distribution is leveled out over time, with the PS
also being on the outer leaflet as a result (35), making the
membrane of apoptotic cells more negatively charged and, in
this way, more like the membrane of bacteria. The surface-
located PS is also an important “eat-me” flag that ensures
phagocytic clearance of the apoptotic cell (18). Annexin V is a
Ca2-dependent, cell-impermeant protein with a high affinity
for PS. When it is conjugated to a fluorochrome, it is widely
used for the detection and quantification of apoptosis by flow
cytometry.
Given the ability of LL-37 to distinguish between prokary-
otic and eukaryotic membranes and the fact that the compo-
sition of eukaryotic membranes changes when a cell becomes
apoptotic, we investigated whether the peptide could distin-
guish between viable and apoptotic leukocytes. Using primary
human neutrophils, a cell type that has a short half-life in vivo
and that rapidly enters apoptosis in culture, we found that
LL-37 selectively permeabilized the membranes of apoptotic
cells under serum-free conditions, leaving viable cells unaf-
fected in this respect. A specificity similar to that for apoptotic
cells was also found for NK cells, another inflammatory leu-
kocyte, which was rendered apoptotic by treatment with hy-
drogen peroxide. The selective permeabilization of apoptotic
neutrophils was very rapid and seemingly independent of
known LL-37 surface receptors and/or active cell signaling.
Peptide-induced permeabilization in effect shifted apoptotic
cells into a necrotic phenotype, whereby intracellular constit-
uents were released into the extracellular milieu; leakiness was
effectively counteracted by the presence of human serum or
high-density lipoprotein (HDL) in a similar manner, as micro-
bial killing by LL-37 was blocked by these substances. The
mere surface exposure of the negatively charged PS, a conse-
quence of apoptosis, was not responsible for the selective per-
meabilization of apoptotic cells. We concluded that LL-37
possesses selective permeabilizing activity on apoptotic leuko-
cytes in a manner seemingly analogous to its activity against
bacterial membranes. In pathological settings with high levels
of cathelicidin expression in the absence of serum constituents
(such as psoriatic lesions), the permeabilization of apoptotic
leukocytes by LL-37 could be of importance in determining the
eventual outcome of acute inflammation.
MATERIALS AND METHODS
Reagents. LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)
was synthesized by N-(9-fluorenyl)methoxycarbonyl chemistry at the Nucleic
Acid/Protein Service Unit at the University of British Columbia (Vancouver,
British Columbia, Canada). Scrambled LL-37 (sLL-37; RSLEGTDRFPFVRLK
NSRKLEFKDIKGIKREQFVKIL) was purchased from CSS-Albachem Ltd.
(East Lothian, United Kingdom). WKYMVM was from Alta Bioscience (Bir-
mingham, United Kingdom), and WRW4 was from Genscript Corp. (Scotch
Plains, NJ). Hp(2-20) was synthesized and purified by high-pressure liquid chro-
matography (Innovagen, Lund, Sweden). Ficoll-Paque was from Pharmacia
(Uppsala, Sweden), and Ficoll-Hypaque was from Nycomed (Oslo, Norway).
Dextran was purchased from Amersham Biosciences (Uppsala, Sweden). The
A-6013 agarose used for the casting of all plates for the inhibition zone assays
was from Sigma Chemical Co. (St. Louis, MO), as were oxidized ATP (oxATP),
HDL, cytochalasin B, lidocaine, colchicine, and calcein. The antibody -CD95
was from Nordic BioSite (Täby, Sweden). Annexin V-fluorescein isothiocyanate
(FITC), annexin V-allophycocyanin (APC), 7-amino-actinomycin D (7-AAD),
and the BD IMag NK cell isolation kit were supplied by BD Biosciences (San
Jose, CA). RPMI 1640 medium was from PAA Laboratories (Pasching, Austria).
The lipids used for liposome preparation (1,2-dipalmitoyl-sn-glycero-3-phos-
phatidylethanolamine [DPPE], 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine
[DPPC], 1,2-dipalmitoyl-sn-glycero-3-phosphatidyl-rac-glycerol, sodium salt
[DPPG], dioleoyl-sn-glycero-3-phosphatidylserine [DOPS], and cholesterol)
were purchased from Larodan (Malmö, Sweden).
Isolation and culture of human cells. Human neutrophils were isolated by a
standard technique (11, 12) from buffy coats obtained from the blood of healthy
donors at the Sahlgrenska Hospital, Gothenburg, Sweden. In short, dextran
sedimentation was performed at 1  g, followed by hypotonic lysis of the re-
maining erythrocytes and centrifugation in a Ficoll-Paque gradient. Thereafter,
the neutrophils were washed twice and resuspended in RPMI 1640 medium
supplemented with 10% fetal calf serum to a density of 5  106 cells/ml. Cells
(500 l) were added to polypropylene tubes and incubated at 37°C in 5% CO2 for
20 h for the induction of spontaneous apoptosis. For increased apoptosis, azide-
free -CD95 monoclonal antibody (10 g/ml) was coincubated with the cells,
which resulted in approximately 20% viable neutrophils and 80% apoptotic
neutrophils.
For the isolation of NK cells, peripheral venous blood was incubated with
Iscove’s modified Dulbecco’s medium, dextran, and acid citrate dextrose for 15
min at room temperature. The supernatant was centrifuged through a Ficoll-
Hypaque (Lymphoprep) density gradient, and the mononuclear cells at the
interface were collected and further processed by countercurrent centrifugal
elutriation (57). In short, this technique allows cell separation on the basis of the
cell sedimentation rate in a spinning rotor at 2,150 rpm balanced by a counter-
directed flow through a chamber. By varying the flow rate, different cell fractions
were separated on the basis of their sizes. The NK-cell-enriched lymphocyte
fractions were collected at flow rates of between 14 and 15 ml/min, and the cells
were then further isolated through negative selection with magnetic beads (BD
IMag NK cell isolation kit), according to the instructions provided by the man-
ufacturer. Finally, the isolated NK cells were incubated overnight in Iscove’s
modified Dulbecco’s medium supplemented with 10% normal human serum at
37°C in 5% CO2. For the induction of the early apoptotic characteristics in the
NK cells, 100,000 to 200,000 cells incubated overnight were exposed to 200 M
H2O2 for 6 h at 37°C in 5% CO2 (23, 24, 53).
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Evaluation of apoptosis. The neutrophils that had been incubated overnight,
as described above, were washed and resuspended in annexin V binding buffer
(AVBB; 1 mM HEPES, 14 mM NaCl, 0.25 mM CaCl2; pH 7.4) to 6.25  106
cells/ml. Samples (70 l) were stained with 5 l annexin V-FITC for 5 min at
ambient temperature, whereupon 7-AAD was added, and the staining was con-
tinued for 10 min before the addition of AVBB to give a final volume of 500 l.
In some experiments, annexin V-FITC was exchanged for -CD16–FITC: 100-l
samples were stained with 10 l antibody for 10 min at 0°C, whereupon staining
with 7-AAD was performed as described above. Peptides diluted in water were
added 5 min prior to analysis, if not indicated otherwise. HDL (650 g/ml),
bovine serum albumin (0.5%; wt/vol), or 10% salt mimicking serum salt (11.3
mM NaCl, 2.4 mM NaHCO3, 0.06 mM MgCl2, 0.13 mM CaCl2, 0.39 mM KCl)
(28) was added to the indicated samples before the addition of peptide. Samples
were analyzed by fluorescent-activated cell sorter analysis before and after the
addition of peptides. For samples treated with the formyl peptide receptor-like
1 (FPRL1) antagonist, WRW4 (5 M) was added 5 min (at 37°C) prior to the
addition of peptide. The same procedure was used for the P2X7 inhibitor oxATP
(900 M), but by the procedure with oxATP, the samples were preincubated with
the inhibitor for 30 min. The concentrations and incubation times for the inhib-
itors have previously been shown to specifically block Ca2 flux induced through
FPRL1 and P2X7, respectively (15). The inhibitors of membrane repair cytocha-
lasin B (10 g/ml), colchicine (10 M), or lidocaine (5 mM) were coincubated
with the cells overnight and were added to all buffers used for the subsequent
experiments, as indicated.
The H2O2-treated NK cells were washed and resuspended in AVBB. Each
sample was stained at ambient temperature with 5 l annexin V-FITC for 5 min,
followed by staining with 5 l 7-AAD, for a final volume of 100 l, for another
10 min. The samples were thereafter diluted to 300 l with AVBB before
analysis. Flow cytometry was performed before and 5 min after the addition of
LL-37 (5 g/ml was used for NK cells, as these cells are more susceptible than
neutrophils to the cytotoxic action of LL-37).
Determination of direct microbicidal activity. Escherichia coli strain MG1655
was grown overnight in Luria-Bertani (LB) broth (3) at 37°C on a rotary shaker.
A modified inhibition zone assay was used for the detection of direct microbi-
cidal activity (21, 26, 27). In short, standard LB agar (LB broth supplemented
with 1% [wt/vol] agarose) containing bacteria (approximately 5  105 CFU in
logarithmic growth phase per milliliter agar) was poured into petri dishes (di-
ameter, 92 mm). Wells (diameter, 3 mm; depth, 1 mm) were punched in the agar,
and peptide preparations (3 l) diluted in distilled water were added to the wells,
whereupon the plates were incubated at ambient temperature for 45 min and
then at 37°C overnight. The peptide was used in the assays at amounts ranging
from 1.88 g/well to 7.5 g/well. Inhibition zones were calculated as the diameter
of the clear zones, free of visible bacteria, surrounding the wells. HDL (650
g/ml) was added to the agar plates before the plates were cast.
Liposome preparation. Lipids (DPPE, DPPC, DPPG, and cholesterol) were
dissolved in chloroform-methanol (1:1) to a concentration of 20 mg/ml. DOPS
was dissolved in chloroform to 25 mg/ml. The lipid mixtures (final concentration
of total lipids, 2.5 mM) were dissolved in chloroform-methanol (1:1) and dried
under reduced nitrogen pressure at 45°C, with subsequent drying under vacuum
for 1 h. Liposomes containing the following were prepared: DPPE-DPPC-cho-
lesterol (1:1:1; lipids typically found in eukaryotic membranes), DPPE-DPPG
(7:3; phospholipids typically found in bacterial membranes), and DPPE-DPPC-
cholesterol-DOPS (3:3:3:1; lipids typically found in eukaryotic plasma mem-
branes with 10% PS). During the subsequent preparation steps, the liposomes
were kept at 50°C at all times to avoid solidification of the dipalmitoyl lipids. The
dried lipid film was dissolved in 1 ml Tris buffer (150 mM NaCl, 10 mM Tris, 1
mM EDTA; pH 7.4) containing self-quenching concentrations of calcein (80
mM), and the mixture was vigorously vortexed and then given a short sonication.
Large unilamellar vesicles were obtained by passing the suspension 20 times
through 400-, 200-, and 100-nm-pore-size polycarbonate filters (Eschborn, Ger-
many) on a handheld extruder. Extraliposomal calcein was removed by filtration
through Sephadex G-50 resin. The release of calcein to the extraliposomal
medium upon peptide addition was monitored continuously by measuring the
fluorescence intensity on a Perkin-Elmer LS55 fluorescence spectrometer (exci-
tation , 494 nm; emission , 513 nm). The maximum fluorescence intensity,
which corresponded to 100% leakage, was determined by adding Triton X-100
(0.1%) to the liposomes.
Intracellular Ca2 measurements. Intracellular Ca2 was measured by a pre-
viously described method (42). In short, neutrophils incubated overnight for the
induction of apoptosis were resuspended in cell loading medium (1% fetal calf
serum in Krebs-Ringer phosphate buffer containing glucose [10 mM glucose, 1
mM Ca2, 1.5 mM Mg2; pH 7.3]) and loaded with Fluo-3 (4 mg/ml) and
Fura-Red (10 mg/ml) reagents at 37°C for 30 min. The cells were washed twice,
resuspended in AVBB to a final concentration of 6  106/ml, and stained with
annexin V-APC at ambient temperature for 15 min. The samples were diluted to
8.75  105 cells/ml, and 0.5 ml was prewarmed at 37°C for 5 min. The level of
intracellular Ca2 accumulation in individual cells upon the addition of WK
YMVM (107 M) was assessed by flow cytometry over 5 min. The fluorescence
emissions of the Fluo-3 and Fura-Red reagents were measured in the FL-1 and
the FL-3 channels, respectively. The data were analyzed by using the kinetics
mode of FlowJo software (version 5.7.1; FlowJo, LLC, Ashland, OR), and the
relative intracellular Ca2 concentration was presented as the ratio between the
mean fluorescence intensity of the Fluo-3 reagent and that of the Fura-Red
reagent over time. The analysis of Ca2 accumulation was performed after gating
of viable and apoptotic cells by the use of annexin V-APC staining.
To establish that the apoptotic neutrophils were properly labeled with the
Fluo-3 and Fura-Red reagents, ionomycin (500 nM) was included as a positive
control stimulus. This ionophore forms pores in the plasma membrane, giving
rise to an artificial, signaling-independent rise in the intracellular calcium con-
centration. Addition of ionomycin resulted in an increase in the intracellular
calcium concentration in the apoptotic cells as well as the viable cells (data not
shown).
Measurements of LDH and MPO release from LL-37-treated neutrophils.
Neutrophils (5  106/ml) were incubated overnight in 5% CO2 at 37°C, and
-CD95 (10 g/ml) was included for the induction of apoptosis or was not
included. The cells were washed and diluted to 1  106/ml before treatment with
LL-37 (50 g/ml) for 10 min. All samples were divided in two, and one portion
of each sample was lysed with Triton X-100 (1%) for 1 min, after which the cell
debris was removed by centrifugation. The amount of the cytosolic enzyme
lactate dehydrogenase (LDH) released was measured with a cytotoxicity detec-
tion kit from Roche Diagnostics GmbH (Mannheim, Germany), according to the
manufacturer’s directions. The myeloperoxidase (MPO) content in the neutro-
phils was measured by determination of the amount of enzyme activity by mixing
50 l of the cell supernatants described above with 100 l peroxidase substrate
(1,2-phenylenediamine dihydrochloride [Dako Denmark A/S]) in a 96-well plate
and incubation of the plate overnight at room temperature. The absorbance at
492 nm was then measured.
Statistical analysis. The results are expressed as means  standard deviations
(SDs). Unpaired and paired t tests were used for statistical analysis, and P values
are two tailed with 95% confidence intervals. For comparisons of multiple data
sets, one-way analysis of variance with Bonferroni’s multiple-comparison tests
was performed. The data were analyzed with GraphPad Prism software (version
4.02; GraphPad Software, San Diego, CA).
RESULTS
Direct microbicidal action of LL-37 and discrimination be-
tween membranes of different compositions. LL-37 is a host
defense peptide with dual actions that both works directly by
permeabilizing microbial membranes and has receptor-de-
pendent, immunomodulatory actions on leukocytes as a
means of protecting against infections. The direct microbi-
cidal effects of LL-37 and the sLL-37 control peptide against
E. coli were assessed in inhibition zone assays; LL-37 in-
duced a clear zone around the well that was free of visible
bacteria, while sLL-37 had no direct microbicidal effect (Fig.
1A). The lethal concentration was calculated to 6.3 g/ml
for E. coli (strain MG1655) under the specific medium con-
ditions used in the assay. The lethal concentration was de-
termined from the diameter of the inhibition zone by a
previously described method (26) and was defined as the
lowest concentration that just inhibited colony formation in
the thin agar plates. Under the serum-free conditions used,
LL-37 (100 g/ml) had no effect on the integrity of the cell
membranes of freshly prepared neutrophils, as shown by a
lack of 7-AAD staining (Fig. 1B). This dye is incapable of
passing intact cell membranes and therefore functions as a
useful marker of membrane integrity (46). These experi-
ments show that LL-37 can be directly microbicidal in the
5-g/ml range (as determined by calculation of the lethal
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concentration from the results obtained from the inhibition
zone assays), whereas concentrations up to 100 g/ml were
not cytotoxic for neutrophils under serum-free conditions.
To further characterize the ability of LL-37 to discriminate
between bacterial and eukaryotic membranes, we tested the
effect of LL-37 on liposomes containing the lipids typically
found in bacterial as well as in eukaryotic membranes in a
calcein release assay. Bacterial membranes are slightly more
negatively charged than eukaryotic membranes, and liposomes
containing large amounts of neutral PE and the negatively
charged phosphatidylglycerol (PG) were synthesized. For the
eukaryotic membrane-like liposomes, cholesterol was incorpo-
rated together with the two neutral phospholipids PE and PC.
As expected, LL-37 readily permeabilized the bacterial mem-
brane-like liposomes (Fig. 1C). The eukaryotic membrane-like
liposomes were permeabilized to a limited extent (approxi-
mately 15%), but they were obviously much more resistant
than the bacterial membrane-like liposomes to the lytic action
of LL-37. Taken together, these data show that LL-37 is clearly
capable of differentiating between membranes with different
compositions.
Selective permeabilization of apoptotic neutrophils by LL-37.
LL-37 had no cytotoxic effect on freshly prepared human neu-
trophils (Fig. 1B). In order to study the effect of LL-37 on
viable and apoptotic membranes of primary leukocytes, we
employed human neutrophils, which gradually enter spontane-
ous apoptosis during in vitro culture. In this set of experiments,
neutrophils incubated overnight spontaneously entered apop-
tosis, leaving a mixed population of cells with 66% viable cells
(annexin V negative, 7-AAD negative) and 31% apoptotic cells
(annexin V positive, 7-AAD negative), as assessed by flow
cytometry (Fig. 2A, left panel). By use of this standardized
protocol, very few cells (less than 3%) displayed a necrotic
phenotype with permeable membranes, as indicated by the
lack of 7-AAD-positive events. The use of this mixed culture
enabled us to investigate viable and apoptotic cells simulta-
neously, and addition of LL-37 (50 g/ml, 5 min of incubation)
to the mixed population selectively permeabilized the apop-
totic cells that acquired the 7-AAD stain under serum-free
conditions (Fig. 2A, middle panel, upper right quadrant). The
membranes of annexin V-negative cells were still intact (7-
AAD negative) after the addition of peptide (Fig. 2A; middle
panel, lower left quadrant). sLL-37 (50 g/ml, 5 min of incu-
bation) did not permeabilize any cell type (Fig. 2A, right
panel), indicating that the cationic nature of LL-37 is not
sufficient to permeabilize apoptotic neutrophils. sLL-37 at a
FIG. 1. LL-37 can distinguish between membranes with different compositions. (A) The direct microbicidal activity of LL-37 (1.88, 3.75, and
7.5 g/well) against E. coli was determined in an inhibition zone assay. LL-37 gave rise to clear, bacteria-free zones around the wells (upper panel),
while sLL-37 (1.88, 3.75, and 7.5 g/well) was inactive (lower panel). (B) Freshly separated neutrophils were not sensitive to the direct microbicidal,
lytic action of LL-37 (100 g/ml), as shown by the lack of 7-AAD fluorescence intensity plotted against the forward scatter. 7-AAD is a nucleic
acid stain used for the detection of the loss of membrane integrity in cells. The results of one experiment with the percentage of cells in each region
are shown. (C) LL-37 (5 ng/ml) readily permeabilized bacterial membrane-like liposomes (gray line) composed of PE-PG (7:3), while the
eukaryotic membrane-like liposomes (black line), composed of PE-PC-cholesterol (1:1:1), were more resistant to the permeabilizing effect of
LL-37. The percentage of total calcein released, as assessed by the addition of Triton X-100, is plotted against time. The means  SDs (n  3)
obtained at 0, 50, 100, 150, and 200 s are shown. The amounts of calcein released at 100, 150, and 200 s were compared; and significant differences
between the amounts released were was established (P 	 0.01 at each point, as indicated [**]; n  3). The arrow indicates the time of addition
of peptide.
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concentration of 500 g/ml was also ineffective (data not
shown).
In order to rule out the possibility that an undefined inter-
action between LL-37 and annexin V caused the permeabili-
zation, experiments were conducted with CD16 instead of an-
nexin V as a marker for neutrophil apoptosis (Fig. 2B, left
panel). CD16 is a surface protein present on viable neutrophils
(Fig. 2B, left panel, lower right quadrant) that is lost upon
apoptosis (Fig. 2B, left panel, lower left quadrant), and only
cells negative for CD16 (i.e., apoptotic cells) became 7-AAD
positive after addition of peptide (Fig. 2B, right panel). After
addition of LL-37, the apoptotic cell population was permeant
not only to the nuclear dye 7-AAD but also, apparently, to the
-CD16 antibody that gained access to intracellular CD16 and,
as a result, conferred a CD16 signal to the permeabilized cells
(Fig. 2B, right panel).
Selective permeabilization of apoptotic NK cells by LL-37.
Inflammatory cells other than neutrophils have the ability to
enter apoptosis as well. NK cells are cytotoxic, large granular
lymphocytes important for eradicating viruses and combating
tumor cells. One efficient way to drive NK cell apoptosis is to
subject these cells to extracellular reactive oxygen species (23).
To test whether the selective permeabilization of apoptotic
cells applied only to neutrophils or if it represents a more
general mechanism that acts on other leukocytes as well, NK
cells were isolated and subjected to H2O2 treatment for the
induction of apoptosis. Untreated NK cells incubated for 6 h
displayed only 5% apoptotic cells, as assessed by annexin V
and 7-AAD labeling (Fig. 3A). When the cells were coincu-
bated with H2O2 (200 M), a larger population (17%) became
apoptotic (Fig. 3B), resulting in a mixed population of viable
and apoptotic NK cells. A population of NK cells (16%) also
appeared to be permeabilized after the addition of H2O2 (Fig.
3B, upper right quadrant). After this mixed population was
washed, it was treated with LL-37 (5 g/ml, 5 min of incuba-
tion), and with these leukocytes, the apoptotic cells were also
FIG. 2. Selective permeabilization of apoptotic neutrophils by LL-37. (A) Neutrophils incubated for 20 h spontaneously entered apoptosis,
resulting in 66% viable cells and 31% apoptotic cells, as assessed by annexin V and 7-AAD staining and visualized by flow cytometry (left panel).
When LL-37 (50 g/ml) was added to these cells, all apoptotic (annexin V-positive) cells were permeabilized (7-AAD positive), while the viable
(annexin V-negative) population was unaffected (middle panel) 5 min after addition of the peptide. sLL-37 (50 g/ml) was inactive when it was
added to the system (right panel). The results presented here represent those of one of three experiments performed for this experimental series.
(B) Apoptosis was also assessed by CD16 shedding (left panel). Only the apoptotic neutrophils (CD16 negative) were permeabilized by the
addition of LL-37 and stained positive for 7-AAD. The -CD16 antibody also gained access to intracellular CD16 upon permeabilization, as shown
by the increase in the fluorescence intensity of CD16 (right panel). The plots represent those from one of two independent experiments that were
performed. Each plot shows the means  SDs from one representative experiment.
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primarily permeabilized (Fig. 3C). When the results for the
LL-37-treated viable population were compared to those for
the H2O2-treated control cells, no significant difference was
found (P  0.07; n  3). A lower standard concentration of
LL-37 was used against the NK cells than against the neutro-
phils (5 g/ml and 50 g/ml, respectively), owing to the fact
that NK cells were more susceptible to the cytotoxic action of
LL-37. At 10 g/ml, a substantial amount of cytotoxicity
against NK cells was observed (the proportion of viable cells
dropped from 82.6% to 38.5%; data not shown). At 5 g/ml of
LL-37, mainly apoptotic (annexin V-positive) NK cells were
permeabilized, whereas the permeabilization of viable cells
was not statistically significantly reduced. These data indicate
that the selective permeabilization of apoptotic cells is inde-
pendent of the type of leukocyte.
Characterization of selective permeabilization. Dose titra-
tion experiments revealed that the permeabilizing effect on
apoptotic neutrophils was concentration dependent starting at
approximately 10 g/ml, and a full effect was reached at 50
g/ml of LL-37. The half-maximal effective concentration
(EC50) was determined for the selective permeabilization of
apoptotic cells by plotting the mean value of the percentage of
apoptotic cells at concentrations 0, 5, 10, and 50 g/ml for
three separate experiments and fitting a straight line to the
data set (R2  0.99); the EC50 for the permeabilization of
apoptotic neutrophils was 27 g/ml. At 500 g/ml, a more
general cytotoxic effect was observed; in addition to the per-
meabilization of all apoptotic cells, viable neutrophils were
also affected (Fig. 4A) (P 	 0.001 compared to the results for
viable neutrophils treated with buffer). The EC50 was also
determined for the cytotoxic action of LL-37 against viable
cells by plotting the mean value of the percentage of viable
cells obtained after treatment with LL-37 at concentrations of
0, 5, 10, 50, 100, and 500 g/ml from three separate experi-
ments. A straight line was fitted to the data set (R2  0.97), the
trend line was extrapolated, and the EC50 was determined to
be 700 g/ml. Due to technical limitations, we could not use
concentrations of LL-37 higher than 500 g/ml. On the basis of
EC50s, the concentration needed for the permeabilization of
viable neutrophils (general cytotoxicity) was found to be ap-
proximately 25 times higher than that needed for the perme-
abilization of apoptotic neutrophils. Time and titration exper-
iments showed that the specificity was intact (i.e., viable cells
were unaffected) for at least the first 5 min (P 
 0.05 compared
to the results obtained by treatment with buffer alone). Almost
all annexin V-positive cells became leaky within 5 min of LL-37
addition (Fig. 4B). In an attempt to study the leakage within
the first 5 min, we analyzed the process (7-AAD fluorescence)
kinetically in a flow cytometer, having first gated the cells on
the basis of annexin V staining (Fig. 4C, left panel). Increased
7-AAD staining was apparent immediately after addition of
LL-37 (Fig. 4C, right panel) in the annexin V-positive cells
(red), whereas the annexin V-negative population (green)
never became 7-AAD positive. These results again showed that
only apoptotic cells were permeabilized by LL-37 and that the
leakage started immediately after addition of peptide.
Cationicity alone was not sufficient to confer direct micro-
bicidal action (Fig. 1A) or specific permeabilization (Fig. 2A,
right panel), since sLL-37 displayed no activity in these assays
(at the highest concentrations used of 7.5 g/well and 500
g/ml, respectively). We next tested the direct microbicidal
and immunomodulatory peptide Hp(2-20), which combines
cationicity with an alpha-helical nature, i.e., classical features
of cationic host defense peptides (13). This peptide was unable
to permeabilize leukocytes (viable or apoptotic) up to concen-
trations of 2 mM (data not shown), showing that the selective
action described for LL-37 is not a general feature of cationic,
alpha-helical host defense peptides.
The effect of LL-37 on apoptotic neutrophils is independent
of known surface receptors and Ca2 signaling. LL-37 has
been reported to employ a variety of surface receptors for the
mediation of its immunomodulatory effects; for neutrophils,
two of the most likely receptor candidates are FPRL1 and
P2X7 (17, 39). We used the antagonists WRW4 (4) and oxATP
(38) to block FPRL1 and P2X7, respectively. In the presence of
these two antagonists, the apoptotic cells were still permeab-
FIG. 3. Selective permeabilization of apoptotic NK cells by LL-37. (A) Isolated NK cells were incubated for 6 h and stained with annexin V
and 7-AAD. Only a small amount of cells displayed apoptotic characteristics (4.7  1.2%; n  3). (B) When the cells were incubated in the
presence of H2O2 (200 M) for 6 h, the population of apoptotic NK cells increased (16.8  3.3%; n  3). The population of permeabilized NK
cells also increased upon addition of H2O2 (from 5.3  2.2% to 16.0  4.2%; n  3). (C) When LL-37 (5 g/ml) was added to the H2O2-treated
NK cells, the apoptotic population was permeabilized and stained positive for 7-AAD, in accordance with the results seen for neutrophils. At this
concentration, no significant permeabilization of the viable population compared to that for the population treated with H2O2 alone was seen (P 
0.07; n  3).
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ilized (Fig. 5A), indicating that the permeabilization was inde-
pendent of known surface receptors. According to the general
dogma, apoptotic cells are nonfunctional and should thus be
unable to transmit intracellular signals (2). When FPRL1 and
P2X7 are activated, they transmit signals that result in the
mobilization of intracellular calcium (15). Using flow cytom-
etry with mixed neutrophil samples containing both viable and
apoptotic cells, we gated the cells on the basis of annexin V
staining and measured the intracellular calcium mobilization in
both types of cells simultaneously (Fig. 5B). Stimulation of the
mixed population with the potent FPRL1 ligand WKYMVM
resulted in a classic intracellular calcium flux (Fig. 5B, right
panel) for the viable cells (green), whereas the apoptotic cells
(red) were completely unresponsive. These data indicate that
the permeabilizing effect of LL-37 on apoptotic cells is most
likely independent of surface receptors and/or active cell sig-
naling. In this respect, the permeabilizing effect was different
from other (mostly receptor-dependent) immunomodulatory
effects on leukocytes reported previously (10). In conclusion,
the effect of LL-37 on apoptotic leukocytes is closely related to
the direct microbicidal, permeabilizing effect of LL-37 rather
than immunomodulating, receptor-dependent effects.
Inhibition by serum components. We hypothesized that the
mechanism behind the observed specific permeabilization of
apoptotic cells by LL-37 had more in common with its direct
microbicidal effects than its immunomodulatory actions. The
direct microbicidal effect of LL-37 is known to be inhibited by
various serum components like HDL and apolipoprotein A1
(32, 55), and in our microbicidal assay, the presence of HDL
also markedly inhibited bacterial killing by the peptide. When
HDL was added to the inhibition zone plates at levels expected
to be found in serum (650 g/ml), the inhibition zone size
generated by LL-37 was markedly decreased (Fig. 6A).
We next subjected a mixed population of neutrophils (viable
and apoptotic) to LL-37 in the presence or the absence of
either 10% human serum or HDL (650 g/ml). Both serum
and HDL completely blocked the LL-37-induced permeabili-
zation of apoptotic neutrophils (Fig. 6B). The immunomodu-
latory, receptor-dependent effects of LL-37 have previously
been shown to be intact in the presence of serum (17), in which
HDL is a prominent protein. These data further strengthen the
hypothesis that the observed effect is, in fact, receptor inde-
pendent. When a salt solution composed to mimic the compo-
sition of 10% serum or bovine serum albumin (0.5%; wt/vol)
was added, no inhibitory effects were observed (data not
shown). These data imply that the presence of proteins in
general and serum salts does not impair the function of LL-37.
Negatively charged PS is insufficient to mediate membrane
permeabilization by LL-37. One plausible cause of the specific
action of LL-37 on apoptotic cells could be the changes in
membrane composition that accompany apoptosis, such as the
surface exposure of the phospholipid PS. This negatively
charged molecule could theoretically confer an affinity for the
positively charged peptide, similar to the reported electrostatic
interaction between LL-37 and LPS (30, 31). We checked
whether LL-37 displays a direct affinity for PS by testing
whether it binds to phospholipids and glycosphingolipids im-
mobilized on a solid phase (50). When an attempt was made to
bind LL-37 to total lipid extracts from human erythrocytes (40
g) and control mixtures of acid glycosphingolipids from var-
ious sources (40 g each), which were separated on thin-layer
chromatograms, or to pure PE, PC, and PS (4 g each), no
specific binding of LL-37 to any of these compounds was ob-
served (data not shown). In a microtiter well assay, the anionic
GM1 ganglioside
[Gal3GalNAc4(NeuAc3)Gal4Glc1Cer] and the neutral
phospholipid PE were included as controls. LL-37 exerted no
specificity toward PS compared to its specificity toward the
other two lipids found in eukaryotic membranes included in
this assay (data not shown).
We next checked whether the presence of PS could contrib-
ute to making membrances sensitive to the lytic action of
LL-37 by incorporating PS into liposomes containing the phos-
pholipids typically found in eukaryotic membranes and subse-
quently measuring the level of calcein leakage after addition of
the peptide. The incorporation of PS into liposomes containing
FIG. 4. The permeabilizing effect of LL-37 on neutrophils is con-
centration dependent and rapid. (A) Different concentrations of LL-37
ranging from 0 to 500 g/ml were tested; increased concentrations led
to an increased permeabilizing effect on the apoptotic cells, and at 500
g/ml, a more general cytotoxic action that also affected viable neu-
trophils was observed. The percentage of cells is plotted against the
LL-37 concentration; and the populations were viable (blue), apoptotic
(red), and permeabilized (black). Mean  SDs (n  3) are shown. The
results for each population were compared to those for an untreated
sample, and significance was established, as indicated, by analysis of
variance and Bonferroni’s test for multiple comparisons. (B) Within 5
min after the addition of LL-37 (50 g/ml), the permeabilizing action
was complete. The membranes of viable cells retained their integrity
for at least 5 min. The percentage of cells is plotted against time; and
the populations were viable (blue), apoptotic (red), and permeabilized
(black). Mean  SDs (n  3) are shown. Statistical significance was
determined as indicated above for panel A. (C) After the gating of
viable (green) and apoptotic (red) cells with the aid of annexin V
staining (left panel), the increase in the intensity of 7-AAD staining
after the addition of LL-37 (50 g/ml) was monitored in real time.
Only the apoptotic cells displayed an increase in 7-AAD intensity
(right panel), and the permeabilization started immediately following
addition of the peptide (arrow). The results represent those of one of
two experiments that were performed. **, P 	 0.01; ***, P 	 0.001.
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phospholipids typically found in eukaryotic membranes did not
confer any permeabilizing activity on LL-37 (Fig. 7). The total
amounts of calcein released (determined by calculation of the
area under the curve) for the two liposome preparations were
determined and when the means were compared, no significant
difference between the two was found (P  0.08; n  3).
The presence of PS did not change the susceptibilities of the
liposomes to the lytic activity of LL-37, and the peptide did not
seem to have any direct affinity for PS. We next hypothesized
that LL-37 does not have any specific affinity for the apoptotic
cells but instead interacts with both viable and apoptotic cells
to the same extent and in this way induces limited membrane
damage. The differences in the outcomes would then be due to
the fact that the nonfunctional apoptotic cells are unable to
repair the disturbed membrane, whereas the viable cells are
quick to reseal the disruption. Viable cells are equipped with a
complex machinery that allows them to repair membrane dam-
age, and that machinery often involves a variety of cytoskeletal
FIG. 5. The effect of LL-37 on neutrophils is independent of known receptors and Ca2 signaling. (A) A mixed population of viable and
apoptotic neutrophils was treated with the two antagonists WRW4 (5 M) and oxATP (900 M), which antagonize two known LL-37 neutrophil
receptors, FPRL1 and P2X7, respectively. In the presence of the antagonists, LL-37 (50 g/ml) still permeabilized apoptotic, annexin V-positive
cells. Paired t tests were performed to establish statistical significance (n  3). (B) An overnight preparation of incubated neutrophils was assessed
for annexin V staining, and a mixed population of both viable (green) and apoptotic (red) neutrophils (left panel) was shown. The mixed population
was stimulated with the potent neutrophil FPRL1 ligand WKYMVM (107 M), and the transient Ca2 release was monitored by flow cytometry.
The viable cells (green line) responded with a rise in the intracellular Ca2 concentration, while the apoptotic cells (red line) were totally
irresponsive. The results of one representative experiment are shown. The FL-1/FL-3 ratio was plotted against time (right panel). *, P 	 0.05; ***,
P 	 0.001.
FIG. 6. The permeabilizing effect of LL-37 on apoptotic neutrophils is inhibited by human serum and HDL. (A) When HDL (650 g/ml) was
added to the inhibition zone plates, the clear zone surrounding the well after the addition of LL-37 (1.88 g/well) decreased markedly. (B) In a
control experiment, apoptotic neutrophils were readily permeabilized by the addition of LL-37 (50 g/ml; left panel). When LL-37 was added to
cells in a solution containing 10% normal human serum, the permeabilizing effect was totally blocked (middle panel). The addition of HDL (650
g/ml) to the neutrophil population prior to the addition of LL-37 (50 g/ml) also inhibited the permeabilizing effect of LL-37 on apoptotic
neutrophils (right panel). Representative plots from three independent experiments and means  SDs summarized from three independent
experiments are shown.
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filaments such as actin and microtubuli (36). We therefore
subjected mixed neutrophil populations containing both viable
and apoptotic cells to different inhibitors of cytoskeletal fila-
ment function in order to see whether such treatment would
also enable the permeabilization of viable cells. Treatment of
cells with cytochalasin B (which inhibits actin polymerization)
(29) or colchicine (which perturbs microtubule assembly) (8)
before addition of LL-37 did not make the viable cells sensitive
to the lytic action of LL-37 (data not shown). In addition, the
local anesthetic lidocaine, which is known to modify cell mem-
brane fluidity (59), did not alter the pattern of susceptibility to
LL-37; i.e., the peptide still permeabilized only the annexin
V-positive cells (data not shown).
Permeabilization of apoptotic cells by LL-37 is associated
with leakage of intracellular as well as intragranular constit-
uents. Among the inflammatory leukocytes, neutrophils harbor
an especially potent arsenal of proteolytic enzymes that could
be very harmful to surrounding cells and tissues if they were
released in an uncontrolled fashion. Apoptotic cells with an
intact cell membrane retain their intracellular substances, and
to see if permeabilization by LL-37 resulted in true leakage, we
measured the extracellular presence of the cytoplasmic enzyme
LDH. Peptide treatment of mixed neutrophil samples resulted
in the release of LDH, and the levels of release correlated well
with the level of apoptosis in the original cell sample; -CD95-
treated cells (74.8  2.0% apoptotic cells; mean  SD, n  3)
released significantly more LDH (P  0.009) after addition of
LL-37 than the spontaneously apoptotic cells did (35.5  4.9%
apoptotic cells; mean  SD, n  3) (Fig. 8A).
Most potent enzymes of neutrophils are, however, not stored
in the cytoplasm but, rather in intracellular, membrane-en-
closed granules such as the azurophil granules (19). We looked
at the release of the azurophil granule protein MPO from
-CD95-treated neutrophils and found that LL-37 indeed pro-
voked the release of significant amounts of MPO from these
cells (Fig. 8B). Taken together, these data show that LL-37 is
able to permeabilize the cell membranes of apoptotic neutro-
phils, leading to the leakage of cytoplasmic contents. In addition,
the fact that MPO was released from LL-37-treated apoptotic
neutrophils also indicates that the granular membranes are per-
meabilized, facilitating the extracellular release of various poten-
tially deleterious substances.
DISCUSSION
The human cathelicidin LL-37 was originally identified as a
cationic alpha-helical antibacterial peptide capable of micro-
bial killing mediated by its interaction with the microbial mem-
branes (1, 16, 31). Clearly, the peptide is capable of distin-
guishing between membranes with different compositions, and
eukaryotic cells are much less susceptible to membrane attacks
from LL-37 than, e.g., bacterial membranes. More recently, it
has also been shown that LL-37 is capable of modulating the
activity of several important immune cells (9). Similar to cer-
tain other peptides (7, 13, 51, 58), LL-37 displays a functional
dualism, in that it directly kills microbes and modulates im-
mune cell function; both of these activities are likely important
for host defense. It is well known that leukocytes change the
composition of their membranes during, e.g., apoptotic cell
death. The differences between the membranes of viable and
apoptotic cells relate not only to the expression of various
surface proteins but also to their phospholipids compositions
(35). On the basis of these facts and the ability of LL-37 to
distinguish between different types of membranes, we reasoned
that the peptide could possibly discriminate between viable
and apoptotic leukocytes. Primary human neutrophils gradu-
ally enter apoptosis spontaneously during in vitro culture, en-
abling easy access to mixed cell samples containing both viable
and apoptotic cells from the same donor. We thus used neu-
trophils as a model cell and showed that LL-37 selectively
induced the permeabilization of apoptotic neutrophils, leaving
the viable cells intact. In addition, a similar pattern of selective
FIG. 7. The selectivity of LL-37 for lysis of apoptotic cells is inde-
pendent of PS exposure. Liposomes containing typical eukaryotic lip-
ids were prepared without PS (green line) or with 10% PS (red line).
LL-37 (5 ng/ml) was added, as indicated by the arrow, to the different
liposomes, and calcein leakage was monitored over time. The intro-
duction of PS in liposomes containing the phospholipids typically
found in eukaryotic membranes had no effect. The percentage of total
calcein released, as assessed by the addition of Triton X-100, is plotted
against time. The ranges for the two data sets are shown. The total
amount of calcein released over 225 s (determined from the area under
the curve) was established and did not differ significantly (P  0.08;
n  3) between the two types of liposomes.
FIG. 8. Release of LDH and MPO from LL-37-treated apoptotic
neutrophils. (A) Neutrophils were incubated together with or without
the apoptosis inducer -CD95; the result was 75% apoptotic cells and
45% apoptotic cells, respectively, in this set of experiments. These cells
were treated with 50 g/ml of LL-37 for 10 min, and the amount of the
cytosolic enzyme LDH released was measured. It corresponded well
with the fraction of apoptotic cells seen for each treatment, indicating
the complete release of LDH from apoptotic neutrophils. Means 
SDs (n  3) are shown. Statistical significance was established by an
unpaired t test. (B) The release of the intragranular matrix protein
MPO was also measured in -CD95-treated neutrophils. The amount
of MPO released was significantly higher for LL-37-treated cells than
for untreated cells. Means  SDs (n  3) are shown. A paired t test
was used for statistical analysis. **, P 	 0.01.
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permeabilization of apoptotic cells was seen for NK cells ren-
dered apoptotic by hydrogen peroxide treatment, indicating
that the effect was not limited to neutrophils. NK cells were
more susceptible to the lytic action of LL-37, and at concen-
trations higher than 5 g/ml, LL-37 displayed a more general
cytotoxicity against purified NK cells. Viable neutrophils were
not permeabilized until LL-37 concentrations exceeded 100
g/ml, and it makes sense that neutrophils, being important
reservoirs for LL-37, should be more resistant to peptide-
induced membrane disruption.
The immunomodulatory actions of LL-37, as opposed to its
direct microbicidal effects, are primarily mediated by receptor
binding. The surface receptors most often implicated in LL-
37-mediated responses in neutrophils are the chemoattractant
receptor FPRL1 (17) and the nucleotide receptor P2X7 (39).
Antagonists for these receptors, WRW4 (an antagonist of
FPRL1 [4] and oxATP (an antagonist of P2X7 [38]), did not
affect the LL-37-induced permeabilization of apoptotic neu-
trophils, nor did they influence the susceptibilities of viable
cells. These findings suggest that neither FPRL1 nor P2X7 is
involved in the specific permeabilization of apoptotic cells. We
also showed that the apoptotic cells in our mixed neutrophil
samples were completely unable to mobilize intracellular cal-
cium in response to FPRL1 activation, indicating that these
cells are, in fact, nonfunctional and incapable of transmitting
intracellular signals. Taken together, the permeabilization of
apoptotic cells is highly unlikely to depend on the interaction
of LL-37 with surface receptors or even active signal transduc-
tion. This makes the effect of LL-37 on apoptotic leukocytes
appear to be much more like its direct microbicidal action than
its immunomodulatory functions. The fact that the presence of
blood constituents (serum or HDL) that inhibit LL-37’s direct
microbicidal effect was also effective at blocking the permeabi-
lization of apoptotic cells supports this view.
LL-37 has previously been shown to inhibit apoptosis (39) as
well as promote the necrosis (6) of human neutrophils, and it
is likely that the induction of secondary necrosis could explain
the former finding, as was proposed in a study published during
the preparation of the manuscript (61). In line with this, our
data presented here imply that in the presence of LL-37, cells
that spontaneously enter apoptosis are rapidly permeabilized
and are eventually lost from subsequent analyses. The viable
cells, however, would be unaffected by the peptide, resulting in
an apparent enrichment of viable cells at the expense of
apoptotic cells, which could lead to the false impression that
LL-37 inhibits apoptosis. We also show that the LL-37-induced
permeabilization of apoptotic cells destroys the integrity of the
plasma membrane, as seen by the leakage of the cytoplasmic
enzyme LDH to the extracellular space. In addition, we could
also see the leakage of MPO, which is stored in the azurophil
granules (19). Since this granule type is responsible for storing
most of the proteolytic enzymes (19) as well as the immuno-
modulatory molecules, this finding is important and indicates
that LL-37-mediated permeabilization could be a potent
means of getting such substances out to an extracellular loca-
tion. The functional consequences of releasing tissue-destroy-
ing enzymes in combination with molecules that facilitate
wound healing remain to be determined. Interestingly, the
levels of MPO released were lower than anticipated, on the
basis of the proportion of apoptotic cells; it is possible that
LL-37 interacts electrostatically with anionic membrane com-
ponents and sticks to the plasma membrane during perme-
abilization. The permeabilization of azurophil granules could
also require a time longer than the time required for perme-
abilization of the plasma membrane. One must also take into
account the possible release of hCAP-18 from the specific
granules in neutrophils upon permeabilization. If LL-37 is
cleaved extracellularly by proteinase 3, the accumulation of
additional LL-37 could result in a positive-feedback loop.
The mere cationicity of a peptide is not sufficient to induce
specific permeabilization, since sLL-37 was inert in terms of
direct microbicidal activity as well as in the permeabilization of
apoptotic cells. Cationicity combined with an alpha-helical
structure was also not enough to permeabilize apoptotic cells,
since Hp(2-20) did not possess this ability, even though it
potently kills bacteria (43). This Helicobacter pylori peptide is
in many ways similar to LL-37 and also shares specificity for
FPRL1 as a neutrophil receptor (13). We first hypothesized
that flipping of the negatively charged PS from the inner leaflet
of the lipid bilayer to the outer leaflet could confer suscepti-
bility to the cationic peptide LL-37. Several studies have shown
that cationic peptides have an increased affinity (and killing
capacity) for cancer cells compared to their affinity for healthy
cells and that this is due to the fact that cancer cells have more
negatively charged plasma membranes (54, 62). This charge
difference partly originates from the various amounts of PS
present on the outer leaflet of the plasma membranes (41).
However, our data generated from liposome studies and chro-
matogram binding assays failed to support a direct role for PS.
It is likely that apoptotic membrane changes other than the
flipping of PS could explain the selective action of LL-37 on
the apoptotic membranes.
In striking contrast to most immunomodulatory functions of
LL-37 that are intact or that even depend on the presence of
serum (48), we found that serum completely blocked the per-
meabilization of apoptotic cells. In this respect, the effect that
we describe seems to be much more related to the direct
microbicidal action of LL-37. With this in mind, it is reasonable
to assume that the ability of LL-37 to permeabilize apoptotic
cells in vivo would be of importance mainly at sites devoid of
serum components, such as the skin or the lungs. LL-37 is very
highly expressed in psoriatic scales of the skin and contributes
to keeping the scales free of microbial pathogens (40). In
addition, psoriatic scales are characterized by the continued
presence of neutrophils, indicative of a chronic state of acute
inflammation (52). Our findings that LL-37 induces permeabi-
lization of apoptotic leukocytes, concomitant with the leakage
of both cytoplasmic and granular proteins, could thus help
explain why a state of acute inflammation fails to resolve at
sites rich in LL-37 and deprived of serum components.
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